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ABSTRACT 
ADAMBERAGE RUKLANTHI DE ALWIS: Dissecting the Human Antibody Response to 
Dengue Virus 
(Under the direction of Aravinda M. de Silva) 
 
 Dengue fever (DF) and severe dengue (SD) are two forms of an emerging infectious 
disease that presents a severe public health crisis predominantly in developing countries. Its 
etiological agent, Dengue virus (DENV), is a mosquito-borne pathogen, which exists as four 
different serotypes (named DENV1 through 4). Primary natural infections in humans 
stimulate a highly cross-reactive antibody response, however, protection is observed to be 
only against the serotype of infection. Extensive work on the mouse antibody response to 
DENV has mapped strongly neutralizing antibodies to the domain III (EDIII) of the DENV 
envelope (E) protein. However, recent work showed that after a natural infection in humans, 
anti-EDIII antibodies contribute very little to protection. Therefore, the human memory 
antibody response against a natural DENV infection remains poorly understood. Our present 
studies characterized both circulating polyclonal antibodies from human sera and human 
monoclonal antibodies from memory B-cells, after late convalescent primary DENV 
infections. The present body of work shows that after late convalescent natural primary 
DENV infections, humans produce two uniquely different antibody groups: 1) A cross-
reactive, weakly neutralizing group that makes up the dominant proportion of anti-DENV 
antibodies, and 2) a minor group of strongly neutralizing, type-specific antibodies. 
Subsequently, we mapped some of these strongly neutralizing type-specific antibodies to a 
novel complex, quaternary epitope that includes the hinge region between domains I and II 
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(EDI-II) of the E protein. Due to the role of the EDI-DII hinge region in DENV fusion and 
entry, this epitope offers a functional advantage. As hypothesized, we observed that all 
neutralizing EDI-DII hinge-binding monoclonal antibodies that were isolated blocked DENV 
infection at a step post-attachment, while the mechanism of neutralization by human 
polyclonal sera was more variable. In parallel, we found that the weakly neutralizing, cross-
reactive group of antibodies was responsible for antibody-mediated enhancement of infection 
by heterotypic DENV serotypes. Further investigation mapped these enhancing cross-
reactive antibodies to the DENV surface glycoproteins prM and E protein. These studies shed 
some light on the protective and enhancing DENV epitopes targeted by the human immune 
response, and set the stage for a safer and efficacious human vaccine against DENV.  
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Introduction 
	  
1.1 Dengue: Epidemiology and clinical disease 
 Dengue is a re-emerging neglected disease that affects individuals in over 100 
countries and is the pre-eminent arthropod-borne viral disease of humans (47, 89). Dengue 
disease is caused by dengue virus (DENV), which exists as four closely related serotypes 
(named DENV1 through DENV4). DENV spreads efficiently between humans primarily 
through the mosquito vectors Aedes aegypti and Aedes albopictus. DENV is estimated to 
infect over 390 million individuals globally each year (8, 11, 89, 131). The mosquito vectors 
reside in subtropical and tropical regions; thereby placing 2.5 billion individuals at risk from 
acquiring a DENV infection. Unfortunately, there are currently no approved therapeutics or 
vaccines against DENV. 
	   Historically,	   due	   to	   similar	   geographical	   circulation	   and	   clinical	   symptoms,	   infections	   by	  
DENV	   and	   the	   alphavirus,	   chikungunya	   virus,	   were	   frequently	   confused	   (15).	   Nevertheless,	  
epidemics	   of	   dengue	   fever	   (DF)-­‐like	   illness	   have	   been	   reported	   as	   far	   back	   as	   the	   10th	   century	  
(reviewed	  in	  (44)).	  However,	  it	  was	  not	  until	  after	  the	  1950s	  that	  severe	  forms	  of	  dengue	  fever,	  such	  
as	   dengue	   hemorrhagic	   fever	   (DHF)	   and	   dengue	   shock	   syndrome (DSS), emerged in the
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Indian subcontinent and Southeast Asia (51). Since the 1970s, severe forms of dengue have 
spread from five to over 100 countries (reviewed in (44)). It is estimated that at least 500,000 
cases of DHF and DSS cases (with 5% mortality) occur globally each year (131). This 
continual rise in morbidity, mortality and geographical spread is due to increasing 
urbanization, globalization, lack of basic infrastructure, and the spread of the mosquito 
vectors to new territories.  	  
 Successful transmission of DENV by the mosquito vector requires circulating titers of 
around 107-109 mosquito infectious doses in an infected person (34). When an Aedes. species 
mosquito injects DENV into the skin of a new susceptible human, the virus undergoes the 
first round of replication in the resident skin dendritic cells, called Langerhans dendritic cells 
(LDCs) (92). The infected LDCs then migrate to the draining lymph node where the virus 
infects monocytes and macrophages (162). Within the lymphatic and circulatory system, the 
virus is then disseminated to other organs, such as the liver, spleen and bone marrow (64). 
Dengue manifests as a broad spectrum of clinical symptoms in humans. Between 50-
95% of DENV infections are asymptomatic or present sub-clinical symptoms. Symptomatic 
DENV infections are predominantly cases of DF, with classical symptoms of fever, 
headache, eye pain, myalgia, athralgia, rash, nausea and abdominal pain, following the 3-7 
day viral incubation period. Most patients recover after fever subsides, while a small 
proportion goes on to develop a systemic vascular leak syndrome (i.e. DHF and or DSS), 
with petechiae, thrombocytopenia and shock (108). Prior classification of DENV-induced 
disease, DF and DHF/DSS, used to be based on a number scale rated from 1 to 4 (with 4 
being most severe and classified as DHF/ DSS) (108). This classification led to delayed 
diagnosis and untimely treatment of severely ill DENV infected patients (30, 119). 
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Therefore, the WHO recently revised the guidelines, and now patients are diagnosed as either 
having dengue or severe dengue (SD) (109). Hence in the present document, we will use SD 
and DHF/DSS interchangeably.  
1.2 DENV genome and life cycle 
DENV belongs to the arthropod-borne, single-stranded positive-sense RNA 
(+ssRNA) virus family called flaviviruses. Other significant human pathogenic flaviviruses 
include West Nile virus (WNV), yellow fever virus (YFV), Japanese encephalitis virus (JEV) 
and tick-borne encephalitis virus (TBEV) (45). Important work on these related flaviviruses 
have contributed significantly to our understanding of the life cycle and structure of DENV 
(reviewed in (120)). Similarly in the presently described work, we have on numerous 
occasions delved into published material on related flaviviruses to gain further insight while 
studying the human antibody response to DENV.   
 Flaviviruses attach to the surface of the host plasma membrane and enter the host cell 
through receptor-mediated endocytosis (149). The internalization receptor for DENV is as 
yet unknown. However, several important attachment factors that aid DENV infection in 
vitro have been identified; these include C-type lectin (DC-SIGN, dendritic cell-specific 
ICAM-3 grabbing non-integrin) (142), glycosaminoglycans (Heparin Sulphate, manose 
receptor in macrophages) (19, 28, 96, 114) and phosphatidylserine receptors (93). As the 
virion travels through the endosomal pathway, the low pH environment within the endosome 
triggers large conformational changes on the virion surface, leading to viral fusion with the 
anionic lipid-containing host membrane of the late endosome (2, 12, 149, 166). Virus 
envelope-host membrane fusion releases viral RNA into the host cytoplasm, where the virus 
hijacks the host protein translation machinery and translates the (+)ssRNA DENV genome 
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into a single polypeptide. As shown in Figure 1.1A, the viral polypeptide (with protein 
sequence C-prM-E-NS1-NS2A-NS2B-NS3-NS4A-NS4B-NS5) is subsequently processed by 
viral and host proteases into three structural (C, capsid; prM, membrane precursor; E, 
envelope) and seven nonstructural proteins (NS) (reviewed in (120)). During protein 
synthesis on the rough endoplasmic reticulum (ER), several viral membrane proteins are 
anchored into the ER membrane and the process of viral assembly begins within the ER 
lumen (Figure 1.1B). Viral translation initiates formation of convoluted membrane structures, 
where the viral NS proteins form replication complexes and actively replicate the RNA 
genome (88, 146). The newly transcribed viral genomic RNA strands are encapsulated within 
a nucleocapsid, which in turn is packaged within an ER-membrane derived envelope 
containing prM and E proteins in a trimeric conformation (Figure 1.1B and C) (reviewed in 
(120)). These assembled viral particles are immature and non-infectious (Figure 1.1C). While 
the immature virions are transported through the trans-Golgi network (TGN), they undergo 
glycosylation modifications and processing by the low pH-dependent host protease, furin 
(Figure 1.1B and C) (133, 164). Mature, infectious virions are subsequently exocytosed from 
the host cell.   
1.3 DENV surface glycoproteins 
When a DENV virion is initially assembled, each virion surface is embedded with 
heterodimers of the two glycoproteins, prM and E. The prM protein primarily functions to 
prevent premature fusion of the E glycoprotein with host cell membranes, and chaperones the 
folding and assembly of E protein (86). The prM protein may also play roles in immune 
evasion, by eliciting weakly neutralizing and infection-enhancing antibodies in the human 
host (31, 121). Despite the low amino acid sequence identity (~30%) in prM protein within 
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the flavivirus family, there is high prM protein sequence conservation (~70%) among the 
four DENV serotypes (31). The prM protein contains approximately 166 amino acids 
arranged in three domains; 1) the pr peptide (91 amino acids) which folds into a 7 stranded β-
sheet, 2) the M portion, which is predicted to consist of an amphipathic helix, and 3) two C-
terminal transmembrane segments (M-T1 and M-T2) (Figure 1.2C), where M-T2 contains 
the signal sequence for the secretion of E protein (78, 91). X-ray crystallography and cryo-
electron microscopy (cryo-EM) structures indicate that in the immature virus, the pr peptide 
resides on the distal end of the E protein and covers the fusion peptide to prevent viral fusion 
within the TGN membranes (78, 170). During DENV maturation (Figure 1.1C), the prM 
protein is cleaved by host furin into the soluble pr peptide and the membrane-anchored M 
protein (~75 amino acids) (2, 164). Structural studies indicate that the M protein is partially 
hidden below the surface-exposed E proteins in the mature virion (as shown in the cartoon 
representation in Figure 1.2C), and thereby presumably inaccessible to antibodies and 
predicted to play an insignificant antigenic role (168).  
The flavivirus E glycoprotein (E) (~495 amino acids) is the most surface-exposed 
protein on the mature, infectious virion particle (Figure 1.2A) (75). E protein plays critical 
roles in determining cell tropism, attachment, fusion and entry into host cells. The E protein 
is also the most antigenically significant protein across members of the flaviviral group and 
the major target of neutralizing antibodies (122). The initial identification of four DENV 
serotypes was based on the antigenic differences in the E protein. The existence of four 
distinct DENV serotypes was first identified using immunological assays, and later supported 
by the 60-70% amino acid sequence similarity of the E proteins among the serotypes (156). 
As represented in Figure 1.2C, each E protein consists of three structurally different regions; 
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1) the ectodomain, 2) the two amphipathic helices (E-H1 and E-H2) and conserved stem 
region (CS), and 3) the two C-terminal transmembrane helices (E-T1 and E-T2) (103, 168). 
Since the helices and CS region are both hidden by the E ectodomain and membrane 
associated, very little structural information is known about these regions (168). Several 
molecular and biochemical studies have shown that these regions are involved in viral 
assembly (i.e. through prM-E heterodimer stability, and membrane association), low pH 
rearrangement events and fusion (12, 70, 83, 98, 115, 171). It is also assumed that because 
these helices are not surface exposed they are inaccessible to antibodies and therefore, 
irrelevant for studying neutralizing antibody responses. 
When the ectodomain region of the E protein  (80% of E protein) is expressed 
without the helices, the resultant recombinant E protein is soluble and secreted (27). The x-
ray crystallography structures of several flaviviral E proteins were solved using the soluble E 
ectodomain, also termed recombinant E protein (rE) (Figure 1.2B) (97, 99, 117). The E 
ectodomain is folded into three distinct β-barrel domains (named domain I, II and III); the N-
terminal domain I (EDI) is an eight-stranded β-barrel, connected on one side with four 
peptide chains to the dimerization domain (EDII, domain II) and on the other side with one 
peptide linker to the immunoglobulin (Ig)-like domain (EDIII, domain III). Domain II 
contains the highly conserved fusion peptide, which is inserted into the host membrane 
during viral fusion and entry. Domain III of the E protein has the receptor binding sites (25, 
62, 77). The DENV E protein has putative surface N-linked glycosylation sites at Asn-67 
(EDII) and Asn-153 (EDI), with the latter glycosylation being conserved in most flaviviruses 
(59, 117). The N-glycan at Asn-67 plays roles in viral attachment (by interacting with DC-
SIGN) and viral propagation in mammalian cells, while the sugar at Asn-153 was captured 
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by x-ray crystallography as stabilizing the E protein dimers by stretching across the dimer 
interface to cover a region of the fusion peptide (97, 100, 113, 117).      
 The E protein ectodomain under neutral pH has been solved by x-ray crystallography 
for both DENV2 and DENV3 (97, 99). Despite a two amino acid deletion in EDI of the 
DENV3 E protein, the E protein structures of both serotypes were found to share very high 
structural similarity. One of the few structural differences was observed when the E 
structures of the two serotypes were super-imposed on each other; it was noted that a 10° 
difference in rotation at the EDI-II hinge region of the E protein translated into a 13Å and 
18Å difference in position of the fusion loop and EDIII, respectively (99). Therefore, it is 
important to keep in mind that the EDI-DII hinge region is highly flexible and undergoes 
large conformational changes during viral maturation and the low pH-induced fusion process 
(Figure 1.3B) (168).  
1.4 Virus Structure 
Similar to other flaviviruses, the assembled, infectious DENV virion is 500Å in 
diameter. Each virion consists of the viral genomic RNA-containing nucleocapsid enveloped 
in a lipid membrane containing the two membrane-embedded glycoproteins, (prM/M and E 
protein) (75). The DENV genome encodes a single open reading frame of 11 kb in length, 
with untranslated terminal regions (UTRs) that are critical for regulation of genome 
replication and translation. Highly asymmetrically charged capsid (C) proteins package this 
DENV RNA for virion assembly (87). A host ER membrane-derived lipid envelope 
consisting prM/M and E proteins surrounds the nucleocapsid. Since the inner lipid leaflet and 
the nucleocapsid are ~30Å apart, it is hypothesized that there is very little connection 
between them, and that flavivirus envelope formation is primarily dependent on the prM and 
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E proteins (75, 102, 168, 170). This is further evident by the routine observation of subviral 
particle formation in virus-infected or prM-E transfected cells in culture, where 30 prM-E 
heterodimers are sufficient to arrange into particles with an icosahedral symmetry (T=1), 
induce fusion and stimulate protective immunity (2, 23, 35, 72, 103).   
Mature virion 
Recent x-ray crystallography and cryo-EM images have revolutionized our 
understanding of the DENV virion structure (75, 97-99, 170). The DENV virus is made of 
180 heterodimers of prM/M and E proteins, ordered into an icosahedral structure. The 
surface exposure and arrangement of the glycoproteins on the particle is dependent on the 
maturity of the virus (Figure 1.1C) and the pH of the surrounding environment (75, 103, 117, 
170). The earliest cryo-EM studies of DENV were of the mature, infectious virion (75). In 
the mature virion, E protein monomers are arranged into head-to-tail dimers, with the fusion 
loop of one monomer hidden below EDI and EDIII of the adjacent monomer (see Figure 
1.2B). Three sets of these dimers are arranged into herringbone-structured rafts, and 30 of 
these repeated raft structures assemble into the infectious virion (Figure 1.2A). As the E 
monomers are assembled into the virion particle, the hinge angle between EDI and EDII 
reduces by about 10-20° (Figure 1.3B), and the EDIII is pushed outwards. It was recently 
found that the M protein, which is hidden below the surface-exposed E protein, also has a 
vital role to play in keeping the virion intact (169). The N-terminal 20 amino acid region of 
M protein contains three pH-sensing histidine residues that at neutral pH latch onto the 
membrane-facing side of E protein, and forces the E protein to lie flat on the viral membrane 
and keep the fusion peptide unexposed (169).   
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Cryo-EM studies of TBEV subviral particles lead to the hypothesis that flaviviral 
particles are assembled in a T=3 symmetry (35). However, cryo-EM studies of the infectious 
virion show that the orientation of the 30 rafts in the virion form 5-3-2 axes of symmetry; the 
EDIII of five E proteins come together to form a 5-fold axis, the EDI of three E proteins form 
the 3-fold axis and two E proteins come together to form the 2-fold axis (Figure 1.3A) (75). 
Therefore in the assembled virion, not all the E protein monomers are in the same chemical 
environment, and this could have significant consequences on attachment, fusion and 
neutralizing epitopes available for antibody binding.     
Immature virion 
 Surface structure of the immature DENV virus particle is vastly different from that of 
the mature DENV virus (Figure 1.1C). In the immature prM-E heterodimers, the uncleaved 
prM extends along the length of the E protein, and the pr peptide β-barrel structure sits on the 
fusion loop at the distal tip of EDII preventing premature fusion events (78). In the immature 
virion, these prM-E heterodimers arrange into 60 repeated trimer structures. Unlike the 
smooth outer surface of the mature virion, these trimers give the immature virus an irregular, 
spiky surface and an external diameter of 600 Å (i.e. 100 Å greater than the mature virion) 
(170). The highly flexible hinge region between DI and DII of E protein in the immature 
virus differs by 30°, when compared to the mature virion, and about 5-15° as compared to the 
crystal structures of the soluble E protein (75, 97-99, 170). Differences in the EDI-DII hinge 
angle, E protein epitope exposure and the presence of uncleaved prM could have significant 
consequences on antibody binding, neutralization or enhancement of mature versus immature 
virus. Interestingly, recent EM studies have shown that a vast majority of DENV particles 
exocytosed in cell culture systems are not fully mature (66). In fact, a majority of the cell 
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culture-derived DENV virions were found to be only partially mature, with almost 90% of 
the virions containing uncleaved prM (6, 66, 67, 121). The minimum degree of viral maturity 
required for infectivity is unknown. Recent unpublished data from our lab indicates that the 
ratio of mature and immature virus may have vast consequences on attachment and 
infectivity of different cell lines. Furthermore, It is unknown whether natural in vivo 
infections in humans or mosquitoes also produce DENV virions with a range of maturity.  
Major viral rearrangements: maturation & fusion 
 During the DENV lifecycle, the virion particle undergoes two major conformational 
changes: 1) during viral maturation in the TGN (reviewed in Perera, R et al, 2008 (111)), 
and 2) during viral fusion with the host membrane in the late endosomes. Elegant 
biochemical studies coupled with studies of virus structure have given us some insight into 
the conformational changes the virus experiences during these events. 1) Viral maturation 
occurs in two important steps. Spiky immature virus buds from the ER and enters the TGN, 
where a gradient decrease in the surrounding pH causes pH-sensing histidines in the C-
terminal ectodomain region of prM to induce latching on to the membrane-facing side of the 
E proteins, causing a 30° rotation at the EDI-DII hinge region and forcing the E proteins to 
lie flat on the membrane surface (Figure 1.3B) (111, 164, 169). This results in the 
rearrangement of 60 prM-E trimers into 90 E protein dimers (Figure 1.1C). This low pH-
induced virion conformation exposes the furin cleavage site, enabling efficient processing of 
prM into pr peptide and M protein (133, 164). The pr peptide prevents premature fusion by 
remaining associated with the E protein, until the virion is released from the host cell. Once 
exocytosed, the neutral pH causes the pr peptide to dissociate from the virion, leaving the 
virion ready to infect new host cells. 
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 The second major structural rearrangements of the surface glycoproteins occur during 
viral fusion with the host membrane in the late endosomes (Reviewed in Harrison, SC, 2008 
(56)). In the recent years, DENV membrane fusion and the resulting conformational changes 
in the E, have been studied extensively. Flaviviral fusion is a class II fusion process (117, 
134, 135). The structural rearrangements associated with membrane fusion begin when the 
pH drops in the endosomal compartment, leading to protonation of several histidine residues 
in both E and M glycoproteins (2, 38). This leads to disruption of the E protein raft structures 
and dissociation of E protein dimers into monomers. As a result, EDII of E protein is pushed 
upwards, exposing the fusion loop at the tip of EDII. The E protein monomers rearrange to 
form the low pH-induced unstable trimer structure. As the virus passes through the 
endosomal pathway, the viral fusion loop is inserted into the late endosomal membranes 
enriched with anionic lipids (166). After the insertion of the fusion loop into the outer leaflet 
of the host endosomal membrane, EDIII folds towards EDII and brings the viral membrane 
and host membrane together to form the unstable hemifusion intermediate. This is followed 
by the formation of the fusion pore, and the release of the RNA-containing viral nucleocapsid 
into the cytosol. X-ray crystallography has been able to capture only the pre-fusion and post-
fusion trimer conformations (Figure 1.3)(98, 117). Therefore, while biochemical studies have 
tried to fill in the gaps of our understanding of this fusion process (79, 130), there is still 
much work to be done in this area. Furthermore, during the membrane fusion process, the 
EDI-DII hinge undergoes a large angular change of ~35° (Figure 1.3) (171). Therefore, it is 
conceivable that antibodies or inhibitors that target this region would potently neutralize 
DENV by efficiently blocking fusion.     
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1.5 Human immune response to natural DENV infections 
 DENV causes an acute self-limited infection, which a majority of individuals clear 
asymptomatically. Studies have shown that the human adaptive immune response is 
instrumental in the resolution of DENV infection and prevention of re-infection with the 
same serotype. A human cohort study showed that during secondary infections, cross-
reactive CD8+ T cells contributed to severe disease through a process known as “original 
antigenic sin” (101). However, several recent studies indicate that CD8+ T cells might play a 
more protective role during secondary infections (163). Therefore, the role of T cells in 
primary and secondary infections is unclear and requires further examination. Protection 
against DENV has been directly correlated with the neutralizing antibody response. 
Furthermore, natural infections with DENV lead to the life-long production of protective 
antibodies, preventing re-infection with the serotype of infection. Therefore, it is widely 
accepted that in humans neutralizing antibodies are the primary mediators of protection 
against DENV.  
Primary DENV infections 
The human antibody response following a DENV infection is very similar to other 
acute viral infections. During a primary infection, DENV initially stimulates an IgM response 
within 4-5 days of fever. DENV-specific IgM reaches a peak titer at about 2 weeks and 
decays to undetectable levels around 2-3 months after infection (Figure 1.4)(63). Isotype 
switching occurs and a rapidly rising DENV-specific IgG response is detected within two 
weeks of illness (Figure 1.4). This life-long IgG (predominantly IgG1 and IgG3 subclasses) 
response is highly cross-reactive with all four DENV serotypes and even with other species 
in the flavivirus family (73, 90). Due to the high structural similarity within the E proteins of 
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the four DENV serotypes, this observed cross-reactivity in the antibody response is hardly 
surprisingly. Unfortunately, these cross-binding antibodies prevent the use of simple binding 
assays (such as conventional ELISAs or dipstick assays) to identify the infecting DENV 
serotype, and require the use of more expensive and technically challenging assays, such as 
reverse transcription polymerase chain reaction (RT-PCR) and virus neutralization. These 
cross-reactive antibodies provide a transient cross-protection against the DENV serotypes not 
seen by the immune system (i.e. heterotypic serotypes) (Figure 1.4). Human DENV-
challenge studies in the 1950s, along with epidemiological and more recent computational 
investigations have calculated this transient individual and herd population cross-immunity 
as lasting for approximately 6-12 months and 2-3 yrs, respectively (1, 26, 126). Unlike the 
cross-protective IgG response, the type-specific neutralizing IgG response can be detected 
even 60 years after infection, and is generally assumed to provide life-long immunity against 
the serotype of infection (48, 62, 63, 107). Nevertheless, the main basis of current vaccine 
platforms is to stimulate balanced, life long, neutralizing responses to each of the four DENV 
serotypes.   
Secondary DENV infections  
Due to the lack of long-lasting cross-serotype protection after primary DENV 
infections, individuals are susceptible to secondary infections from heterotypic serotypes (14, 
128). Pre-existing sub-neutralizing, cross-serotype binding antibodies to heterotypic 
serotypes lead to a higher probability of severe disease during secondary infections, which is 
classically thought to be driven by a phenomenon called antibody dependent enhancement 
(ADE). Secondary infections result in a minor, rapidly diminished IgM response, followed 
by a rapid increase in IgG antibodies to titers far exceeding those observed during primary 
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infections. Soon after a secondary infection, both naïve B cells and DENV-specific memory 
B cells are stimulated, and a rapid elevation in neutralizing antibody titers towards the 
primary infection serotype is observed; a phenomenon explained by “original antigenic sin” 
(36, 54, 95). This has strong implications for vaccine strategies, since boosting with 
heterologous serotypes will preferentially amplify the antibody repertoire towards the 
serotypes of initial vaccination. A common feature of secondary infections is the eventual 
development of a broad cross-immunity to include serotypes yet unseen by the immune 
system. Furthermore, severe dengue in tertiary and quaternary infections are rare, suggesting 
the presence of long-lasting antibodies targeting cross-protective epitopes after secondary 
infections (3, 155).   
 DENV Antigens targeted by the human antibody response 
 Natural DENV infections stimulate the development of specific antibodies towards 
several structural and non-structural proteins. By western blot binding analysis, primary 
DENV infections were found to raise antibodies primarily towards E, NS1, NS3 and NS5 
proteins, while secondary infections broaden the response to include NS1, prM and C 
proteins as well (21, 147). It is unclear whether secondary infections truly induce a broader 
antibody response, or whether the overall higher level of antibodies following a secondary 
infection enables the detection of anti-NS1, prM and C antibodies. It is unlikely that 
antibodies directed against the intracellular proteins, NS3 and NS5 proteins, contribute to 
protection or enhancement of the disease (141). On the other hand, NS1 protein is a soluble 
viral glycoprotein that is secreted into the blood stream and detectable during active infection 
(47). DENV NS1 has been implicated in both protective and pathogenic roles (ref). Studies 
with passive transfer of anti-NS1 antibodies were shown to protect mice from lethal DENV 
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challenge (60, 129). Furthermore, several vaccine designs expressing DENV NS1 protein 
(either alone or in combination with E protein) also induced protective responses against 
DENV (22, 24, 161). Similar protective roles of NS1 protein have been shown in several 
other flaviviruses (32). However, anti-NS1 antibodies have also been implicated in severe 
disease by promoting vascular leakage. DENV NS1 was shown to stimulate autoimmune 
antibodies that not only bind NS1, but also cross-react with platelets and endothelial cells, 
leading to endothelial cell damage and inflammation (reviewed in (81)).   
  The DENV E protein is the most surface-exposed protein on the infectious virion, and 
the principal target of neutralizing antibodies (21, 147). Therefore, E protein has been the 
subject of intense research for several decades. A significant portion of these circulating anti-
E protein antibodies are directed towards the highly conserved fusion loop of E protein, and 
are cross-reactive (76, 82, 107). Since primary infections only provide long-term protection 
against the serotype of infection, it is highly unlikely that these cross-reactive, fusion loop-
binding antibodies are cross-neutralizing. Results using mouse model systems led to many 
studies investigating the possibilities of EDIII as being the primary target of neutralizing 
antibodies made in humans. Unexpectedly, these studies with DENV-immune human sera 
showed that natural infections produced only a few anti-EDIII antibodies, and this small 
proportion of anti-EDIII antibodies contributed to a minor proportion (10-15%) of the 
neutralizing capacity of the polyclonal sera (153, 154). Similarly, mutating a critical lateral 
ridge epitope on EDIII in WNV did not significantly affect neutralization titers in infected 
humans or horses (107, 127). This further establishes that flavivirus neutralizing antibodies in 
humans do not target EDIII.   
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Memory B-cells and human monoclonal antibodies  
 For many decades, the DENV antibody field has been restricted to using DENV-
immune human polyclonal sera or mouse monoclonal antibodies (MAbs) to map epitopes 
targeted by the antibody response. Due to the inherent complexity of polyclonal sera, only a 
limited number of studies have tried to map the DENV epitopes recognized by DENV-
immune human sera, and even fewer studies have tried to map the neutralizing epitopes. It is 
only in the past decade, that the technology to efficiently generate human MAbs from human 
peripheral memory B-cells has been worked out. Generation of human MAbs from memory 
B-cells in peripheral blood mononuclear cells (PBMCs) must follow several critical steps; 1) 
isolation of antigen-specific memory B cells, 2) Epstein-Barr virus (EBV) transformation of 
the isolated memory B cell, 3) fusion of EBV-transformed B-cell with a fusion partner to 
create a hybridoma cell line, and 4) purification of the secreted antibody. Memory B-cells 
specific to an antigen of interest are usually particularly rare, making the isolation of these 
cells particularly difficult. Until recently, EBV transformation of memory B-cells was 
inefficient, only transformed CD21+ B-cell subsets, and led to transformed B-cells with poor 
growth, low antibody production and chromosomal instability. Recent studies found that the 
addition of CpG dramatically increases the efficiency of EBV transformation (7, 57, 144). 
Furthermore, recent improvements in cell fusion technologies (such as the generation of 
heterohybridomas) have dramatically improved the number of suitable fusion partners 
available (165). The above-mentioned improvements in human MAb generation have led to 
the very recent isolation and characterization of numerous human MAbs specific to DENV 
virus (6, 29, 31, 132).    
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1.6 Lessons from DENV-specific mouse MAbs 
 Until recently, a majority of studies investigating the epitopes of antibody 
neutralization or enhancement in DENV were conducted by characterizing DENV-specific 
mouse MAbs raised via viral inoculation or vaccination with recombinant E (rE) protein 
(reviewed in (33, 155)). Mouse MAbs have been mapped primarily to the most surface-
exposed E protein. Few prM and NS1 mouse MAbs have been isolated, but these were found 
to be only weakly or moderately neutralizing in vitro. Isolated mouse MAbs have been 
mapped to all domains of E protein; 1) a few were cross-reactive, weakly neutralizing and 
bound the fusion loop in EDII, 2) a few strongly neutralizing MAbs bound the lateral ridge of 
EDI, 3) several strongly neutralizing MAbs bound the dimer interface, and 4) most 
importantly, a large proportion of the strongly neutralizing mouse MAbs targets the EDIII 
(Figure 1.5) (25, 80, 85, 123, 138, 139).  
There are two overlapping epitopes within the EDIII that are recognized by 
neutralizing mouse MAbs: 1) the 4-looped lateral ridge region of EDIII, and, 2) the A-strand 
of EDIII (Figure 1.5B). The lateral regions of EDIII have been identified as containing high 
variability between serotypes, with high conservation within serotypes. Therefore it is 
understandable that the strongly neutralizing mouse MAbs that have been mapped to the 
lateral ridge of EDIII are type-specific (42, 138, 139). Many of the mouse MAbs that mapped 
to the A-strand epitope within EDIII are sub-complex binding (i.e. MAbs binding to two or 
three serotypes, but not to all four serotypes), and only moderately neutralizing (43, 85, 139). 
For many years, EDIII was thought to be the epitope of neutralizing antibodies, even within 
humans. As a result, many vaccine platforms were initially designed with recombinant EDIII 
antigen and anti-EDIII antibodies were researched for therapeutic applications (9, 48, 61). As 
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noted above, recent studies indicated that natural infections in humans were found to only 
rarely elicit EDIII-binding antibodies, and that human neutralizing antibodies targeted an 
epitope that is yet unmapped.  
1.7 Mechanisms of DENV neutralization 
 Despite differences in the neutralizing epitopes targeted by humans and mice, the use 
of mouse MAbs in mechanistic studies has vastly expanded our knowledge of the 
mechanisms of DENV neutralization (reviewed in (33)). The antibody-mediated 
neutralization of flaviviruses (including DENV) is a “multiple-hit” phenomenon, where 
neutralization entails a virion to be bound with an antibody stoichiometry that exceeds a 
required threshold number of bound antibodies for neutralization (Figure 1.6). Work by 
Pierson and colleagues using WNV and a panel of anti-EDIII mouse MAbs, have calculated 
the antibody threshold number for flaviviruses as being ~30. This means that for successful 
antibody neutralization of a flavivirus particle that contains 180 E protein epitopes, there 
needs to be > 30 antibody molecules bound to that virion (94, 112). It is hypothesized that 
when antibodies are bound to virions at a stoichiometry less than the threshold number, then 
there is the risk of ADE (33). It is unclear whether this threshold requirement of at least 30 
antibody molecules to neutralize a virion is true for all epitopes. Furthermore, the effect on 
the threshold number when a polyclonal mix of antibodies is binding to several different 
epitopes on the same virus (as is the case when DENV enters a DENV-immune human body) 
is also not known. Nonetheless, exceeding the antibody threshold requirement of 
neutralization is governed by at least two important factors; 1) antibody affinity, and 2) 
epitope accessibility (reviewed in (33)).  
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Antibody affinity 
Antibody affinity defines the percentage of epitopes on the virion that are occupied 
by that antibody at a given concentration. Therefore, at any given concentration, antibodies 
with higher affinity will bind to the virion in greater numbers than low affinity antibodies. 
Similarly, E protein mutations that reduce antibody affinity, will lower the number of viral 
epitopes occupied at any given concentration, and reduce the neutralization potential of that 
antibody. Several studies have observed that decreases in antibody affinity due to intra-
serotype, strain variation (i.e. 4-10% within E protein) lead to reduced neutralization of those 
strains (13, 138, 152). It is unclear whether these intra-serotype variations also affect in vivo 
protection against re-infection from any strain within a particular serotype. 
Epitope accessibility due to complex virion structure 
Due to the complex structural properties of flaviviruses (and more particularly 
DENV), epitope accessibility is multifaceted. As detailed above, the 180 E proteins are 
arranged in a dense 5-3-2-fold axes of symmetry, dividing the E proteins on the mature virion 
into three different chemical environments. Therefore, depending on the epitope recognized 
by a particular antibody, steric constraints of that epitope would decrease the epitope’s 
accessibility for binding (20, 68, 69, 85, 106). For example, cryo-EM structures of the 
neutralizing mouse MAb, E16, in complex with WNV showed that although E16 binds the 
highly exposed lateral ridge region on EDIII, it can only occupy 120 of the available 180 
EDIII epitopes on the mature virion. It was observed that E16 could not occupy the EDIII 
epitopes at the 5-fold axes of symmetry due to their close proximity to each other (68). Since 
the threshold number for neutralization is less than the maximum accessible epitopes 
available, greater than 30 molecules of E16 can bind and neutralize a virion. On the other 
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hand, in the mature virion the highly conserved fusion peptide is buried beneath EDI and 
EDIII of the opposing E protein, and inaccessible to binding by anti-fusion loop MAbs, such 
as E53. Therefore, MAbs similar to E53 need to bind almost all accessible epitopes to exceed 
the threshold of neutralization, making these MAbs only weakly neutralizing (20, 137).   
DENV structural dynamics 
 Despite our earlier detailed description of the mature flavivirus virion, we know that 
proteins assembled into viral particles are not static structures. In fact, viral surface proteins 
are thought to be capable of constant movement or “breathing” (65, 160). This dynamic 
movement was shown to also be true of DENV, and enable the exposure of epitopes that 
would otherwise have been inaccessible. The mouse MAb, 1A1D-2, is potently neutralizing, 
DENV-subcomplex binding and more specifically, recognizes an epitope on the A-strand of 
EDIII (85, 123). Detailed mapping of 1A1D-2 showed that this MAb binds an epitope that is 
hidden in the mature virion. Experiments at 4°C showed that 1A1D did not bind the virus at 
low temperatures, while 1A1D binds and efficiently neutralized DENV at 37°C. Cryo-EM 
studies showed that “breathing” of the DENV virion at 37°C allowed binding of 1A1D-2, 
which caused E proteins to rotate in a manner that further exposed its epitope (85). Studies 
with 1A1D-2 and the more recently described DENV1-E11 MAb are evidence of the effects 
of DENV structural dynamics on the accessibility of epitopes to antibody binding (Figure 
1.6) (4, 85).     
Epitope accessibility & DENV maturation 
 DENV virus populations released from cell culture are heterogenous in the ratio of 
cleaved and uncleaved prM, containing a combination of completely immature, completely 
mature and partially mature-immature virions. Recent studies show that heterogeneity in the 
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virus population is higher than previously assumed, with up to 90% of the virions containing 
uncleaved prM (66). Although the minimum requirement of cleaved prM for infectivity is 
unknown, a majority of partially mature virions are observed to be infectious (66). The 
arrangement of E proteins during the mature E dimer conformation is vastly different from 
the immature prM-E trimer conformation (Figure 1.1C). This vast difference in conformation 
has drastic consequences on epitope accessibility (Figure 1.6), with many instances where a 
subset of the virus population is resistant to neutralization even at saturating antibody 
concentrations (105, 112). For example, it was observed that the fusion loop was more 
exposed in the immature E trimer conformation. Hence, several anti-fusion loop MAbs are 
better at neutralizing more immature virus, leaving completely mature virions resistant to 
neutralization from these MAbs (105). Although no detailed cryo-EM mapping of an anti-
prM antibody has been conducted yet, it is also easily conceivable that antibodies targeting 
prM are especially sensitive to DENV maturation.    
Complement protein, C1q, & decrease in threshold number 
It has been known for years that serum complement components can boost the 
neutralization of flaviviruses by antibodies (reviewed in (33)). However, it was only within 
the past few years that the complement protein responsible for this observed increase in 
neutralization was identified as being C1q. As part of the classical complement pathway, the 
~460 kDa C1q multimeric protein activates the pathway by binding the Fc-portion of 
antibodies. In humans, C1q preferentially binds to IgG3 and IgG1 with higher affinity, than 
IgG2 and IgG4. Recent work has directly shown that exogenously added C1q can augment 
the neutralization of flavivirus by antibodies. This increase in neutralization in the presence 
of C1q is possibly due to the ability of C1q to cross-link antibodies, increasing the avidity 
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and therefore, decreasing the antibody stoichiometry or threshold number required for 
neutralization (Figure 1.6) (94). The effects of C1q on antibody neutralization should be 
considered when testing DENV-specific MAbs and DENV-immune polyclonal sera in in 
vitro neutralization assays.   
Pre-attachment and post-attachments blocking Abs 
 DENV-specific MAbs have been documented to neutralize DENV using two main 
mechanisms. Many MAbs prevent a productive DENV infection by binding regions on the 
virion surface that are involved in receptor attachment, and are named pre-attachment 
blocking antibodies. Another group of MAbs (named post-attachment antibodies) allow the 
attachment of DENV to host cells, but block an essential step in the entry process and 
prevent viral fusion (25, 40, 58, 106, 123, 136, 143, 151). Post-attachment antibodies bind 
regions on the virus that are critical for the low pH-induced large conformational change 
required for fusion. MAbs that neutralize post-attachment bind several different epitopes on 
the E protein, including EDIII and the fusion loop (40, 123, 136, 143, 151). Both pre-
attachment and post-attachment blocking MAbs can be strongly neutralizing (25, 40, 58, 106, 
123, 136, 143, 151). Only one study has investigated the dominant mechanism of 
neutralization in DENV-immune polyclonal human sera (58). This study found that human 
serum from acutely DENV-infected patients primarily blocked attachment of DENV (58). 
However, this study used serum samples that were not conducive to investigate long-term 
protection. Therefore, it is still unclear which mechanism of neutralization is dominant in 
DENV-immune polyclonal sera.     
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1.8 Antibody dependent enhancement of DENV: the other edge of the double-edged 
sword.  
One of the most compelling explanations for the higher proportions of severe disease 
during secondary heterotypic DENV infections (when compared to primary infections) is the 
phenomenon of ADE (52, 53, 150). As shown in Figure 1.7, ADE of DENV infection is 
expected to occur when pre-existing sub-neutralizing antibodies in the body (such as from a 
primary infection) bind to a heterotypic virus during a subsequent infection, and facilitate the 
entry of the virus through Fc receptor (FcR)-mediated endocytosis into FcR-bearing myeloid 
cells (such as monocytes and macrophages). Through mechanisms that are largely unclear 
and possibly furin cleavage-dependent, the antibody-bound virus escapes the phagolysosome 
and establishes a productive infection within the host cell (Figure 1.7) (reviewed in (52)). It 
is important to remember that primary infections can also sometimes lead to DHF/ DSS, 
which means that severe DENV-induced disease is multi-factorial and ADE is only one 
important mediator of severe disease.     
Apart from inducing severe secondary infections, there are several other 
epidemiological observations that tie the theory of ADE to DENV infections. 1) In DENV 
endemic regions, infants between the ages of 6 and 12 months are a high-risk group for 
severe forms of DENV such as DHF or DSS (17, 18, 71). Since the infant immune system is 
facing DENV for the first time, this occurrence is independent of a cellular adaptive immune 
response. One of the explanations for a time-dependent severe disease phenotype in infants is 
the ADE of DENV infection by passively transferred maternal antibodies. The DENV-
specific maternal antibodies initially protect the infant for several months, but as the maternal 
antibody decays over time and reaches sub-neutralizing titers, the infant is at risk of an ADE-
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mediated DENV infection for several months (17, 18, 71). 2) Severe disease in both 
secondary infections and infant cases are observed to reach high serum viremia titers (150). 
This is not always due to higher virulence of the infecting virus strain (49). Several studies 
have clearly observed that a DENV infection through the ADE pathway (as opposed to the 
conventional receptor-mediated entry pathway) leads to significantly higher replication and 
secretion of infectious virus (41, 55).         
 ADE of DENV infection is easily reproducible in cell culture using FcR-bearing 
cells and DENV-specific MAbs or DENV-immune polyclonal sera. Many cell lines, both 
primary (PBMCs, primary dendritic cells, monocytes and macrophages) and immortalized 
cells (K562, U937, THP-1), are presently being used to recapitulate the ADE phenomenon in 
vitro (6, 10, 16, 41, 74, 124, 145, 159). A majority of these immortalized cell lines are only 
permissive to DENV infection in the presence of DENV-specific antibodies, hence removing 
the complexity of traditional mechanisms of entry while studying ADE. It was initially 
postulated that the higher viremia when infected through ADE is not due to more efficient 
FcR-mediated uptake of virus and higher numbers of infected cells (aka extrinsic ADE) 
(reviewed in (155)). However, recent in vitro studies show that entry of DENV through ADE 
is not very efficient, and does not infect more cells than the traditional method of entry (145). 
Instead the FcR-mediated mechanism of uptake of virus into the host cell suppresses the anti-
viral responses within that cell, which allows greater viral replication and output (a process 
termed intrinsic ADE) (145). Despite the discrepancies in the exact cytokine profiles 
between ADE of DENV across different cell lines, it was generally observed that DENV 
infection through ADE subverted the host antiviral response by decreasing and increasing 
secreted levels of type I interferon (IFN) and interleukin (IL)10, respectively (10, 16, 74, 
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124). Whether FcR-mediated uptake is more immune suppressive than the traditional method 
of receptor-mediated entry, is yet unclear. Further studies need to be conducted to define the 
exact molecular mechanism of how the virus escapes the phagolysosomes, and the 
proceeding steps that lead to a suppression of the cellular anti-viral response.   
 The concept of ADE (as opposed to the competing ‘cytokine storm’ explanation) 
causing severe disease in DENV infected patients has been a topic of much debate for several 
decades (118). Because DENV is an obligate pathogen of humans (including non-human 
primates) and the mosquito vector, there is no natural DENV small-animal model, which has 
hampered in vivo investigations of ADE. Although DENV infection is generally 
asymptomatic in non-human primates, DENV replicates to low titers in several non-human 
primate models. DENV infection following passive transfer of DENV-immune sera or 
DENV-specific MAbs into monkeys showed signs of ADE through a 10-100-fold increase in 
viremia, when compared to virus only treated monkeys (41, 50). However, since non-human 
primates do not show severe DENV-like symptoms, they are not considered a very good 
animal model for dengue disease/DHF. One of the most successful animal models for 
studying ADE of DENV is the type I and II IFN receptor knockout mouse model, AG129 
(148). When AG129 mice are passively injected with DENV-specific MAbs or polyclonal 
sera and then challenged with a mouse adapted virus strain, within 5 to 6 days the mice 
develop a lethal vascular leakage disease that is similar to DHF in humans. During ADE, The 
infected cells within the AG129 are FcR-bearing cells (such as monocytes and macrophages 
etc), and sinusoidal endothelial cells in the liver (5, 167). Similar to the DENV-induced 
disease in humans, the lethal vascular leakage disease in these mice also presents 
thrombocytopenia and elevated levels of cytokines, such as TNFα, IL-6 and IL-10 (5, 167). 
	  
	  
26	  
Therefore, although the absence of type I and II IFN-receptors makes the AG129 mouse 
model imperfect for studying immune responses to DENV, it represents the human DHF 
disease closely and serves well as a passive antibody transfer model for mapping out the 
DENV epitopes targeted by enhancing antibodies. Almost all DENV-specific MAbs or 
polyclonal sera, whether neutralizing or not, when diluted out far enough, will enhance 
DENV infection. Therefore, it is critical to identify the heterotypic DENV epitopes targeted 
by antibodies in human sera at physiological concentrations. Determining the targets of 
enhancing antibodies in human sera will hopefully enable the design of safer, non-DENV-
enhancing vaccines.  
1.9 Prospective DENV vaccines  
 The presence of four related serotypes, each capable of inducing cross-reactive 
antibodies that at sub-neutralizing concentrations can enhance infection of heterotypic virus, 
makes DENV vaccine development a very challenging task. Vaccine developers have several 
factors to keep in mind when trying to create a DENV vaccine (reviewed in (104)). First, 
since most DENV endemic countries have all four DENV serotypes co-circulating, it is 
imperative that the vaccine elicits a protective response against each of the four serotypes. 
Second, this protective response needs to be life-long. If antibody levels fall to sub-
neutralizing levels, this places the vaccinee at risk of enhanced DENV infection and 
therefore, more severe disease. Third, as with all vaccines, a DENV vaccine must be safe and 
produce minimum symptoms in the recipients. Fourth, the immunization protocol must 
include the entire population, since even adults are at risk from tertiary and quaternary 
infections. Finally, since the countries most affected by DENV are developing countries with 
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poor health care, any approved DENV vaccine must be economical and affordable for 
individuals residing in these countries. 
 Scientists are using many strategies to develop a DENV vaccine. Nonliving vaccine 
platforms being tested against DENV are inactivated subunit, subviral particles and whole 
virus vaccine. Although, nonliving vaccines have the advantage of being safe, these vaccines 
are not very efficient at stimulating strong adaptive responses, and hence require adjuvants 
and serial boosts. Furthermore, subunit vaccines currently being developed using E 
ectodomain protein do not present the immune system with the same repeated E protein raft 
structure that is displayed on the whole virion. Several studies have pursued the development 
of subviral particle through the expression of prM and E proteins, where vaccine recipients 
are either immunized with purified subviral particles (84) or with viral vectors (such as 
adenovirus, vaccinia, or alphavirus) that express DENV prM and E proteins (37, 116, 157, 
158). Although subviral particles have a T=1 symmetry, they also lack some of the complex 
epitopes formed when E assembles into the virion particle. Whether this repeated E protein 
raft structure is essential for raising life-long DENV neutralizing antibodies is unclear. 
 The three DENV vaccines most advanced in clinical trials are live attenuated 
vaccines. One is a live, attenuated DENV vaccine (LAV) developed by the National Institute 
of Health. This vaccine contains a DENV4 genetic background with attenuation mutational 
deletions within the 3’UTR region. The prM and E proteins from the three other serotypes 
were inserted into this attenuated DENV4 background. This vaccine has just passed phase I 
clinical trials, and there have also been successful human challenge studies (140). The second 
LAV, DENVax, was initially developed by the Center for Disease Control (CDC) and later 
acquired by the private company, Inviragen (110). This vaccine utilizes the weakened 
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DENV2 strain, PDK-53, into which the prM and E proteins from the other three serotypes 
are inserted. This vaccine is also in clinical trials at the moment. The third LAV, 
ChimeriVax, is a chimeric virus between DENV and the highly successful (and presently 
licensed) yellow fever vaccine strain, YFV 17D (46).  The prM and E proteins are expressed 
in the YFV 17D background, thereby producing 4 chimeric, monovalent viruses. This 
ChimeriVax vaccine, designated CYD-TDV (licensed by Sanofi Pasteur) has reached phase 
IIB clinical trials. Unfortunately, these clinical trial data, published late last year, showed that 
this vaccine had an overall protective efficacy of only ~30% against natural DENV 
infections, with no protection against DENV2 infections (125). Several hypotheses about 
genotypic differences between immunized and circulating viruses are being put forward 
(unpublished data from Sanofi Pasteur). Since we know that the most successful DENV 
immunizations in humans at present are natural infections, we need to ask another vital 
question; are the vaccines being developed eliciting similar T cell and B cell responses as 
natural wild type DENV infections? Unfortunately, with very little known about the DENV 
epitopes targeted by protective T cells and neutralizing antibodies, the answer to this question 
is still pending.    
1.10 Objectives of this dissertation 
 At a time when DENV is endemic in over 100 countries with over 390 million new 
infections globally, we known very little about the neutralizing and enhancing human 
antibody response after a natural DENV infection. The lack of a suitable animal model led to 
the generation of MAbs in immune-compromised mouse models (39). For many years, 
mouse MAb based studies were used to gain insight into the neutralization and enhancement 
of DENV. Type-specific neutralization was mapped to DIII of the E glycoprotein (25, 80, 85, 
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123, 138, 139). However, as described above, more recent studies have clearly shown that 
EDIII is not the target of human neutralizing antibodies following natural flaviviral infections 
(107, 127, 153, 154). Therefore, there is a significant knowledge gap in our understanding of 
the epitopes targeted by the human antibody response after a natural DENV infection. One of 
the goals of this dissertation is to expand our knowledge of the human antibody response 
after primary DENV infections. To achieve this goal, we have devised a simple technique to 
fractionate DENV-specific antibodies in human immune sera into groups, and then 
characterize their binding and functional properties. Additionally, in collaboration with other 
groups, we have also generated, isolated and characterized the binding and functional 
properties of DENV-specific human MAbs from individuals with past natural DENV 
infections.	  
 A recent study has mapped a potently neutralizing anti-WNV human MAb to a 
complex viral surface epitope centered on the DI-DII hinge region of the E protein. This 
epitope is not conserved on the soluble E protein and hence, this potent anti-WNV MAb does 
not bind soluble E protein (69, 151). Primary DENV-immune human sera are very reactive to 
soluble DENV E protein from all serotypes. Despite the large cross-reactivity across 
serotypes, late convalescent sera after primary DENV infections only neutralize the serotype 
of infection. This indicates that the neutralizing antibodies in human sera are very rare and 
possibly very difficult to isolate. Fortunately, advances in human B-cell technologies have 
vastly improved the transformation and fusion of human memory B-cells, so that even rare 
populations of memory B-cells can be isolated and the secreted MAbs can be characterized 
(7, 57, 144, 165). Another central goal of this dissertation is to isolate and characterize 
strongly neutralizing human MAbs, and identify the neutralizing epitopes targeted by human 
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antibodies. Successful characterization of the neutralizing epitopes will allow us to probe and 
understand the mechanisms of DENV neutralization by human MAbs, and how they differ 
from those already described using DENV-specific mouse MAbs.      
 Almost any DENV-specific MAb (binding E or prM protein) can enhance DENV 
infection in vitro. Therefore, the importance of characterizing the enhancement properties of 
MAbs is unclear. What is critical is to define the epitopes of antibodies in DENV-immune 
human sera that enhance infection of heterotypic serotypes. Hence, the third goal of this 
dissertation is to characterize the epitopes targeted by human polyclonal antibodies that 
enhance heterotypic infection. These experiments will be conducted using in vitro ADE 
assays and the in vivo AG129 mouse model. In summary, the primary goal of this 
dissertation is to expand our understanding of the neutralizing and enhancing human 
antibody response to DENV, for purposes of understanding the biology of antibody-mediated 
protection in DENV infection and for the rational development of successful vaccines.     
  
  
Hypothesis: We hypothesize that humans exposed to primary dengue infections develop two 
unique antibody sub-populations that 1) neutralize homotypic and 2) enhance heterotypic 
serotypes of virus. Moreover, we propose that human antibodies neutralize DENV at a post-
attachment step by binding to novel conformational epitopes that include the DI-DII hinge of 
the dengue envelope (E) protein. 
 
Aim 1. To characterize the binding and neutralization properties of the human antibody 
response to natural DENV infections, by studying the DENV-specific memory B-cell and 
plasma cell response.  
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Aim 2. To map and characterize the neutralizing epitope(s) targeted by the human antibody 
response after a natural DENV infection, by mapping both DENV-immune human polyclonal 
sera and strongly neutralizing human monoclonal antibodies.  Furthermore, mechanistic 
studies will be conducted to gain insight into the mechanism of DENV neutralization by 
human antibodies.   
Aim 3. To determine the epitopes of enhancing antibodies circulating in humans after a 
primary DENV infection. In vitro observations will be extended to in vivo experiments, using 
the AG129 ADE mouse model.  
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Figure 1.1 DENV genome and life cycle. A) The DENV RNA is translated into 10 
proteins, (i.e. 3 structural and 7 non-structural proteins) which are processed by viral and 
host proteases. B) The DENV virion binds its putative receptor and enters the host cell 
through clathrin-mediated endocytosis, undergoes low pH fusion with the host membrane 
in the late endosome, undergoes replication and translation in the cytosol, assembly in the 
ER, post-translational modifications and processing of the virion in the TGN, after which 
infectious virions are exocytosed. During different stages in the DENV life cycle, the 
virion can exist in one of three important virion structures, i.e. 1) mature virion, 2) 
immature virion, and 3) the post-fusion conformation.  C) The effects on virion structure 
and prM-E conformation before, during and after prM processing. Figures A) & C) taken 
and modified from Perera, R et al, Current opinions in microbiology, 2008, while figure 
B was taken and modified from Mukhopadhyay, S et al, Nature reviews microbiology, 
2005 (103, 111). 
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Figure 1.2 DENV E glycoprotein structure and its arrangement on the mature virion. 
A) Six E proteins are arranged into 30 repeated E protein raft structures, which assemble into 
the infectious DENV virion with 5-3-2 axes of symmetry. B) Each E protein raft is made of 
three E protein dimers. C) Flaviviral E protein is a transmembrane glycoprotein, made of 
three distinct domains, two amphipathic helices, conserved stem region and two 
transmembrane helices. Figure panels A), B) & C) were taken and modified from 
Mukhopadhyay, S et al, Nature reviews microbiology, 2005 (103).     
 
	  
	  
	  
A C
B3’ 3’
5’
2’
	  
	  
35	  
 
 
Figure 1.3 DENV E protein undergoes large conformational changes during virus 
maturation and viral fusion. A) X-ray crystallographic structure of the post-fusion 
conformation of DENV2 E protein. B) The EDI-DII hinge angel changes drastically during 
virus maturation and fusion with host membrane. Figure modified from Mukhopadhyay, S et 
al, Nature reviews microbiology, 2005 (103).   
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Figure 1.4 The antibody response in humans following natural primary DENV 
infections. Protective polyclonal response after a primary DENV infection is only transiently 
cross-protective, while life-long protection is type-specific and against the serotype of 
infection.  
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Figure 1.5 Epitope mapping of DENV-specific mouse MAbs. While neutralizing mouse 
MAbs against DENV have been mapped to all domains within the E protein (A), the majority 
of mouse MAbs were mapped to the lateral ridge and A-strand epitopes of EDIII (B). Image 
taken and modified from Wahala, WMPB et al, PLOS Pathogens, 2010 (152).  
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Figure 1.6 Structural dynamics, virion maturation and presence of complement affect 
the antibody threshold of DENV neutralization. Using mouse MAbs, successful 
neutralization of DENV was predicted to require at least ~30 antibody molecules bound per 
virion. It is predicted that antibody-virion stoichiometry less than the ~30 threshold will 
provide conditions for ADE. Image taken from Dowd, KA et al, Virology, 2011 (33).        
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Figure 1.7 Antibody dependent enhancement of DENV. In the presence of sub-
neutralizing concentrations of DENV-specific antibodies (IgG), antibody-coated virus can 
enter FcR-bearing cells (such as monocytes and macrophages), suppress the host cell anti-
viral response and release high viral loads. Image taken and modified from Murphy, BR et al, 
Annu. Rev. Immunol., 2011 (104). 
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CHAPTER TWO 
In-depth analysis of the antibody response of individuals exposed to primary  
dengue virus infection 
  
2.1. Overview 
Humans who experience a primary dengue virus (DENV) infection develop 
antibodies that preferentially neutralize the homologous serotype responsible for infection. 
Affected individuals also generate cross-reactive antibodies against heterologous DENV 
serotypes, which are non-neutralizing.  Dengue cross-reactive, non-neutralizing antibodies 
can enhance infection of Fc receptor bearing cells and, potentially, exacerbate disease. The 
actual binding sites of human antibody on the DENV particle are not well defined. We 
characterized the specificity and neutralization potency of polyclonal serum antibodies and 
memory B-cell derived monoclonal antibodies (hMAbs) from 2 individuals exposed to 
primary DENV infections.  Most DENV-specific hMAbs were serotype cross-reactive and 
weakly neutralizing.  Moreover, many hMAbs bound to the viral pre-membrane protein and 
other sites on the virus that were not preserved when the viral envelope protein was produced 
as a soluble, recombinant antigen (rE protein). Nonetheless, by modifying the screening 
procedure to detect rare antibodies that bound to rE, we were able to isolate and map human 
antibodies that strongly neutralized the homologous serotype of DENV. Our MAbs results 
_____________________ 
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indicate that, in these two individuals exposed to primary DENV infections, a small fraction 
of the total antibody response was responsible for virus neutralization. 
2.2 Introduction 1 
 2 
Dengue virus (DENV) complex consists of 4 serotypes. People exposed to primary 
DENV infections develop robust antibody responses that cross-react with all serotypes 
(Reviewed in (30)). Despite the extensive cross-reactivity, individuals only develop long 
term, protective immunity against the homologous serotype responsible for the primary 
infection (11, 32). Indeed, the risk of progressing to DHF is greater during secondary 
compared to primary infection (12). A prevailing theory that explains severe dengue during 
secondary infection is that pre-existing, non-neutralizing dengue specific antibodies enhance 
DENV entry and replication in Fc-receptor-bearing cells, which leads to a higher viremia and 
more severe disease (12). Antibodies have been demonstrated to enhance DENV in cell 
culture (13, 14) and in animal models of dengue pathogenesis (1, 8, 43).  
Our current understanding of how antibodies interact with DENV and other 
flaviviruses is primarily based on studies utilizing mouse monoclonal antibodies (MAbs) 
(Reviewed in (26)). The DENV envelope (E) protein is the principle target of neutralizing 
antibodies. Antibody neutralization occurs by blocking critical functions of the E protein, 
including attachment to host cells and low pH-dependent fusion of the viral and host cell 
membranes (27). The crystal structures of the E protein of several flaviviruses have been 
solved (19, 20, 23, 28). Individual subunits of E protein consist of three beta-barrel domains 
designated domains I (EDI), II (EDII) and III (EDIII), with the native protein forming a 
head-to-tail homodimer. Mouse MAbs that bind to all three domains of DENV E have been 
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generated and characterized (6, 9, 10, 17, 18, 31, 36, 37). Although neutralizing mouse MAbs 
have been mapped to all three domains of E, the most strongly neutralizing MAbs recognize 
epitopes on the lateral ridge and A strand of EDIII (35). 
Following a primary DENV infection, humans develop antibodies that cross-react 
with all 4 serotypes, but mainly neutralize the homologous serotype responsible for the 
infection (Reviewed in (32)). Studies with human immune sera and, more recently, human 
monoclonal antibodies have demonstrated that the dominant antibody response is cross-
reactive and weakly neutralizing (2, 5, 7, 16, 34, 40). Multiple viral antigens including E 
protein, pre-membrane (prM/M) protein and non-structural protein 1 (NS1) are recognized by 
the human humoral response (2, 5, 7, 16, 34, 40). Nonetheless, few studies have defined the 
actual epitopes of DENV recognized by type-specific and cross-reactive human antibodies at 
the structural level and compared this to the epitopes defined using mouse antibodies. The 
target(s) of dengue type-specific, strongly neutralizing human antibodies remain unknown. 
The goal of this study was to study two subjects in-depth to define the major antigens and 
epitopes recognized by antibodies that develop following primary human DENV infection. 
Defining the human B-cell epitopes on DENV is a key step towards understanding how 
antibodies can both enhance and inhibit the severity of DENV infections. 
 
2.3   Materials and Methods 
 
Viruses, recombinant proteins and immune sera. 
 DENV1 WestPac-74, DENV2 S-16803, DENV3 CH-53489, and DENV4 TVP-360, 
provided by Dr. Robert Putnak (Walter Reed Army Institute of Research, Silver Spring, MD) 
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were used in the present study (40).  Recombinant envelope (rE) proteins from the 4 DENV 
serotypes were kindly provided by Dr. Beth-Ann Coller (Hawaii Biotech, Inc) (19). The 
recombinant proteins bind to conformational MAbs and X-ray crystallography studies have 
demonstrated that these proteins retained a native-like structure (19, 20). Convalescent 
DENV immune sera were obtained from volunteers who had experienced natural DENV 
infections during travel abroad. The protocol for recruiting and collecting blood samples 
from people was approved by the Institutional Review Board of the University of North 
Carolina at Chapel Hill. Written informed consent was obtained from all subjects before 
collecting blood. 
 
Whole DENV and recombinant E antigen ELISAs  
 ELISA plates were coated with 50 ng of purified virus or 100 ng of rE in carbonate 
buffer at pH 9.6 for 2 hrs at room temperature and incubated with blocking buffer (0.05% 
TBS-T containing 3% skim milk or 3% normal goat serum) at 37oC for 1 hr. Human immune 
sera or hMAbs serially diluted in blocking buffer were added for 1hr at 37oC followed by 
alkaline phosphatase-conjugated goat anti-human IgG (Sigma) for 1 hr at 37°C. Finally, p-
nitrophenyl phosphate substrate (Sigma) was added to each well and the reaction was 
allowed to develop for 15 minutes before recording optical density at 405 nm on a 
spectrophotometer. 
 
DENV Neutralization assays 
 DENV neutralizing antibodies was measured by a focus reduction neutralization test 
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(FRNT) with Vero cells or using a flow cytometry-based neutralization assay with the U937 
human monocytic cell line stably transfected with DC-SIGN as previously described (15).  
 
Production of human MAbs (hMAbs) from dengue immune travelers 
 Peripheral blood samples were obtained from two healthy adult donors who were 
infected by DENV during foreign travel. The dengue neutralization profiles confirmed 
previous primary DENV2 (Donor 013) and DENV3 (Donor 033) infections (Table S1). From 
both donor hMAbs were produced as previously described (3). B-cells producing DENV 
specific antibody were identified by screening culture supernatants by flow cytometry for 
antibodies that bound to C6/36 insect cells infected with DENV2 (Donor 013) or DENV3 
(Donor 033) (3). A secondary screen to identify antibodies that bound to the rE was 
performed by ELISA as previously described (3). 
 
Epitope mapping of EDIII binding hMAbs 
 DENV antibody escape mutant viruses were selected for by infecting Vero cells with 
DENV2 (strain S-16803) in the presence of hMAb concentrations estimated to neutralize 
greater than 99% of infectious virus (i.e. 1.0 µg/ml for DVC 3.7 and 1.5 µg/ml for DVC 
10.16).  Equivalent GC copy numbers of control and antibody treated viruses were repeatedly 
passaged in the presence of hMAbs until equivalent DENV genomic copy numbers were 
observed for MAb treated and control samples (4-6 passages under antibody pressure). 
Escape mutant viruses were plaque purified and amplified. E genes were amplified by RT-
PCR and sequenced to identify mutations linked to antibody escape. Antibody binding sites 
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were also mapped by using yeast cells expressing a library of EDIII as previously described 
(25). Mutations were mapped onto the DENV2 EDIII structure using the atomic coordinates 
of DENV2 EDIII (RCSB accession number 1OAN) and displayed using PyMOL Molecular 
Graphics System, Version 1.3 (Schrödinger, LLC).  
 
2.4   Results 
The objective of the current study was to characterize the primary human antibody 
response to DENV by comparing immune sera and MAbs derived from two individuals 
previously exposed to primary DENV infections. Donor 033 had reported a high fever 
following a visit to India in 2005 and laboratory investigations confirmed a primary DENV3 
infection (data not shown). One year later, when serum and peripheral blood mononuclear 
cells (PBMCs) were isolated, the subject had a neutralizing antibody response that primarily 
targeted DENV3 (Table S1). Donor 013 developed a fever, clinically diagnosed as dengue, 
while visiting a Pacific Island in 1996. Eight years later when serum and PBMCs were 
isolated for the current study, the subject had a neutralizing antibody profile consistent with a 
past primary DENV2 infection (Table S1). 
Initially we characterized the binding properties of serum polyclonal antibodies in 
both subjects using purified DENVs and recombinant DENV E proteins from the 4 serotypes. 
We calculated endpoint titers (reciprocal of highest serum dilution that was positive in the 
assay) to estimate relative levels of antibody against whole virus and rE antigens (Table 1). 
The quantity of antibody binding to E was only 10 to 35% of the quantity that bound to 
whole virus suggesting that antibodies bound to sites on the virus that were not present on rE 
protein (Table 1). Thus, in both subjects the predominant antibodies binding to dengue 
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virions were serotype cross-reactive and directed to epitopes on the virus and, to a lesser 
extent, to epitopes on rE protein.  
 
Identification of DENV-reactive memory B cells following primary infection 
We have previously reported that dengue reactive memory B cells are common 
following both primary and secondary DENV infection (2). To further characterize the 
human B cell response in donor 033, we immortalized memory B cells. PBMCs were isolated 
and IgG+ memory B cells were immortalized with EBV and CpG as previously described 
(38). The immortalized B cell culture supernatants were screened for antibodies that bound to 
C6/36 insect cells infected with DENV3. Thirty five percent of the B cell cultures generated 
from donor 033 was positive following this initial screen (Table 2). From the dengue positive 
cultures only 7.5% of the cultures bound to rE protein (Table 2). To further characterize the 
binding and functional properties of human antibodies, we isolated hMAbs from donor 033.  
 
Isolation and characterization of DENV-specific hMAbs from donor 033  
To isolate hMAbs specific for DENV from donor 033, positive B cell cultures were 
cloned by limiting dilution and 16 clones were isolated and expanded. All the hybridomas 
produced IgG1 with the single exception DV20.10, which was IgG3 (Table S2). To identify 
antibodies that bound to structural viral antigens, the hMAbs were tested for binding to 
purified DENV3 particles in ELISA. Fourteen out of 16 hMAbs bound to DENV3 virus.Of 
the 14 hMAbs that bound to DENV3 particles, 13 hMAbs cross-reacted with all  four dengue 
serotypes dengue complex reactive and one antibody (hMAb DV51.3) bound to serotypes 1 
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and 3, but not 2 and 4 (dengue sub complex reactive)(Table S2). Dengue virions were 
solubilized and subjected to Western blot analysis to identify the viral structural proteins 
recognized by hMAbs. Ten of the 14 hMAbs bound to prM and only a single hMAb 
(DV64.3) bound to E protein (Figure 1). Three hMAbs did not bind to viral antigens by 
Western blot, although they reacted with DENV3 virion. The 16 hMAbs were also tested for 
binding to rE protein in ELISA. Only hMAb DV64.31, which had also recognized E protein 
by Western Blot, bound to rE protein from all 4 DENV serotypes (Table S2).  
We next tested the ability of the 16 antibodies generated from donor 033 to neutralize 
DENV. Five hMAbs, including the two that did not bind to the virion, lacked neutralizing 
activity (Figure 2). The remaining antibodies ranged from weak to moderately neutralizing 
and had DENV3 50% neutralization titers that ranged from 0.09 to 1 µg/ml (Figure 2A). The 
neutralizing antibodies had similar 50% neutralization titers against all 4 serotypes, which 
was consistent with their broad binding specificity (data not shown). In general, prM 
antibodies had neutralization curves that were shallow and did not reach 100% neutralization, 
indicating that a fraction of the virus population was resistant to antibody neutralization 
(Figure 2B). The single E reactive antibody (DV64.31) exhibited a steeper neutralization 
curve and neutralized 100% of virus at high concentrations (Figure 2C). In summary, the 
hMAbs generated from donor 033, who had experienced a primary DENV3 infection, were 
broadly cross-reactive, weakly neutralizing, and mainly directed to epitopes on prM. None of 
the hMAbs mimicked the functional properties of immune serum from donor 033 that 
displayed strong type-specific neutralization of DENV3 (Table S1). A complete summary of 
the functional profiles of all sixteen hMAbs from donor 033 is included as supplementary 
material (Table S2).  
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Characterization of Human MAbs generated from donor 013 
Next, we characterized the dengue specific memory B cell response in donor 013, 
who had recovered from a primary DENV2 infection. We have previously reported on some 
of the properties of B cells and hMAbs generated from this donor (2). Here we expand on 
these previous results by comparing properties of serum antibodies and hMAbs from this 
donor and by epitope mapping a subset of hMAbs from this donor. When immortalized B 
cell culture supernatants from donor 013 were screened for antibodies that bound to C6/36 
insect cells infected with DENV2, 28% (567/2016) of the cultures were found positive for 
DENV-specific B cells following this initial screen (Table 2). From the DENV positive 
cultures only 2.9% of the cultures bound to rE protein (Table 2). Thus, as in the case of donor 
033, although dengue specific memory B cells were frequent, only a small fraction of the 
positive cultures from donor 013 produced antibodies that bound to rE protein.  
Since a relatively unbiased selection scheme for producing hMAbs from donor 033 
indicated that most hMAbs were cross-reactive, weakly neutralizing and directed to antigens 
other than rE, we altered the selection scheme for donor 013 to enrich for hMAbs that 
recognized rE from DENV2. After the initial screening of memory B cell culture 
supernatants, the relatively rare rE protein binding cultures were selected for cloning and 
expansion. Ten rE binding hMAbs were produced (all IgG1). When the antibodies were 
tested for binding to heterologous serotypes, 5 hMAbs were DENV2 type-specific, 2 hMAbs 
were dengue subcomplex-specific and 3 hMAbs were dengue complex-specific (Figure 3A). 
Six of the ten hMAbs bound to EDIII from DENV2 (Figure 3A). The hMAbs from donor 
013 displayed variable neutralization properties (Figure 3A-C), with 2 non-neutralizing 
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hMAbs (DV1.6, and 21.5; 50% neutralization titers > 1 ug/ml) , 4 weakly to moderately 
neutralizing hMAbs (DV14.21, 35.3, 25.5 and 18.21;50% neutralization titers between 0.1 
and 1 ug/ml) and 4 strongly neutralizing hMAbs (DV3.7, 10.16, 13.6 and 23.13; 50% 
neutralization titers < 0.1 ug/ml). The strongly neutralizing hMAbs, including those that were 
cross-reactive in binding assays, neutralized DENV2 better than the other serotypes (Figure 
3). Thus, by biasing the initial screen for hMAbs that bound to rE protein, we identified 
hMAbs with neutralization profiles that were more similar to the immune sera of donor 013, 
which strongly neutralized DENV2. 
Epitope mapping donor 013 hMAbs binding to EDIII 
Several hMAbs from donor 013 bound to EDIII (Figure 3). Two approaches were 
used to map the binding sites of these hMAbs on EDIII. Two strongly neutralizing hMAbs 
that bound EDIII, which were type- (DV3.7) or subcomplex- (DV10.16) specific, were 
mapped by identifying neutralization escape variants after passaging DENV2 in the presence 
of each antibody (Figure 4A and B). When the escape mutants were sequenced, each had 
acquired a mutation on EDIII. The virus passaged in the presence of hMAb DV3.7 acquired 
the single point mutation V382G (Table 3 and Figure 4C). This residue is located on the 
EDIII lateral ridge, which is a target of previously mapped type-specific strongly neutralizing 
mouse MAbs (9, 37) (Table 3 and Figure 4C). The virus passaged in the presence of hMAb 
DV10.16 acquired the point mutation E311K (Table 3 and Figure 4C). This amino acid is 
located on the A strand of EDIII and forms part of a dengue subcomplex epitope recognized 
by neutralizing mouse MAbs (10, 37) (Table 3 and Figure 4C). 
As an independent approach to mapping EDIII-reactive hMAbs, we used a yeast surface 
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display assay that has been previously used to map numerous flavivirus antibodies (25, 36, 
37). Table 3 summarizes all mutations that resulted in loss of binding or neutralization of 
EDIII antibodies generated from donor 013. All the human EDIII-binding MAbs mapped to 
the lateral ridge or the A strand regions that have previously been described as targets of 
mouse MAbs (37) (Figure 4C).  
2.5  Discussion 
Our main objective was to define viral antigens and epitopes recognized by 2 
individuals exposed to primary DENV infections. In both these subjects the dengue virion 
was a major target of the humoral immune response but many of these antibodies did not 
bind to rE protein. The DENV virion displays 180 E and 180 prM or M proteins that are 
arrayed with pseudo-icosahedral symmetry. Depending on the maturation state of the virus 
particle, the 180 E protein molecules are organized as 90 head-to-tail dimers that lie flat on 
the virion surface or 60 trimers that protrude as spikes from the surface (21). Since the E 
protein, with ~500 amino acids, is considerably larger than the 166 amino acid prM protein, 
the majority of surface exposed viral protein consists of the ectodomain of E. Thus, our 
finding that many antibodies bound to epitopes on the virus that were not preserved on rE 
was somewhat unexpected. These findings are consistent with the results of another study 
from our group (2) as well as a study by Dejnirattisai and colleagues who observed that many 
hMAbs that bound to DENV particles did not bind to rE protein (7).  As the rE protein used 
in the current study lacked ~20% of the protein, which include the membrane proximal 
regions and the transmembrane domains, it is possible that some antibodies bind to these 
regions. Moreover, antibodies may recognize E protein epitopes that are only available in the 
context of the native oligomeric array on the virion. Several hMAbs generated from 
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individuals infected with West Nile virus bound the virion but not rE protein; these hMAbs 
recognized epitopes that were created by adjacent E protein molecules on the surface of the 
virion or formed by hinge regions (39).  
When producing MAbs from donor 013, we increased the probability of identifying 
strongly neutralizing antibodies by biasing the selection scheme for MAbs that specifically 
recognized rE protein.  In contrast to the weak or non-neutralizing hMAbs isolated from 
donor 033, several hMAbs from donor 013 displayed strong type-specific DENV2 
neutralization. Of note, even hMAbs from donor 013 that bound to more than one serotype 
(dengue subcomplex or complex MAbs) displayed type-specific neutralization of DENV2, 
which was the serotype that infected donor 013. Thus, by biasing the selection to enrich for 
rare rE protein binding antibodies, we generated hMAbs from donor 013 that were 
functionally similar to the polyclonal immune serum from the same donor that neutralized 
only DENV2.  It is unclear how the results with hMAbs relate to the neutralization properties 
of polyclonal immune serum from these donors.  One possibility is that the abundance of 
hMABs reflects the functional properties of antibodies in immune sera, where a small 
fraction of DENV-specific antibodies in immune sera are responsible for neutralization.  
Alternatively, it is conceivable that individual antibodies that are weakly neutralizing become 
strongly neutralizing due to cooperative effects that only occur in a polyclonal milieu.  
Further studies are needed to understand how the properties of hMABs from DENV immune 
donors relate to the properties of circulating serum antibody. 
 From the neutralizing MAbs from donor 013 that bound to rE, some bound to the 
lateral ridge and A strand epitopes on EDIII. We also identified several neutralizing hMABs 
(35.3, 18.21, 13.6, 23.13) that bound to rE but not EDIII and these antibodies most likely 
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bind to epitopes on EDI or EDII.  We are especially interested in mapping the binding sites 
of these hMABs as recent studies indicate that epitopes other than the lateral ridge and A 
strand of EDIII can be the targets of strongly neutralizing mouse, horse  and primate 
antibodies (24, 33, 40) (8, 36),   
Our results indicating that prM was a dominant target of the primary antibody 
response are in agreement with other recent studies (2, 7). The prM protein is required for the 
proper folding and assembly of flavivirus particles in the endoplasmic reticulum (42), while 
also preventing adventitious fusion of the virus (41) in the acidic environment of the trans-
Golgi network. Recent studies have demonstrated that DENV virions produced in cell culture 
are often partially processed and contain a mixture of unprocessed prM and fully processed 
M (4). The maturation state and relative amount of prM on a virion can alter the potency of 
antibodies that bind specific epitopes on E, including the cross-reactive antibodies that bind 
the fusion loop in DII (22). Additionally, immature, non-infectious particles became 
infectious in the presence of prM antibody by enhancing the ability of immature dengue 
virions to infect Fc-receptor bearing cells in vitro (7, 29). Given our findings and those of 
others (7) establishing that prM antibodies are common following primary and secondary 
DENV infections, more work needs to be performed to address their contribution to dengue 
pathogenesis in humans.  
In summary, the studies reported here demonstrate an unexpected antibody profile in 
two individuals following primary dengue infection. In both individuals a majority of the 
DENV-specific human antibodies were broadly cross-reactive and weakly neutralizing. 
Many antibodies bound to prM and sites on the virus that were not preserved on rE protein.  
Only a minor fraction of the total dengue specific antibody response was responsible for 
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potent neutralization of the homologous virus. Given the difficulty of identifying suitable 
donors and generating antigen specific hMAbs, we only characterized the antibody response 
in two subjects here. Further studies with more dengue immune subjects are needed to 
determine if our findings are broadly applicable to primary dengue exposure.   
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Figure 2.1  Antigens recognized by hMAbs produced from donor 033. DENV3 virions 
were purified and the viral proteins were separated by SDS-polyacrylamide gel 
electrophoresis.  Western blots were performed to identify the viral antigens recognized by 
hMAbs from donor 033. The figure displays Western blot results for selected hMAbs that 
bound to E protein (64.31) and prM protein (DV38.1, 59.3, 65.5, 4.3, 11.12, and 18.5). 4G2 
and 2H2 are control mouse MAbs that bind E and prM proteins, respectively.  
  
74 
 
 
Figure 2.2  DENV3 neutralization by donor 033 human MAbs. The 50% neutralization 
titers against DENV3 were determined for all 16 hMAbs from donor 033 using a flow 
cytometry based neutralization test that utilizes U937 cells expressing DC-SIGN. (A) Dengue 
antigen recognized and the 50% neutralization titer for each hMAb. The hMAbs for which a 
specific antigen has still not been identified are designated with a *?*. (B) Neutralization 
curves for three representative prM antibodies. Note that prM antibodies have shallow 
neutralization curves, which plateau when ~60% of the virions are neutralized. (C) 
Neutralization curve of the only E protein reactive antibody obtained from donor 033. This 
antibody has a steeper neutralization curve compared to prM antibodies.    
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Figure 2.3  Binding and neutralization properties of donor 013 hMAbs. Ten hMAbs 
from donor 013 were tested for binding dengue virus, recombinant E (rE) and EDIII from 
DENV2. Cross-reactivity was determined by using whole virus antigen from all four 
serotypes. For each hMAb the 50% neutralization titer was determined using flow cytometry 
and U937 cell expressing DC-SIGN. (A) Summary of the binding and neutralization data for 
all hMAbs from donor 013. B, C and D display representative neutralization curves for 
DENV2 type-specific (B), subcomplex- specific (C) and complex-specific (D) hMAbs.  
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Figure 2.4 Epitope mapping of anti-DENV2 hMAbs binding to EDIII. To identify 
antibody binding sites, DENV2 was serially passaged in the presence of neutralizing hMAbs 
DV3.7 or DV10.16. Viruses growing in the presence of hMAbs were plaque purified and 
expanded. Neutralization escape was confirmed by growing the parental and the cloned 
antibody selected viruses in the presence of each hMAb 3.7 (A) or hMAb 10.16 (B).  (C)  
Localization of neutralizing human antibody epitopes on the structure of DENV2 EDIII 
(strain 16681) using residues identified by neutralization escape selection (blue) or yeast 
surface display screening (see Table 3) (orange). Ribbon diagram of DENV-2 EDIII was 
generated from a published X-ray crystallographic structure.  The disulfide bond is 
highlighted in yellow. Human MAbs 3.7 and 25.5 are type-specific antibodies that bind to 
epitopes centered on the lateral ridge while 10.16 is sub-complex-specific and bind to an 
epitope centered on the A strand of EDIII. 
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Table 2.1 Relative levels of virus and rE protein binding antibody in immune sera 
End point binding titer
a Serum Serotype 
Whole virus   rE protein 
rE antibody 
relative to whole 
virus antibody (%)
b 
DENV1 3,579 358 10 Serum 013 
(primary DENV2) DENV2 8,906 1,536 17 
 DENV3 3,579 1,242 35 
 DENV4 3,141 485 15 
     
DENV1 13,164 1,338 10 Serum 033 
(primary DENV3) 
  DENV2 8,906 2,050 23 
 DENV3 20,768 6,931 33 
 DENV4 12,334 1,815 15 
 
 
 
   
 
 
 
 
a 
The end point binding titers are based on ELISAs performed with virus or recombinant E (rE) protein 
antigen and serial dilutions of immune serum. The end point titer was the reciprocal of the highest 
dilution that produced a signal 2 standard deviations above the signal for normal human sera. 
b 
The amount of antibody that bound to rE protein relative to the virus was calculated using the 
following formula: (end point titer for rE antigen/end point titers for whole virus)X 100. When endpoint 
titers were calculated using a E protein cross reactive mouse MAb (4G2), similar end point titers were 
obtained for well coated with virus or recombinant E indicating both antigens had a similar number of 
accessible E molecules. 
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Table 2.2 Screen for isolating DENV-specific human MAbs 
Donor No. of positive cultures 
after primary screen
a 
Proportion of DENV positive 
cultures binding to rE protein
b 
No. of human MAbs 
produced
c Reference 
033 (primary DENV3) 332/960 (35%) 7.50% 16 This study 
013 (primary DENV2) 
567/2016 (28%) 2.90% 10 Betramello et 
al 2010 
 a Primary screen was conducted by flow cytometry using C6/36 cells infected with the homologous serotype. 
b 
Proportion of rE protein reactive cultures was determined by ELISA using recombinant protein from homologous virus. 
c 
For donor 013, the selection of cultures for DENV-specific MAb production was biased to enrich for rE and EDIII reactive MAbs.  
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Table 2.3 Epitope mapping DENV2 EDIII reactive MAbs from donor 013 
DENV2 Yeast EDIII mapping
e Human MAb 
(Donor 013)
a 
Binding 
specificity
b 
DENV2 
neutralization 
potency
c 
Neutralization 
escape mutations
d  Loss of binding  Decreased binding 
EDIII Epitope 
DV3.7 DENV2 type specific Strong V382G   P384A, P384N    K307Q    DIII-lateral   
DV14.21 DENV2 type specific Weak NA 
 K305E, K307N, 
K307I, K310E    G304Y K307Q    DIII-A strand   
DV25.5 DENV2 type specific Moderate NA 
 T303Y, G304Y, 
K307N, K307Q   
 D329Q, G330D, E383G, 
P384A, P384N    DIII-lateral   
DV10.16 DENV 
subcomplex Strong E311K  K305E, K310E   NA  DIII-A strand   
DV21.5 DENV complex None NA  K305E, K310E, K317Y   NA  DIII-A strand   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NA = Not Applicable 
a 
Only EDIII reactive MAbs from donor 013 were mapped. 
b 
The MAbs were tested for binding to the four DENV serotypes. 
c
 Neutralization potency is based on 50% neutralization titers in Figure 3. 
d
 DENV2 escape mutants were obtained with strongly neutralizing MAbs only. 
e 
EDIII mutations that led to a complete loss of binding and partial loss of binding are indicated separately.  
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Supplementary Material 
 
Table 2.S1. Dengue immune human sera used in the present study 
PRNT50 titer
a 
Donor ID 
Location & 
year of 
infection 
Interval 
between 
infection and 
sample 
collection DEN 1 DEN 2 DEN 3 DEN 4 
Infecting 
Serotype 
033
b India 2005 12 months 1:49 1:129 > 1:1,280 1:119 Primary DENV3 
013 South Pacific Island 1997 8 years 1:178 > 1:1280 1:65 1:140 Primary DENV2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a
 The 50 % plaque reduction neutralization titer was determined using Vero cells. 
b
 DENV3 was isolated from the subject in 2005. 
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Table 2.S2. Properties of MAbs from donor 033 (Primary DENV3 infection). 
Whole virus binding ELISA (OD405)  Recombinant E protein ELISA (OD405)  MAb 
ID 
  
IgG 
Isotype 
  DENV1 DENV2 DENV3 DENV4 DENV1 DENV2 DENV3 DENV4 
Recombinant 
DENV3 EDIII 
ELISA (OD 405) 
3 
Target antigen 
(DENV3)
4 
Neut50 (µg/ml) of DENV3 
in U937 DC-SIGN cells 
1.12 γ 1 0.48 0.76 1.13 1.04 0.06 0.07 0.06 0.07 0.00 ? 0.60 
4.30 γ 1 0.99 1.48 1.86 1.88 0.07 0.07 0.07 0.07 0.00 preM 0.10 
11.12 γ 1 1.08 1.77 1.78 1.95 0.07 0.07 0.06 0.06 0.00 preM 0.14 
12.70 γ 1 1.01 1.76 1.71 1.53 0.07 0.07 0.07 0.06 0.00 preM 0.25 
18.50 γ 1 1.18 1.69 1.72 1.86 0.07 0.10 0.08 0.09 0.00 preM 0.20 
20.10 γ 3 0.08 0.09 0.08 0.08 0.09 0.07 0.07 0.07 0.00 ? >1.00 
21.20 γ 1 1.17 1.68 1.63 1.63 0.07 0.07 0.07 0.06 0.00 preM 0.63 
22.70 γ 1 0.74 1.49 1.46 1.55 0.06 0.07 0.06 0.06 0.00 ? >1.00 
32.40 γ 1 1.01 1.68 1.63 1.59 0.06 0.07 0.06 0.06 0.00 preM 1.00 
36.50 γ 1 0.85 1.59 1.49 1.60 0.07 0.07 0.06 0.06 0.00 preM >1.00 
38.10 γ 1 1.09 1.65 1.62 1.62 0.06 0.07 0.07 0.07 0.00 preM 0.50 
47.70 γ 1 0.07 0.09 0.08 0.08 0.07 0.07 0.06 0.06 0.00 ? >1.00 
51.30 γ 1 2.16 0.09 0.82 0.09 0.07 0.07 0.06 0.06 0.00 ? >1.00 
59. 3 γ 1 1.27 1.93 1.72 1.59 0.06 0.07 0.07 0.07 0.00 preM 0.30 
64.31 γ 1 1.33 1.83 2.30 1.85 0.86 1.36 2.05 1.59 0.00 E 0.09 
65.50 γ 1 0.78 1.49 1.53 1.48 0.06 0.07 0.06 0.06 0.00 preM 0.30 
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CHAPTER THREE 
Identification of human neutralizing antibodies that bind to complex epitopes on  
dengue virions 
 
 
3.1 Overview 
 Dengue is a mosquito-borne flavivirus that is spreading at an unprecedented rate and 
has developed into a major health and economic burden in over 50 countries. Even though 
infected individuals develop potent and long-lasting serotype-specific neutralizing antibodies 
(Abs), the epitopes engaged by human neutralizing Abs have not been identified. Here, we 
demonstrate that the dengue virus (DENV)-specific serum Ab response in humans consists of 
a large fraction of cross-reactive, poorly neutralizing Abs and a small fraction of serotype-
specific, potently inhibitory Abs. Although many mouse-generated, strongly neutralizing 
monoclonal antibodies (MAbs) recognize epitopes that are present on recombinant DENV 
envelope (E) proteins, unexpectedly, the majority of neutralizing Abs in human immune sera 
bound to intact virions but not to the ectodomain of purified soluble E proteins. These 
conclusions with polyclonal Abs were confirmed with newly generated human MAbs derived 
from DENV-immune individuals. Two of three strongly neutralizing human MAbs bound to 
E protein epitopes that were preserved on the virion but not on recombinant E (rE) protein. 
We propose that humans produce Abs that neutralize DENV infection by binding a complex, 
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quaternary structure epitope that is expressed only when E proteins are assembled on a virus 
particle. Mapping studies indicate that this epitope has a footprint that spans adjacent E 
protein dimers and includes residues at the hinge between domains I and II of E protein. 
These results have significant implications for the DENV Ab and vaccine field. 
 
3.2  Introduction 
Dengue viruses (DENVs) are emerging arboviruses and the causative agents of 
dengue fever and dengue hemorrhagic fever (DHF). The DENV complex consists of four 
distinct but related viruses, designated as serotypes (1, 19). A person infected with DENV 
develops an antibody (Ab) response that, to varying degrees, cross-reacts with all four 
serotypes. Despite the cross-reactivity, Abs that are produced durably only prevent re-
infection by the same homologous serotype. Serotype-specific neutralizing Abs can be 
detected 60 y after a primary infection, suggesting that Abs provide lifelong protection 
against the homologous serotype (13). People experiencing a secondary DENV infection 
with a different (heterologous) serotype face a greater risk for developing DHF. Ab-
dependent enhancement by cross-reactive, weakly neutralizing Abs is the most widely 
suggested theory explaining the higher risk for DHF associated with secondary infection 
(12). The identity of DENV epitopes recognized by human Abs responsible for potent and 
long-term neutralization remains unknown. This is a significant knowledge gap impeding the 
current global effort to develop dengue vaccines that induce protective neutralizing Abs and 
not cross-reactive Abs with potential to enhance disease. 
The DENV envelope contains two integral membrane proteins designated envelope 
(E) and premembrane/membrane (prM/M) proteins. DENV E protein, which binds to cellular 
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receptors and mediates viral fusion during entry, is thought to be the major target of 
neutralizing Abs (29). The ectodomain of E proteins has been crystallized, and atomic 
structures have been determined for several flaviviruses (22-24, 28). Individual subunits of E 
protein consist of three β-barrel domains designated domains I (EDI), II (EDII), and III 
(EDIII), with the native protein forming a head-to-tail homodimer on the mature virion. The 
mature DENV particle consists of 90 dimers that cover the surface of the virion (16). 
Although several groups have characterized mouse monoclonal antibodies (MAbs) that 
neutralize DENV infection (12, 29) and mapped them to all three domains on the E protein 
(29, 35, 36), the strongest neutralizing mouse MAbs were serotype-specific and bound to two 
overlapping and adjacent epitopes on the lateral ridge and A-strand of EDIII (3, 11, 31, 35, 
36, 39). 
To understand how human Abs neutralize DENV, investigators have begun to 
characterize human immune sera and human monoclonal Abs (hMAbs) (6, 7, 33). Humans 
also produce EDIII-reactive Abs, including strongly neutralizing MAbs that bind to similar 
epitopes recognized by murine EDIII Abs (2, 6). However, several recent observations 
indicate that EDIII-specific Abs alone are unlikely to account for the strong type-specific 
neutralizing Ab responses observed in people following natural infections. DENV-immune 
humans have low levels of serum EDIII-specific Abs, and these sera retained potently 
neutralizing activity even after depletion of EDIII-binding Abs (25, 30, 42). Moreover, 
recombinant DENVs with mutations in EDIII epitopes recognized by neutralizing Abs 
remained sensitive to neutralization by human DENV-immune sera (40). Collectively, these 
observations suggest that humans produce neutralizing Abs that bind to epitopes other than 
those on EDIII. Here, we characterized polyclonal sera and hMAbs generated from DENV-
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immune individuals to identify DENV epitopes engaged by potently neutralizing human Abs. 
We demonstrate that human neutralizing Abs recognize a complex epitope that is preserved 
on the intact virion but is not present on the soluble E protein. 
 
3.3  Methods 
Serum Samples  
 Human serum samples were collected from individuals who had experienced a 
DENV infection during travel to an endemic region. Rhesus macaque (Macaca mulatta) sera 
were taken from animals vaccinated with a VEEV replicon particle (VRP-rE) expressing 
80% of DENV3 E protein. More information is provided in SI Methods. 
 
Virus and rE Proteins  
 The DENV1 (West Pac 74), DENV2 (S-16803), DENV3 (CH-53489 and Thailand 
95), and DENV4 (TVP-360) strains were used in the present study. All viruses used in the 
neutralization assays were grown in C6/36 Aedes albopictus mosquito cells at 28°C and 
titered on Vero-81 cells as previously described (15). DENV was purified as previously 
described (42). The rE proteins from each of the four DENV serotypes were purchased from 
Hawaii Biotech, Inc. 
 
Depletion of DENV-Specific Abs from Human Immune Sera 
 Purified DENVs were adsorbed onto 4.0 µm Polybead polystyrene microspheres 
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following the manufacturer’s instructions (Polysciences, Inc.). Control beads were adsorbed 
with BSA instead. Human immune sera were depleted of virus-specific Abs by incubating 
sera with virus-adsorbed beads at 37 °C. Detailed information is given in SI Methods. 
 
Depletion of DENV rE-Specific Abs from Human and Monkey Immune Sera 
 DENV rE proteins were covalently conjugated to cyanogen bromide (CNBr)-
activated beads following the manufacturer’s protocol (Sigma). Control beads were 
conjugated with the blocking reagent instead of rE protein. DENV rE-specific Abs were 
depleted by incubating human and rhesus macaque immune sera with rE-conjugated beads at 
37 °C. Detailed information is given in SI Methods. 
 
Detection of DENV or rE-Binding Abs by ELISA  
 ELISAs were conducted as previously described (5). Sera were used at dilutions of 
1:40 and 1:25 for the depletion confirmation ELISAs in the virus and rE depletion 
experiments, respectively. More information is provided in SI Methods. 
Detection of rE-Binding Abs by Western Blot  
Detailed information is provided in SI Methods. 
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3.4  Results 
Depletion of Homologous DENV-Specific Abs from Immune Sera 
Studies were undertaken to characterize Abs in human immune sera responsible for 
potent and long-term neutralization of the homologous virus serotype. We assembled a panel 
of eight immune sera from healthy volunteers who had been exposed to primary DENV2 or 
DENV3 infections ∼2–9 yrs before blood collection (Table S1). Human serum from 
individuals lacking a past history of DENV infections (confirmed by ELISA and 
neutralization assays) was used as a negative control. 
To define the Ab subpopulation in immune sera responsible for DENV neutralization, 
we developed a bead-based technique to fractionate DENV-specific Abs in immune sera. 
Polystyrene beads coated with virions of the homologous serotype were incubated with 
immune sera at 37 °C to deplete DENV-binding Abs. Untreated and control-depleted serum 
samples bound to whole virus from each of the four DENV serotypes by ELISA and 
efficiently neutralized DENV (Fig. 1 A and B). Serum samples depleted using beads coated 
with the homologous DENV displayed greatly reduced binding and neutralization of DENV 
(Fig. 1 A and B), indicating that beads coated with the homologous serotype successfully 
removed most DENV-specific Abs from immune sera. 
 
Depletion of Heterologous DENV-Specific Abs from Immune Sera 
Next, we assessed the contribution of DENV cross-reactive Abs in immune sera to 
virus binding and neutralization. We used polystyrene beads coated with virus of a 
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heterologous serotype (a serotype that has not infected the DENV-immune subject) to deplete 
cross-reactive Abs from primary immune sera (Fig. 1 and Table 1). Depletion of primary 
DENV2-immune sera with DENV3-coated beads led to the removal of all cross-reactive 
Abs, with the remaining Abs binding to DENV2 in a type-specific manner (Fig. 1C). 
Reciprocal depletion of primary DENV3-immune sera with DENV2-coated beads removed 
all binding to DENV2 and DENV4 but not to DENV3 and, to a lesser extent, DENV1 (Fig. 
1E). This residual DENV1-binding signal may be attributable to Abs targeting sub-complex 
epitopes that are preferentially shared between DENV1 and DENV3 (11, 18, 36). Removal of 
cross-reactive Abs from primary immune sera did not change the capacity of the sera to 
neutralize the virus responsible for infection (Fig. 1 D and F, Fig. S1, and Table 1). These 
results demonstrate that the DENV-specific human Ab response consists of both cross-
reactive and type-specific Abs. Although the serotype cross-reactive Abs were abundant, in 
the samples we analyzed, their contribution to neutralization was negligible. Thus, type-
specific Abs appear to be primarily responsible for neutralizing the homologous serotype. 
 
Depletion of DENV Recombinant E Protein-Binding Abs from Immune Sera  
The organization of DENV E protein dimers on the surface of the infectious virus has 
been modeled using crystal structures of DENV recombinant E (rE) and cryo-EM 
reconstructions of the virion (16, 17, 22, 44). Furthermore, neutralizing mouse MAbs have 
been mapped extensively to the rE protein, and DENV subunit vaccines using the rE protein 
are currently being developed (3, 4, 10, 11, 35-37, 39). We next assessed whether epitopes 
targeted by neutralizing Abs in human immune sera were preserved on the rE protein. DENV 
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rE protein that was covalently coupled to agarose beads was used to deplete Abs in immune 
sera. Sera were incubated with either control beads or homologous rE-conjugated beads at 
37°C. The structure of DENV rE on the beads was confirmed to be conformationally 
preserved, and rE dimers were confirmed to be intact by successfully depleting mouse MAbs 
previously mapped to the fusion loop (MAb 4G2), EDIII (MAb 9F16) (36), and E dimer 
interface (MAbs DV2-10, DV2-46, and DV2-58) (35) (Fig. S2). We also titrated the amount 
of rE protein on the beads required to deplete rE-binding Abs efficiently from immune sera 
(Fig. S3). Both untreated and control-depleted immune sera bound to rE from all four 
serotypes, but the binding was greatest for the homologous serotype (Fig. 2 A and B). 
Depletion of primary immune sera using homologous rE ablated binding to rE from each of 
the four serotypes (Fig. 2 A and B). Successful depletion of rE-binding Abs was also 
confirmed by Western blot, where rE and solubilized virions were used as the antigen on the 
blot (Fig. 2C). By Western blot, we could not detect binding to rE protein (which is missing 
20% of the native protein at the C terminus) or to full-length E protein from the virus (Fig. 
2C). These results established that beads coated with the rE from the homologous serotype 
efficiently removed all Abs recognizing purified rE protein. We also measured the relative 
proportion of virion-binding Abs in human immune sera that bound to rE by comparing the 
binding of untreated, control-depleted, and rE-depleted sera with the homologous virus by 
ELISA. Results demonstrated an approximate 45 ± 7% reduction in DENV binding 
following the removal of rE-binding Abs (Fig. S4 and Table S2), indicating that 
approximately half of the DENV-specific Abs in primary immune sera recognized the intact 
virus but not rE protein. 
Next, we assessed the neutralizing activity of six immune sera depleted of rE-binding 
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Abs. Unexpectedly, four of the six immune sera displayed no loss of neutralization potency 
after removal of rE-binding Abs (Fig. 2 D and E and Table 2). One of the three primary 
DENV2-immune sera and all three of the primary DENV3-immune sera tested displayed no 
significant loss of neutralization against the homotypic virus after removal of rE-specific 
Abs. In contrast, two of the three primary DENV2-immune sera displayed a statistically 
significant two- to threefold drop (P <0.05) in the 50% neutralization (Neut50) titer when rE-
specific Abs were removed (Table 2). Sera from rhesus macaques (Macaca mulatta) 
immunized with Venezuelan equine encephalitis virus (VEEV) replicons expressing DENV3 
E85 protein were used as a positive control in these experiments. These animals should 
develop neutralizing Abs that bind to rE protein; accordingly, rE-coated beads removed 
>98% of the neutralizing Abs from these vaccine sera (Fig. 2F). We conclude that although 
there was some variation among human immune sera in the contribution of rE-reactive Abs 
to homotypic DENV neutralization, a large fraction of DENV neutralizing Abs in humans 
consists of neutralizing Abs that bind to intact virions but not the rE protein. 
 
Characterization of hMAbs That Strongly Neutralize DENV 
As an alternate approach to identify neutralizing viral epitopes targeted by DENV-
immune individuals, we generated a panel of hMAbs that strongly neutralized DENV. These 
Abs were generated by transforming memory B cells from DENV-immune subjects with 
EBV and generating hMAbs by electro-fusion as previously described (33). Because strongly 
neutralizing hMAbs comprise a minor fraction of the total hMAbs isolated from immune 
subjects (2, 6, 7), we used a two-step screen to isolate strongly inhibitory Abs: We first 
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identified Abs that bound to DENV virions and then tested them for neutralizing activity. We 
isolated three strongly neutralizing type-specific hMAbs (Neut50 value <0.2 µg/mL), 
designated 1F4, 2D22, and 5J7, that inhibited infection of DENV1, DENV2, and DENV3, 
respectively. Two of these hMAbs bound to the intact virus but not to rE (Table 3). 
  
Generation of DENV Mutants That Escape Neutralization by hMAbs 
 To map the epitopes engaged by neutralizing hMAbs, we subjected the appropriate 
DENV serotype to Ab pressure and selected for neutralization escape mutant viruses in vitro. 
DENV1, DENV2, or DENV3 was passaged several times under varying concentrations (0.2–
10 µg/mL) of the neutralizing hMAb 1F4, 2D22, or 5J7, respectively. The original WT virus 
was passaged in parallel in the absence of hMAb treatment. Structural genes of the mutant 
and WT viruses were sequenced and compared to identify the mutation(s) responsible for 
neutralization escape. We successfully isolated two escape mutants against DENV1 type-
specific MAb 1F4, with two independent single-nucleotide mutations resulting in amino acid 
changes at position 274 (G→E) in the DI-DII hinge and 47 (K→E) in DI of the E protein 
(Fig. 3 A and D) that conferred loss of neutralization. K47 and G274 are located 13.2 Å apart 
and likely comprise part of the same 1F4 epitope. For the DENV2-specific neutralizing 
hMAb 2D22, we isolated one mutant with an EDIII mutation at residue 323 (R→G) that 
resulted in neutralization escape (Fig. 3 B and E). Selection with the neutralizing DENV3 
specific hMAb 5J7 resulted in an escape mutant with a lysine insertion in the E DI-DII hinge 
region between the amino acid residues Q269 and N270 (Fig. 3 C and F). All the mutated 
residues are surface exposed on the structure of the E protein dimer and within the footprint 
of a complex epitope described for an hMAb (CR4354) that strongly neutralized West Nile 
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virus (WNV) (14, 34) (Fig. 3G and H and Table 3). 
 
3.5  Discussion 
Although it has been known for several decades that humans develop strongly 
neutralizing Abs following DENV infection, the relevant Abs and epitopes on the virus have 
not been identified. This is a major gap in knowledge, given the important roles postulated 
for Abs in clearing DENV or enhancing infection and disease. Here, the results from seven 
DENV-immune individuals demonstrate that the DENV-specific human Ab response 
consists of distinct populations of serotype cross-reactive and type-specific Abs. The type-
specific Abs were responsible for potent neutralization of DENV. Although cross-reactive 
Abs were abundant in human immune sera, their contribution to neutralization was relatively 
negligible. 
DENV serotype-specific neutralizing Abs generated in mice bind to epitopes that are 
present on the soluble form of rE protein (3, 6, 7, 11, 31, 33, 39). We report here that a 
substantial fraction of DENV-reactive Abs in human immune sera, including type-specific 
neutralizing Abs, bound to the intact virion but not to rE protein. Some of these virion-
specific Abs likely bind to prM or M proteins, which also are displayed on the virion surface. 
However, prM/M is unlikely to be the primary target of neutralizing Abs, because several 
studies have shown that human anti-prM Abs are highly cross-reactive and weakly 
neutralizing (2, 6, 7). The rE protein used in this study was only 80% of the full-length E 
protein and lacked the amphipathic helices, conserved stem anchor, and transmembrane 
regions. Cryo-EM reconstructions of mature virions demonstrate that the amphipathic 
helices, stem anchor, and transmembrane segments are not exposed on the surface, and 
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therefore are unlikely to be the targets of type-specific neutralizing Abs (16, 22, 44). Based 
on the results of Ab depletion studies with human immune sera, we suggest that the packing 
of E proteins on the virion surface creates unique epitopes involving two or more E protein 
molecules in adjacent symmetry groups, and that these quaternary epitopes are targets of the 
human neutralizing Ab response. Similar complex quaternary epitopes that are recognized by 
potently neutralizing hMAbs have been described for several other viruses, including WNV 
and HIV (8, 14, 34). 
Our studies with hMAbs also confirmed that humans can produce strongly 
neutralizing Abs that bind a quaternary epitope expressed on intact virus particles but not on 
rE protein. The strongly neutralizing hMAbs 1F4 and 5J7 selected for viruses that escaped 
neutralization with mutations or insertions either on or near the E DI-DII hinge region. 
Consistent with this, other MAbs that strongly neutralize flaviviruses also have been reported 
to recognize the hinge region between EDI and EDII (9, 14, 21, 26, 38). Additionally, we 
identified a mutation at position 323 on EDIII that resulted in neutralization escape from the 
anti-DENV2 hMAb 2D22. This Ab likely also recognized a structurally complex neutralizing 
epitope, because it bound to DENV2 particles but not to EDIII or rE from DENV2. 
Collectively, the location of all four escape mutations identified for hMAbs 1F4, 2D22, and 
5J7 (representing Abs that neutralize 3 different serotypes in a type-specific manner) map to 
a region that overlaps with an epitope recently described for the CR4354 hMAb that strongly 
neutralized WNV in vitro and in vivo (14, 38), and bound to virions but not to soluble E 
protein. Cryo-EM studies revealed that the CR4354 footprint spanned the DI-DII hinge from 
one E protein dimer and DIII of the adjacent E dimer (14). Abs that bind to this epitope were 
postulated to be strongly neutralizing for two reasons: (i) each mature virion should have 120 
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of these epitopes available for interaction, of which 90% could be simultaneously occupied 
by Ab (14), and (ii) Abs binding to this EDI–EDII complex epitope could cross-link adjacent 
E dimmers and inhibit trimer formation, which is a prerequisite for viral fusion. Because all 
the escape mutants that we identified localized within the footprint of CR4354, we propose 
that this region is also a target of human neutralizing Abs against DENV. Structure studies 
are in progress to further define the relationships of 1F4, 2D22, and 5J7 with one another and 
with CR4354. 
The EDI/II hinge region is not the only target of neutralizing hMAbs. Strongly 
neutralizing hMAbs that bind to EDIII (including A strand and lateral ridge epitopes 
recognized by mouse Abs) have been isolated from memory B cells of DENV-immune 
subjects (2, 6, 7, 33). Further studies are needed to estimate the variety and frequency of 
DENV-specific memory B cells encoding for strongly neutralizing Abs. Such estimates are 
not possible from the existing DENV hMAb literature because of the different methods used 
to screen for DENV-specific memory B cells and the different criteria used to select B-cell 
clones and hMAbs for in-depth study (2, 6, 7, 33). Previous studies have demonstrated that 
human immune sera depleted of EDIII Abs retained most of their neutralizing activity (42). 
Similar to WNV, recombinant DENV with mutations in EDIII lateral ridge and A-strand 
epitopes remained sensitive to neutralization by human immune sera (25, 30, 41). In the 
current study, we report that depletion of Abs that bind homologous rE also had more modest 
effects on neutralization potency, whereas removal of Abs that bound intact homologous 
virus resulted in a large decrease in neutralization titer. Collectively, these observations 
suggest that Abs in human immune sera that recognize the intact virus only account for the 
majority of the inhibitory activity relative to those binding EDIII and rE protein. 
 100	  
Our findings reporting on a target of neutralizing human Abs after natural infection 
are relevant to the development of DENV vaccines and the evaluation of vaccines currently 
under development. The leading dengue vaccine candidates currently being tested in clinical 
trials consist of tetravalent formulations of live-attenuated dengue or dengue/yellow fever 
chimeric viruses (20, 27). Studies are needed to determine if these live viral vaccines also 
induce neutralizing Abs that bind to quaternary epitopes expressed on the intact virion but 
not on soluble E protein. 
 
3.6  Supporting Information 
SI Methods 
Serum Samples 
 Human blood donor recruitment and sample collection were in compliance with the 
Institutional Review Board of the University of North Carolina at Chapel Hill. All 
individuals were informed, and written consent was obtained before blood donation. The 
rhesus macaques (∼7 y of age) were vaccinated with a VEEV replicon particle (VRP-rE) 
expressing amino acids 1–424 of DENV3 E ectodomain (85% of full-length E protein, also 
designated as E85), boosted at 7 wk. The serum used for the present experiments was 
collected at 3 wk after the boost. 
 
Depletion of DENV-Specific Abs from Human Immune Sera 
 Beads were washed three times with 0.1 M borate buffer (pH 8.5) and incubated with 
the relevant purified DENV in borate buffer overnight at room temperature (RT). Control 
beads were incubated overnight with an equivalent amount of BSA. The control and virus-
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adsorbed beads were blocked with BSA (10 mg/mL) in borate buffer for 30 min at RT three 
times and washed six times with PBS. Human immune sera were depleted of virus-specific 
Abs by incubating sera with virus-adsorbed beads for 2 h at 37 °C with end-over-end mixing. 
Each immune serum was subjected to at least three sequential rounds of depletions before 
confirming successful removal of the respective Abs by coated (antigen directly coated on 
plate) and capture (antigen captured by the mouse MAb 4G2) ELISA. 
 
Depletion of DENV rE-Specific Abs from Human and Monkey Immune Sera 
 Cyanogen bromide (CNBr)-activated beads were covalently conjugated with rE 
protein following the manufacturer’s protocol (Sigma). CNBr beads were washed four times 
with distilled water, followed by three additional washes with coupling buffer [0.1M 
NaHCO3, 0.5 M NaCl (pH 8.5)]. The relevant DENV rEprotein diluted in coupling buffer 
was incubated with CNBr-activated beads for 2 h at RT. Control beads were incubated longer 
with the blocking reagent instead of rE protein. The unreacted groups on the rE-conjugated 
beads and control beads were blocked and incubated with 0.2 M glycine (pH 8.0), washed 
three times with coupling buffer, and then washed four times with PBS. Human and rhesus 
macaque immune sera were incubated with rE conjugated beads for 2 h at 37 °C. Each serum 
sample was subjected to at least three sequential rounds of Ab depletion before confirming 
successful removal of the respective Abs detectable by coated or capture ELISA. 
 
 
Detection of DENV or rE-Binding Abs by ELISA 
 ELISA plates were coated with either 50 ng per well of intact purified virus or 100 ng 
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per well of rE protein in carbonate buffer (pH 9.6) for 2 h at RT. Plates were blocked with 
3% (vol/vol) normal goat sera in Trisbuffered saline (TBS) containing 0.05% (vol/vol) 
Tween 20 (blocking buffer). Undepleted, control-depleted, and antigendepleted immune 
serum were diluted in blocking buffer and incubated on plates for 1 h at 37°C. Sera were 
used at dilutions of 1:40 and 1:25 for the depletion confirmation ELISAs in the virus and rE 
depletion experiments, respectively. DENV or rE reactive Abs were detected using an 
alkaline phosphatase-conjugated goat anti-human IgG secondary Ab and paranitrophenyl 
phosphate substrate as previously described (5). 
 
Detection of rE-Binding Abs by Western Blot  
 Purified DENV (700 ng per well) and DENV rE protein (500 ng per well) were 
diluted with nonreducing SDS sample buffer, loaded onto a 12% polyacrylamide SDS/PAGE 
gel, and electrophoresed. Viral proteins were transferred onto polyvinylidene fluoride 
membranes and blocked overnight at 4°C with 5% (wt/vol) dried nonfat milk. Membrane 
was then probed with immune sera (diluted 1:1,000) for 1 h at 37°C, washed three times with 
TBS containing 0.2% (vol/vol) Tween-20, incubated with a goat anti-human IgG-HRP 
secondary for 1 h at 37°C, washed three times, and developed using ECL substrate. 
 
Measuring DENV neutralization by immune sera and monoclonal antibodies 
 Neutralizing activity of both immune sera and monoclonal antibodies were measured 
using a flow cytometrybased neutralization assay with U937 monocytic cells stably 
transfected with dendritic cell-specific intercellular adhesion molecule-3-grabbing non-
integrin (DC-SIGN) as previously described (15). Briefly, virus and antibody mixtures were 
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pre-incubated for 1 hr at 37°C, prior to the addition of DC-SIGN expressing U937 cells 
(U937+DC-SIGN). After 2 hrs of incubation at 37°C with virus-antibody immune 
complexes, cells were washed twice with infection media. Cells were fixed and 
permeabilized 24 hrs after infection, probed with 2H2 (anti-prM antibody) conjugated to 488 
and infected cells quantified using a Guava flow-cytometer (Milipore). 
 Focus reduction neutralization assays (FRNT) were conducted using Vero-81 cells as 
described previously (15). Briefly, virus and serially diluted serum were pre-incubated for 1 
hr at 37°C, incubated with Vero-81 cells (grown to 80% confluency) for 2 hrs at 37°C and 
then overlaid with methylcellulose containing nutrient media. The cells were fixed at either 
day 3 (for DENV2 and DENV4) or day 4 (for DENV1 and DENV3) and stained for foci 
using the anti-E MAb, 4G2, and goat anti-mouse HRP and True blue substrate. 
 
Generation of Anti-DENV hMAbs  
 Supernatants from EBV-transformed lymphoblastoid cell lines were screened for 
binding to DENV by ELISA and, in some cases, tested for neutralization of DENV using a 
flow cytometry-based assay. Positive wells were fused with HMMA2.5 myeloma cells to 
generate hybridoma lines as previously described (33, 43). Hybridoma lines then were 
biologically cloned and grown in serum-free medium (no. 12045084, Gibco Hybridoma-
SFM; Invitrogen), and hMAbs were purified using protein G chromatography. 
 
 
 
Generation and Characterization of hMAb Neutralization Escape 
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 Mutant Viruses. Virus-Ab mixtures were added to Vero cells and passaged every 3–5 
d in the presence of Ab to enrich for escape mutant viruses. Virus growth in the presence of 
Ab was monitored by quantitative RT-PCR and by immunofluorescent detection of DENV 
antigens in cell monolayers. Following four to six passages under Ab selection, the capsid, 
prM, and E genes of the escape variants were amplified by RT-PCR and sequenced to 
identify mutations associated with the Ab escape phenotype. 
 
Statistical Analysis  
 Sigmoidal binding and neutralization curves were compared between undepleted, 
control-depleted, and virus-depleted or rE-depleted groups using a one-way ANOVA 
analysis, followed by a Tukey multiple comparison test at P <0.05. The one-dilution binding 
data (represented in bar charts) for control-depleted and virus-depleted or rE-depleted 
samples were compared using an unpaired Student t test of means. All statistical analyses 
were conducted using GraphPad Prism4. 
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Figure 3.1 Binding and neutralization properties of primary DENV-immune sera 
depleted of total or cross-reactive DENV-binding Abs. Total DENV-specific Abs were 
removed from DENV3 primary immune serum (e.g., subject 011) using polystyrene beads 
coated with purified DENV3 and tested for DENV binding (A) and neutralization (B). The 
sera depleted with the homologous serotype did not bind to any of the four DENVs and failed 
to neutralize DENV3. Similar results were observed for four other primary immune sera (two 
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DENV2 and two DENV3 sera) depleted with the homologous serotype responsible for 
infection. Primary DENV2 (C and D) and DENV3 (E and F) immune sera were depleted of 
cross-reactive Abs using beads coated with virus of a heterologous serotype and tested for 
DENV binding (C and E) and neutralization of the homologous serotype (D and F). Immune 
sera depleted of cross-reactive Abs contained type-specific Abs that bound to virus from the 
homologous serotype only. Immune sera depleted of cross-reactive Abs were as potently 
neutralizing as undepleted or control-depleted sera. Results presented here for cross-reactive 
Ab depletions are representative of data obtained with four primary DENV2 and three 
primary DENV3 human immune sera (Table 1). *P < 0.001 by an unpaired Student t test of 
mean binding values. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 107	  
	  
Figure 3.2 Binding and neutralization properties of primary DENV-immune sera 
depleted of rE-binding Abs. DENV rE from the homotypic strain was coupled covalently to 
agarose beads and incubated with the relevant DENV-immune sera to deplete DENV rE-
specific Abs. (A and B) Binding of immune sera to rE protein. Primary DENV2 (A) and 
DENV3-immune (B) sera were depleted with DENV2 and DENV3 rE proteins, respectively, 
and binding to rE protein from each of the four serotypes was measured by ELISA. Depletion 
with the rE from the homologous serotype led to a loss of binding to rE protein from each of 
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the four serotypes. (C) Successful removal of all rE-reactive Abs from sera (e.g., primary 
DENV3-immune subject 003) also was confirmed by Western blot analysis. Purified 
homotypic DENV (700 ng per well) and rE protein (500 ng per well) were electrophoresed, 
transferred to nitrocellulose membrane, and probed with undepleted, control-depleted, or rE-
depleted sera (at a 1:1,000 dilution). (D and E) Neutralization of the homologous DENV by 
rE-depleted sera was measured using a U937+DC-SIGN flow cytometry-based assay. 
Homologous DENV neutralization by primary DENV2 (D; subject 031) and primary 
DENV3 (E; subject 003) human immune sera depleted of rE-binding Abs was tested. No 
reduction in neutralization potency was observed following removal of rE-binding Abs from 
either of these two serum samples. A total of six primary immune sera were depleted of rE-
binding Abs and tested (Table 2). (F) Nonhuman primates vaccinated with rE develop 
neutralizing Abs that can be depleted with rE antigen. Rhesus macaques (M. mulatta) were 
vaccinated and boosted with an alphavirus vector expressing DENV3 E ectodomain, and sera 
were collected 10 wk post-vaccination. Depletion of rE-binding Abs from sera of vaccinated 
animals (e.g., M630) removed greater than 98% (value estimated by comparing Neut50 values 
between control-depleted and rE-depleted sera) of the neutralizing Abs. Data are 
representative of two vaccinated rhesus macaque controls. 
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Figure 3.3 Epitope mapping of escape mutants generated from type-specific 
neutralizing hMAbs. Neutralization profiles of respective WT and escape mutants against 
1F4 (A), 2D22 (B), and 5J7 (C). Neutralization escape by the mutant viruses was confirmed 
using U937 + DC-SIGN cells in a flow cytometry-based neutralization assay for 1F4 and 
2D22, and by focus reduction neutralization assay (FRNT) for 5J7. Display enlarged views 
indicate the positions of the original amino acids of the escape mutations on EDIII and the 
EDI-EDII hinge region for 1F4 (D), 2D22 (E), and 5J7 (F). Images were generated with 
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DENV1, DENV2, and DENV3 E dimer structures, respectively. The DENV2 and DENV3 E 
dimer structures [Research Collaboratory for Structural Bioinformatics (RCSB) accession 
nos. 1OAN and 1UZG, respectively] (22, 23) were modeled using the UniProt protein 
database viewer and PyMOL (Schrödinger) to generate structures for DENV1 and DENV3 
(Thai 95) E dimers. (G) Alignment of E protein segments from DENV and WNV identified 
in the neutralizing hMAb-binding epitope of CR4354. Mutations leading to escape from 1F4 
(blue), 2D22 (green), or 5J7 (pink) are highlighted on relevant regions of the aligned DENV 
E protein sequences. A portion of the CR4354 epitope that overlaps with the corresponding 
DENV escape mutations described here is highlighted in bold on the aligned WNV (New 
York 2000) sequence. (H) Escape mutations were mapped onto the E polymeric structure 
generated for TBEV (RCSB accession no. 1K4R) (16). The positions of escape mutations 
generated from 1F4, 2D22, and 5J7 are highlighted on the structure in blue (Gly274, K47), 
green (Arg323, His282, Asp362), and pink (Gln271, Asn272) (i.e., residues surrounding the 
lysine insertion), respectively. The footprint of the anti-WNV CR4354 hMAb that spans E 
protein dimers is circled with a white line. Note that all escape mutationsfor 1F4, 2D22, and 
5J7 fall within the CR4354 footprint. *Neut50 values for each escape mutant differed 
significantly from the respective WT virus (P < 0.0001). 
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Table 3.1 Homologous DENV serotype neutralization titers of 
immune sera depleted of cross-reactive antibodies from subjects 
following primary infection. 
Reciprocal of 50% neutralization titer against the 
homologous virus (SEM)a,b Infection 
Serotype Sample ID
 
Undepleted Control depleted Cross-reactive Ab depleted 
001 2600  (2040-2700) 
1650  
(1100-1650) 
1412 
 (1060-1600) 
013 350  (260-470) 
320  
(260-380) 
420  
(370-550) 
019 1202  (1000-1550) 
1047  
(930-1580) 
1000  
(800-1420) 
Primary 
DENV2 
031 1150  (1000-1310) 
790  
(650-950) 
640  
(540-740) 
003 250  (230-350) 210 (160-260) 
300  
(250-360) 
011 320  (265-390) 
300  
(260-380) 
252  
(211-300) 
Primary 
DENV3 
118 628  (510-770) 
720  
(610-860) 
618  
(500-750) 
 
 
 
 
 
 
 
 
 
 
aData is representative of experiments repeated at least thrice for each serum 
sample. The flow-based neutralization assay using U937 cells stably 
expressing DC-SIGN (U937+DC-SIGN) was used to generate the reciprocal 
Neut50 values. The Neut50 values of undepleted, control depleted and cross-
reactive antibody depleted sera were compared for each serum by one-way 
ANOVA analysis. No statistical significance was found between control 
depleted and cross-reactive depleted groups for any of the tested sera. 
bStandard error of mean (SEM) for reciprocal Neut50 values were calculated 
from the sigmoidal neutralization curves using GraphPad Prism4 and given in 
parenthesis.	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Table 3.2 Homologous DENV serotype neutralization titers of 
primary immune sera depleted of rE-binding antibodies. 
Reciprocal of 50% Neutralization titer against the 
homologous virus (SEM)a Infection 
Serotype 
Sample 
ID Undepleted Control depleted rE depleted 
001b 660  (510-840) 
850  
(690-950) 
260  
(210-310) 
019c 1250  (1010-1500) 
1120  
(950-1350) 
500  
(400-600) 
Primary 
DENV2 
031 1020  (790-1300) 
860  
(670-1150) 
900  
(690-1190) 
003 180  (155-250) 
225  
(210-310) 
215  
(150-220) 
105 180  (140-235) 
200  
(160-275) 
160  
(130-185) 
Primary 
DENV3 
118 1580  (1180-2020) 
1480  
(1200-1790) 
1120  
(900-1400) 
aData is representative of experiments repeated at least thrice for each 
serum sample. Standard errors of mean (SEM) for reciprocal Neut50 
values were calculated from the sigmoidal neutralization curves using 
GraphPad Prism4 and are given in parenthesis.  
bThere was a statistically significant difference between the undepleted/ 
control depleted and rE depleted groups for sample by a one-way 
ANOVA analysis followed by a Tukey’s multiple comparison test at P 
<0.01. 
cThere was a statistically significant difference between the undepleted 
and rE depleted groups when analyzed by a one-way ANOVA at P<0.05.
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Binding (2 µg/ml)a  Neut50 titer (µg/ml)d 
MAbs 
Virus rE EDIII prMc  DENV1 DENV2 DENV3 DENV4 
Escape 
mutant Escape Mutation 
Mutation 
Location 
Analogous 
residue in 
WNV 
(Comparison 
to CR4354 
epitope)e 
              
1F4 Type-
Specific 
(DENV1) 
- - -  0.11 >10 >10 >10 1 G274E DI-DII 
hinge 
276 (Contact 
site) 
          2 K47E DI 49 (Contact 
site) 
2D22b Type-
Specific 
(DENV2) 
- - -  >10 0.08 >10 >10 3 R323G DIII 326 (Near 
contact site 
328) 
5J7b Type-
Specific 
(DENV3) 
+ - -  >10 >10 0.10 >10 4 Q269_N270insK DI-DII 
hinge 
Before 274 
(near contact 
site 276) 
aBinding of Human MAbs (at 2 µg/ml) to DENV antigens were measured by ELISA.  
bBinding and neutralization properties of 2D22 and 5J7 were taken from previous study (32).  
cBinding to prM was determined by western blot analysis.  
dNeut50 values were generated using the flow-based neutralization assay with U937-DC-SIGN cells. Values in bold indicate the lowest 
Neut50 concentration and the most neutralization sensitive serotype for each MAb.  
eComparison of the escape mutations generated against 1F4, 2D22 and 5J7 to the CR4354 epitope in WNV (14, 38).
Table 3.3 Binding and neutralization properties of isolated strongly neutralizing human MAbs	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Figure 3.S1 Comparison of neutralization properties of primary DENV-immune human 
sera depleted with either one heterologous virus or all three heterologous viruses. (A) 
Depletion of primary DENV2-immune sera (e.g., subject 019) with DENV3, or DENV1, 
DENV3, and DENV4 had no statistically significant effect on the Neut50 against the 
homotypic virus, DENV2. (B) Depletion of primary DENV3-immune sera (e.g., subject 003) 
with DENV2 or DENV1, DENV2, and DENV4 had no statistically significant effect on the 
Neut50 against DENV3. Data are representative of single experiments conducted in duplicate. 
The Neut50 values of undepleted, control-depleted, and cross-reactive depleted sera were 
compared for each serum using one-way ANOVA analysis followed by a Tukey multiple 
comparison test at P < 0.05. 	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Figure 3.S2 Confirmation of the DENV2 rE structure on the CNBr-activated beads 
using mouse MAbs. Mouse MAbs 9F16 (E DIII-specific) (36); 4G2 (fusion loopspecific); 
DV2-30, DV2-46, and DV2-58 (dimer interface-specific) (35); and hMAbs 2D22 (virus-
specific) were incubated three consecutive times with either control beads or DENV2 rE-
conjugated beads for 2 h at 37 °C. The depleted samples were tested for binding to DENV2 
rE by capture ELISA. (A) All previously mapped mouse MAbs that bound epitopes on 
DENV rE protein were successfully depleted with rE protein covalently conjugated to beads. 
(B) Virus-specific hMAb 2D22 was not depleted by rE protein. Data are representative of 
individual experiments conducted in duplicate. *P < 0.001 by an unpaired Student t test of 
mean binding values. 	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Figure 3.S3 Titration of DENV rE quantities that were covalently conjugated to beads. 
CNBr-activated beads were mixed with varying quantities (i.e., 0, 0.02, 0.2, 2, 10, 20, and 40 
µg/mL) of DENV2 and DENV3 rE protein and were then incubated with primary DENV2 
(i.e., subject 001) and DENV3 (i.e., subject 003) sera, respectively. The remaining 
supernatant was tested for the presence of homologous rE-binding Abs by capture ELISA. 
The gray arrow represents the amount of rE added to beads during ensuing rE depletion 
experiments with immune sera. 	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Figure 3.S4 Binding properties of rE-depleted sera to the homotypic DENV. Removal of 
rE binding Abs from primary DENV2 (A) and DENV3 (B) sera resulted in a statistically 
significant (P < 0.05) 45 ± 7% decrease in binding (EC50) to the homologous virus. Statistical 
analysis was conducted using a one-way ANOVA. Data are representative of three primary 
DENV2 and three primary DENV3 human immune sera (Table S2). 	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Table 3.S1 A panel of late convalescent DENV-immune sera from individuals with past 
primary DENV2 or DENV3 infections.   
DENV Neutralizationb 
(FRNT50 reciprocal titer) 
DENV serotype 
Sample 
ID 
Location of 
Infection 
Year of 
Infection 
Interval between 
infection and 
sample collection 
1 2 3 4 
Infecting 
Serotype 
001a Sri Lanka 1996 9 years < 20 271 <20 42 
013a South Pacific 1997 8 years 178 >1280 65 140 
019 Thailand 1997 8 years 95 >1280 120 105 
031 South Pacific 1997 8 years 28 > 320 88   167 
Primary 
DENV2 
003a Thailand 2001 4 years 30 87 338 <20 
011a El Salvador 1998 7 years 84 124 1032 169 
105 Thailand 2002 8 years <20 <20 210 <20 
118 Nicaragua 2009 1.5 years 60 32 980 76 
Primary 
DENV3 
 
aThe FRNT50 values for these serum samples were reported in a previous study (42).    
bFRNT50 values in bold signify the highest 50% neutralization reciprocal titers for each 
serum sample.  
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Table 3.S2 Binding properties of DENV-immune sera with and without rE-binding 
antibodies to the homologous virus serotype. 
50% Reciprocal binding titers to the homologous virus 
(SEM)a Infection 
Serotype Sample ID Undepleted Control depleted Homotypic rE Depletedd 
001b 280 (260-290) 310 (290-335) 133 (130-140) Primary 
DENV2 031b 445 (415-475) 455 (435-475) 260 (240-275)b 
003b 216 (205-225) 190 (180-200) 108 (105-115)b 
105b 60 (53-66) 63(60-68) 37b (34-42) Primary 
DENV3 
118c 440 (400-490) 350 (325-375) 265c (250-280) 
 
aData representative of experiments repeated at least twice for each serum sample. Standard 
error of mean for each reciprocal 50% reciprocal binding titer (EC50) given in parentheses. 
bThere is a statistically significant difference between the control depleted and rE depleted 
groups by a one way ANOVA analysis followed by a Tukey’s multiple comparison test at 
P <0.001. 
cThere is a statistically significant difference between the control depleted and rE depleted 
group when analyzed by a one way ANOVA at P<0.05.  
dThe rE-reactive antibodies account for about 45±7 % of the total homotypic virus binding 
antibodies.  
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CHAPTER FOUR 
Further characterization of the neutralizing human antibody response to dengue virus. 
 
 
4.1 Overview 
 
At present, numerous tetravalent vaccine platforms are being developed in hopes of 
eliciting long-term, balanced neutralizing antibody responses against each of the four DENV 
serotypes. We recently mapped several strongly neutralizing, type-specific human MAbs to 
the EDI-DII hinge region. In the present chapter, we map the EDI-DII hinge epitope in 
further detail and confirm that this region is important for long-term type-specific protection 
in humans. Furthermore, we studied the mechanistic contribution of EDI-DII hinge for 
antibody neutralization. Finally, we extend some of our in vitro observations to experiments 
in vivo, in the AG129 mouse model.    
 
4.2 Introduction 	  	   The	  antibody	  response	  is	  the	  primary	  immune	  mechanism	  of	  protection	  against	  DENV	   infections	   in	   humans.	   Until	   recently,	   data	   with	   mouse	   MAbs	   indicated	   that	  protection	  from	  DENV	  infections	  was	  due	  to	  neutralizing	  antibodies	  targeting	  the	  DIII	  region	  of	  the	  DENV	  E	  protein	  (19,	  20,	  33,	  57,	  58).	  Studies	  with	  human	  polyclonal	  sera	  have	  indicated	  that	  humans	  make	  very	  little	  EDIII	  antibodies,	  and	  this	  minor	  fraction	  of	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EDIII-specific antibodies do not contribute significantly to long-term protection in humans 
(42, 44, 51, 64, 65). 
 
 Discrepancies in DENV-specific antibody responses in mouse versus humans, led to 
increased focus on the antibody response in humans. Recent studies (including data in 
chapter 2) have shown that the majority of antibodies produced by humans are cross-reactive, 
weakly neutralizing and bind to either prM or E protein (4, 15, 17, 53). It was observed that 
potently neutralizing antibodies were rare and difficult to isolate. Work described in Chapter 
3 of this dissertation lead to the successful isolation and mapping of several strongly 
neutralizing, type-specific MAbs derived from human PBMCs (16). Similar to the previously 
mapped WNV-specific human MAb (27, 63), CR4354, these strongly neutralizing MAbs 
were mapped to a complex, quaternary epitope that focused around the flexible DI-DII hinge 
of the E protein (16). However, it is unclear whether the EDI-DII hinge is also the target of 
type-specific protection by DENV-immune human polyclonal sera.    
  Four peptide linkers connecting DI and DII of the E protein forms the EDI-DII hinge. 
During the life cycle of DENV, this hinge region undergoes angular changes of close to 40° 
and plays important roles during maturation and fusion (7, 29, 35-37, 47, 54, 55). A low pH-
induced E trimer to dimer conformational change in the TGN during virus maturation 
induces almost a 30° angular change in the EDI-DII hinge (45, 70, 72). During viral fusion, 
the low pH-induced E dimer to trimer conformational change in the endosomes forces a 40° 
angular change in the EDI-DII hinge (36, 47, 54, 55). Interestingly, single mutations in the 
EDI-DII hinge region lead to changes in the pH-threshold of viral fusion, indicating that this 
hinge also plays an important role in maintaining the pH-threshold of fusion (3, 7, 22, 26, 31, 
35, 40). It is possible that antibodies binding the EDI-DII hinge efficiently neutralize the 
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virus, not by blocking attachment, but by blocking the large conformational change that leads 
to viral fusion.  
 Despite the evidence of broadly cross-protective long-term immunity after a 
secondary DENV infection (reviewed in (66)), non-EDIII-binding, strongly cross-
neutralizing antibodies have not been described in literature. Two regions on the DENV 
structural proteins show high protein sequence conservation across the four serotypes, 1) the 
fusion loop in the distal end of EDII, and 2) the cleavable pr portion of prM. Studies have 
shown that both primary and secondary infections induce large quantities of fusion loop-
specific MAbs (30, 32, 44), while secondary infections also elicit large amounts of anti-prM 
antibodies (10, 62). The physiological relevance of prM-specific antibodies, capable of 
binding to only immature or partially mature virus during a natural infection, is yet unknown. 
Unfortunately, previously mapped anti-fusion loop and anti-prM antibodies (from both 
humans and mice) have only been weak to moderately cross-neutralizing MAbs (4, 8, 12, 15, 
17, 48, 53). Therefore, the potently cross-protective epitope(s) targeted by the human 
antibody response is yet to be discovered.   
 The present chapter attempts to further characterize the EDI-DII hinge epitope with 
MAbs and DENV-immune sera. Since EDI-DII hinge region plays a critical role in viral 
fusion, we also investigated the mechanism of neutralization of isolated neutralizing MAbs 
and primary DENV-immune human sera. Additionally, in an attempt to map cross-protective 
immunity, we mapped several strongly cross-neutralizing human MAbs to a non-fusion loop 
region on EDII. Furthermore, several in vitro results were tested in vivo using the AG129 
mouse model.      
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4.3 Methods 
Virus and cell lines 
 The WHO reference strains of DENV1 (West Pacific 74), DENV2 (S-16803), 
DENV3 (CH53489) and DENV4 (TVP-360) were used in the present study. Working virus 
stocks for neutralization assays were grown in the mosquito cell line, C6/36, as previously 
described in Wahala, W.M.P.B et al, 2009 (65). Briefly, C6/36 cells at 80% confluency were 
infected with DENV (MOI=0.01), incubated at 28°C (under 5% CO2), harvested at 6-8 days, 
and stored at -80°C until use. DENV viruses were originally obtained by Dr. Robert Putnak 
(Walter Reed Army Institute of Research, Silver Spring, MD).  
 Vero-81 and C6/36 cells were obtained from ATCC. U937 cells stably expressing 
DC-SIGN were kindly provided by Mark Heise Lab (UNC Chapel Hill). 
 
Human DENV-immune sera and MAbs 
DENV-immune sera were obtained from individuals approximately 2 to 10 years 
after experiencing a DENV infection during travel to a DENV endemic region. Blood 
donations were taken in compliance with the Institutional Review Board of the University of 
North Carolina at Chapel Hill. 
The DENV-specific human MAbs, 1F4, 2D22, 5J7, 1C19 and 1N5, used in this study 
were isolated, generated, and purified from human memory B-cells by Scott Smith in the 
laboratory of Dr. James Crowe at Vanderbilt University (VU) as previously described (16, 
53). Briefly, these MAbs were isolated by a two step screening process, where human 
memory B cells obtained from DENV-immune subjects were first tested for binding to 
purified DENV antigens (i.e. DENV1-4 at a 1:1:1:1 mixture) and then tested for protection 
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using the in vitro flow-based U937+DC-SIGN neutralization assay. 1F4, 2D22 and 5J7 were 
isolated from a secondary DENV-immune, primary DENV2-immune, and primary DENV3-
immune subjects, respectively, while both 1C19 and 1N5 were isolated from subjects with 
secondary DENV3 infections. The molecular Fab fragments of 1F4, 2D22 and 5J7 were 
generated by sequencing heavy and light chains from the hybridoma, inserting the genes into 
expression plasmids, and co-transfecting the plasmids into 293F cells. The expressed Fab 
was then purified using a lambda select or Kappa select column (GE). All Fab fragments 
were generated by Scott Smith in the laboratory of Dr. James Crowe at VU.  
Generation of neutralization escape mutants 
 Neutralization resistant mutants against 5J7, 1C19 and 1N5, were generated as 
previously described (15, 16). Briefly, DENV3 (CH53489) was passaged five times in Vero 
cells under increasing 5J7 concentrations. Similarly, DENV2 (S-16803) was passaged under 
increasing 1C19 or 1N5 antibody pressure. Growth of virus under antibody pressure was 
monitored through cytopathic effect on Vero cells, Q-RT-PCR of virus in supernatant, or 
focus assay of infected cells for detection of viral antigen. The C, prM and E genes of 
prospective neutralization escape mutants were amplified by RT-PCR and sequenced to 
determine the mutation(s) responsible for neutralization escape.       
 
Epitope mapping using mutant prM-E proteins 
 Epitope mapping studies of human MAbs were conducted using a prM-E mutant 
panel as described previously (12). Briefly, mutations were introduced to prM-E genes from 
DENV3 (CH54389) or DENV4 (TVP-360). Mutant prM-E proteins were expressed in HEK-
293 cells, cells fixed and permeabilized, stained with MAb being tested, followed by staining 
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with a secondary antibody conjugated to horse peroxidase (HRP), incubation with HRP 
substrate and measurement of resulting luminescence. Antibody reactivities to mutant prM-E 
proteins were assessed by comparing binding to the wild type prM-E protein. Using the 
above technique, epitope mapping data for 5J7 and 1C19 was generated by Kristen Kahle 
and Jen Pfaff from Integral Molecular, Inc.      
 
Mapping antibodies using an infectious clone 
 We used the previously described DENV3 infectious clone made with the parent 
clone UNC3001 (DENV3 genotype III), which is a 1986 DENV3 clinical isolate from Sri 
Lanka (34). The DENV3 genome was cloned as a set of four cDNA fragments (named DEN 
A through D, with sizes 2.0 kb, 1.1 kb, 3.9 kb, and 3.7 kb, respectively). DEN A plasmid 
encoding the DENV3 E gene with 26 amino acid mutations in the EDI-DII hinge region was 
synthesized by Bio Basic Inc (Ontario, Canada). Plasmids were amplified in E.coli, purified, 
ligated and transfected into Vero cells. Vero cells were incubated at 37°C under CO2 for 4 
days. Resulting virus was passaged as described in Messer, W.B. et al, 2012 (34), and frozen 
at 80°C until use. The EDI-DII hinge mutant DENV3 virus (UNC3001-A12) had 26 amino 
acids mutated to the corresponding DENV4 amino acid in the same region (more 
specifically, K51Q, E52Q, V53L, L55T, T58K, Y59L, K124R, T126E, N128K, L129V, 
M199L, K200T, K203N, T205A, L207M, K210R, L214F, A222S, V270I, D271Q, S272N, 
G273S, D274G, N276T, H277S, M278I). The WT DENV3 (UNC3001) and EDI-DII hinge 
mutant DENV3 virus (UNC3001-A12) were generated by William B. Messer and Jeremy P. 
Huynh in Raph Baric lab at UNC Chapel Hill.         
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ELISA binding assays 
(i) Binding of 1N5 and 1C19 to DENV antigen and recombinant proteins. ELISA 
analysis of 1N5 and 1C19 binding to purified DENV antigen and recombinant proteins (rE, 
EDI/DII, EDIII and pr) were conducted as previously described (15, 16, 53). Briefly, DENV 
virus antigen or recombinant proteins were coated on to ELISA plates in carbonate buffer 
(pH 9.6) or captured by a DENV-specific mouse MAb (2H2 for pr/prM and 4G2 for E 
protein). Plates were then blocked with 1x TBS (with 0.05% Tween20) buffer containing 3% 
normal goat serum. 1N5 and 1C19 were tested at 2 µg/ml in blocking buffer. Secondary 
antibody (anti-human HRP) was used at 1:2500, followed by para-nitrophenylphosphate 
(pNPP) substrate. Purified DENV virus antigen and recombinant proteins (rE, EDI/DII, 
EDIII and pr) were generated as previously described (15, 16, 53). 
(ii) Binding analysis of 1N5 and 1C19 to mutant DENV virus. Binding curves of 1N5 
and 1C19 with WT and respective DENV2 escape mutants were generated using an ELISA 
protocol similar to the one described above. The only differences are, that equal amounts of 
WT and escape mutant virus were captured onto the plate with the mouse MAbs, 4G2 and 
2H2. And the human MAbs, 1N5 and 1C19, were used over a concentration range of 2 µg/ml 
to 0.002 µg/ml.  
 
DENV neutralization assays 
(i) Flow-based U937+DC-SIGN cell assay was conducted as described previously (15, 
28, 65). 
(ii) Flow-based Vero cell assay was conducted as described previously (15, 65).  
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(iii) Pre- and post-attachment neutralization assay was conducted as previously 
described (13, 25, 63). Briefly, as shown in Figure 4.6A, Vero cells were seeded in 24 well 
plates 48 hours prior to infection. On the day of the experiment, cells, antibodies and media 
were chilled by incubating at 4°C for 30 mins. For the pre-attachment neutralization assay, 
virus and antibodies were incubated at 4°C for 1 hr, then added to chilled vero cells and 
incubated for another 1 hr at 4°C. Cells were then washed three times with cold 1x PBS 
(4°C), and overlay media containing 1% methylcellulose was added to each well. Plate was 
then incubated at 37°C (under CO2) about 4-5 days post-infection, after which cells were 
fixed and stained. For the post-attachment neutralization assay, pre-chilled virus was added 
to pre-chilled vero cells and incubated at 4C for 1 hr. Cells were then washed twice with cold 
1x PBS (4°C), and incubated with diluted antibodies for another hour at 4°C. Cells were then 
washed once with chilled 1x PBS and incubated at 37C (under CO2), until cells are fixed and 
stained. Cells were fixed and stained as previously described (28, 65), where fixing with 80% 
methanol is followed by blocking with 5% non-fat dried milk in 1x PBS, staining with 4G2 
(for detection of DENV2-4) or 2H2 (for detection of DENV1), and anti-mouse HRP 
conjugated secondary antibody. Infection was detected as foci using a trypan blue substrate    
 
In vivo neutralization experiments with AG129 
 All in vivo experiments in AG129 mice were conducted by Katherine Williams in the 
laboratory of Dr. Eva Harris (UC, Berkley) using a previously described protocol (67). 
AG129 mice were administered human sera diluted to a final volume of 400 µl exactly 24 hrs 
prior to intra-venous (i.v.) challenge with DENV2 D2S10 (103 pfu). Between four to six 
hours prior to DENV2 infection, 100 µl per mouse of whole blood was extracted through a 
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small retro-orbital or sub-mandibular bleed, serum isolated by high speed centrifugation and 
serum used in the in vitro U937+DC-SIGN neutralization assay. After four days of infection, 
the mice were sacrificed, and several organs (i.e. spleen, bone marrow, liver and serum) were 
harvested, and viremia measured by quantitative-reverse transcription PCR (Q-RT-PCR).    
   
 
4.4 Results 
Further characterization of the 5J7 epitope 
 Prior escape mutant studies mapped several strongly neutralizing trype-specific 
human MAbs, including 5J7, to the DI-DII hinge of the E protein. A highly rare lysine 
insertion between amino acids 269 and 270 in the E protein enables DENV3 to significantly 
escape neutralization by 5J7 (16). Further passaging of WT DENV3 virus under 5J7 antibody 
pressure, generated two additional mutants (L53P and K128G) that were found to 
significantly escape neutralization by 5J7 (shown in Figure 4.1A). When the mutant residues 
were mapped on to the DENV3 E protein structure (RCSB 1UZG), all three escape mutation 
positions were in the EDI-DII hinge region. Furthermore, the three mutation positions were 
spatially situated within 20Å of each other (K128G-L53P = 11.4 Å; K128G-Q269_N270insK 
=14.4 Å; L53P-Q269_N270insK= 14.2 Å) and could easily form the footprint of an antibody 
epitope.    
Unlike 1F4 and 2D22, 5J7 binding was not restricted to an epitope created only when 
E proteins are assembled into the mature virion particle (16). Since 5J7 was found to bind the 
soluble recombinant E protein (rE), an attempt was made to expand the 5J7 epitope using a 
high throughput binding assay developed by Integral Molecular, Inc (12). The technique has 
been previously used to successfully map a cross-reactive fusion-loop binding MAb (12). 
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This binding assay involved the testing of 5J7 binding against a mutant panel of 
intracellularly expressed recombinant prM-E proteins. As indicated in Figure 4.1B, seven E 
protein mutants (Q52L, Q52R, L53P, L53Q, E126K, K128R and E133K) resulted in <20% 
reactivity with 5J7 as compared to the WT prM-E protein. Not so surprisingly, the amino 
acid positions 52, 53, 126, 128 and 133 fall within the EDI-DII hinge region, and are within 
20Å of each other. These mutation positions both confirm our escape mutant data and expand 
the footprint of the 5J7 epitope.   
  
The EDI-DII hinge region is a major target of type-specific protection in humans   
 As shown in chapter 3, several potently neutralizing type-specific antibodies directed 
at the EDI-DII hinge region were isolated from human memory B-cells of individuals with 
past natural DENV infections (16). However, antibodies of this nature were rare, making it 
difficult to gain insight into the dominant viral target of protective antibodies in DENV-
immune humans. Therefore, we utilized our knowledge of the 5J7-binding site, and 
compared the variable amino acid residues between DENV3 and DENV4 that fell within 
12Å of the 5J7 epitope on the EDI-DII hinge region in the E protein structure. As shown in 
Figure 4.2A, twenty-six variable amino acid sites were identified as possible critical binding 
sites within this epitope. We inserted twenty-six DENV4 residues (i.e. K51Q, E52Q, V53L, 
L55T, T58K, Y59L, K124R, T126E, N128K, L129V, M199L, K200T, K203N, T205A, 
L207M, K210R, L214F, A222S, U270I, D271Q, S272N, G273S, D274G, N276T, H277S, 
M278I) in to the EDI-DII hinge of the DENV3 infectious clone (UNC3001), and termed the 
hinge mutant virus as UNC3001-A12. It is important to note that the prediction of critical 
amino acid residues on the EDI-DII hinge region and the insertion of these 26 mutations into 
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the DENV3 infectious clone were work conducted in the laboratory of Ralph Baric 
(specifically by William B. Messer, Jeremy Huynh and Boyd Young). 
 Insertion of 26 mutations into the EDI-DII hinge of DENV3 gave a productive, live 
virus (UNC3001-A12) that grew to titers similar to the WT virus (UNC3001) in C6/36 
mosquito cells (replication kinetic data not shown). The non-EDI-DII hinge binding anti-
EDII MAb, 1N5, was used to ensure that mutation of the EDI-DII hinge region did not lead 
to complete misfolding of EDII (Figure 4.2B and D). Additionally, neutralization assays of 
WT and UNC3001-A12 against 5J7 were also used as a control to confirm complete loss of 
neutralization due to mutation of the EDI-DII hinge (Figure 4.2C and E). Neutralization 
experiments with a panel of four primary DENV3-immune human sera showed that mutation 
of the EDI-DII hinge significantly (P<0.001) reduced the neutralizing capacity of the sera 
(Table 4.1). Similar data was also generated by William B. Messer in the laboratory of Ralph 
Baric (data not shown). This implies that humans infected with primary DENV3 mount a 
protective antibody response that target the EDI-DII hinge. Similar neutralization assays with 
two primary DENV4-immune human sera showed that mutation of the EDI-DII hinge in the 
DENV3 virus to DENV4 residues was sufficient to significantly (P<0.001) increase the 
neutralization capacity of the sera (Table 4.1). This gain of neutralization phenotype 
indicated an unexpected, successful transplant of a DENV4 neutralizing epitope into the 
DENV3 virus background. This indicates that antibodies that target the EDI-DII hinge region 
contribute substantially to long-term type-specific protection after primary infections in 
humans.  
In an attempt to gain insight into the epitopes targeted after secondary infections, we 
also used the WT and UNC3001-A12 to conduct preliminary neutralization assays against 
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convalescent serum from individuals who had been exposed to secondary infections. As 
shown in Table 4.1, no significant differences were observed between neutralization of WT 
versus UNC3001-A12. Therefore, although the EDI-DII hinge region is a dominant target of 
type-specific neutralizing antibodies, it may not necessarily be the target of cross-protective 
antibodies.  
Potently cross-protective human MAbs target domain II of the E protein  
 Cross-protective neutralization after DENV infections in humans is observed during 
two main situations, 1) transiently after primary DENV infections, and 2) long-term after 
secondary infections (2, 14, 50). It is thought that transient cross-protection after primary 
DENV infections maybe due to large quantities of low affinity, weakly cross-neutralizing 
antibodies. However, conserved antigenic epitopes in secondary infections may stimulate 
affinity maturation of weakly cross-neutralizing antibodies into higher affinity antibodies that 
provide cross-protection long-term. Apart from moderately cross-neutralizing anti-fusion 
loop antibodies, no potently cross-neutralizing DENV-specific mouse or human MAb have 
been described in the literature (12). Therefore, very little it known about the viral epitope(s) 
that cross-protective human antibodies target.    
 To investigate the cross-protective epitopes of targeted by the human antibody 
response, we isolated two potently cross-neutralizing human MAbs, 1N5 and 1C19. Both 
1N5 and 1C19 were isolated from PBMCs donated by two individuals with a secondary 
DENV3 infection. These PBMCs were kindly given by the laboratory of Dr. Eva Harris (UC, 
Berkley) to the laboratory of Dr. James Crowe (VU) for MAb isolation. As shown in Table 
4.2, 1N5 neutralized all four serotypes with Neut50≤ 0.5 µg/ml, while 1C19 potently 
neutralized DENV1, 2 and 3 (Neut50 < 0.1 µg/ml) and only moderately neutralized DENV4 
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(5 µg/ml <Neut50 > 1 µg/ml). Both antibodies bound virus and rE protein from all four 
serotypes, but did not bind prM by ELISA or Western blot analysis (Table 4.2). Neither 1N5 
nor 1C19 bound EDIII, but as expected bound recombinant EDI/DII protein. This indicated 
to us that unlike the cross-protective mouse MAbs described in literature that were mapped to 
the A strand epitope of EDIII (20, 33, 58), both 1C19 and 1N5 bound to a novel cross-
protective epitope within EDI/DII. 
 In an attempt to map the viral epitopes targeted by cross-protective human antibodies, 
DENV2 (S-16803) was passaged under 1N5 or 1C19 selection pressure, and neutralization 
escape mutants with at least a ten-fold reduction in neutralization were generated against the 
antibodies (Figure 4.3A and B). Two escape mutants with the point mutations M118K and 
E126K were raised against 1N5, while three escape mutants with the single mutations E62Q, 
M118K and T120K were generated against 1C19 (Table 4.3). Mapping the mutated residues 
on the DENV2 E protein structure (RCSB 1OAN) revealed that the escape mutations for both 
human MAbs fell in the middle of EDII (Figure 4.3E). Both 1C19 and 1N5 were found to 
bind equally to their respective escape mutants and WT DENV2 virus (Figure 4.3C and D), 
indicating that although these mutations led to significant escape from neutralization, it did 
not ablate binding to the virus. Surprisingly, the 1C19 MAb was mapped by the intracellular 
prM-E mutant panel to residues R73 and G78 on the DENV E protein, which unlike the 
escape mutant residues lie on a loop above the fusion loop (Figure 4.4). Presently, the R73A 
and G78A mutations that ablated 1C19 binding is being inserted into a DENV2 infectious 
clone for further conformation and characterization.  
  At this moment, it is unclear whether the mapping of 1C19 by neutralization escape 
mutants or by the mutant prM-E panel was more accurate. However, it is worth mentioning 
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that two of the three WT DENV2 samples passaged in Vero cells in the absence of 1C19 
selection also raised neutralization escape viruses with similar mutations (data not shown). 
Further analysis of the neutralization escape mutants revealed that the mutations increased 
the positive charge on the virus. Studies have shown that increase in positive charge in this 
region increases binding of DENV to heparin sulfate on the cell surface (46). It is possible 
that these escape mutations also increased binding to heparin sulfate and thereby, presented 
an indirect mechanism of neutralization escape from 1C19 by increasing infectivity of Vero 
cells. The possible role of heparin sulfate in the neutralization escape from 1C19 in Vero 
cells is being presently investigated.    
 
Insights into the mechanism of protection of strongly neutralizing human antibodies 
Since two of the three potently neutralizing type-specific antibodies were non-rE 
protein binding, cryo-EM studies are being conducted by Shee Mei Lok Lab (National 
University of Singapore) for further detailed characterization of the binding epitopes. The 
Fab fragments of 1F4, 2D22 and 5J7 were produced for mapping of these antibodies by cryo-
EM. As shown in Figure 4.5F, Fab fragments lack both bivalency and the Fc portion of 
whole antibodies. Interestingly, the neutralization potency of some antibodies is dependent 
on the bivalency of the antibody. Therefore, to gain some insight into the mechanism of 
neutralization, we compared the neutralization properties of Fab versus MAbs of 1F4, 2D22 
and 5J7. As shown in Table 4.4, there was about a ~10 fold difference in Neut50 between Fab 
versus MAb for both 1F4 and 2D22. This difference in Neut50 was observed regardless of 
whether the neutralization assay was conducted in Vero cells or the FcγR-bearing cells, 
U937+DC-SIGN. Therefore, bivalency is not required for DENV neutralization by 1F4 and 
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2D22, and the minor difference in Neut50 is probably due to a decrease in affinity in the Fab 
fragment.  
Comparing neutralization profiles of 5J7 Fab versus MAb showed interesting 
differences. Although both Fab and MAb of 5J7 was capable of neutralizing DENV3 to 
100% in Vero cells (Figure 4.5A and B), saturating concentrations of 5J7 Fab were only able 
to neutralize less than 50% of DENV3 in U937+DC-SIGN cells (Figure 4.5 C and D). Past 
studies have shown that the presence of FcγR can have a drastic impact on DENV 
neutralization by certain groups of antibodies (9, 38, 39, 68). However, blocking the FcγR on 
U937+DC-SIGN cells using 1% normal human sera had no effect on DENV3 neutralization 
by 5J7 Fab or MAb (Figure 4.5E). At the moment, the reason for the cell-specific observance 
of the lack of complete DENV3 neutralization with excess 5J7 Fab is unclear, and further 
experiments are presently being conducted to investigate this unusual phenomenon.   
 Most DENV-specific antibodies either neutralize by blocking attachment of DENV to 
host receptor(s) (i.e. pre-attachment blocking) or by inhibiting a step after attachment, and 
thereby preventing viral fusion (i.e. post-attachment blocking). Thus, as shown in Figure 4.6, 
we conducted pre- and post-attachment neutralization assays to investigate the mechanism of 
neutralization of the type-specific neutralizing and cross-neutralizing human MAbs that we 
had isolated. The type-specific MAbs, 1F4, 2D22 and 5J7 strongly neutralized DENV1, 
DENV2 and DENV3, respectively at 4°C (Figure 4.6B, C and D). As shown on Figure 4.6, 
there is no statistical difference in the pre versus post-attachment Neut50 titers of 1F4, 2D22 
and 5J7 (Figure 4.6 B, C and D, respectively), signifying that these three type-specific MAbs 
neutralize primarily at a post-attachment step. The pre- and post-attachment neutralization 
assays were inconclusive for the cross-neutralizing human MAbs, 1N5 and 1C19, since 
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neutralization by these MAbs were temperature sensitive and did not efficiently neutralize 
DENV2 at 4°C (Figure 4.6 E and F). In an attempt to extend mechanistic studies to DENV-
immune human polyclonal sera, we conducted pre- and post-attachment neutralization assays 
with a panel of eight primary DENV immune, late convalescent human sera. We found that 
only four out of the eight sera (i.e. 50%) primarily neutralized DENV at a post-attachment 
step (Table 4.5). Although this observation must be extended to a larger panel of primary 
DENV-immune sera, it seems that type-specific DENV neutralization after natural infections 
is not limited to post-attachment blocking mechanisms.         
  
Antibodies that do not target the structural DENV proteins are also protective in vivo 
 Several in vitro experiments were extended to in vivo experiments with the AG129 
mouse model. Human sera were sent from our laboratory to the laboratory of Dr. Eva Harris, 
and all in vivo experiments in AG129 mice were conducted by Katherine Williams at the 
laboratory of Dr. Eva Harris (UC, Berkley). Neutralization analysis of pre-challenge bleeds 
from AG129 mice 24 hrs after passive transfer of human sera, confirmed prior observed in 
vitro results (in chapter 3) by showing that the removal of cross-reactive antibodies from 
primary DENV2-immune human sera did not significant affect Neut50 titers  (Figure 4.7A). 
Challenge studies with the mouse-adapted DENV2 D2S10 strain showed that removal of 
cross-reactive antibodies from primary DENV2-immune sera did not significantly affect viral 
titers in serum, spleen or bone marrow (Figures 4.7B, C and D).       
 Depletion of DENV2-binding antibodies from primary DENV2-immune human sera 
was used as a control to show successful depletion of DENV neutralizing antibodies. In vitro 
analysis of DENV2-depleted primary DENV2-immune sera showed a removal of greater 
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than 95% of the serum neutralizing potency. Similarly, neutralization analysis of pre-
challenge bleeds from AG129 mice indicated statistically similar Neut50 titers between naïve 
human sera and DENV2-depleted primary DENV2 immune sera (Figure 4.7A). However, it 
was observed in the viral challenge studies that viral titers in serum, spleen and bone marrow 
were significantly different between mice with passively transferred naïve human sera and 
mice with DENV2-depleted primary DENV2-immune sera (Figure 4.7 B, C and D). 
Surprisingly, removal of DENV virus-binding antibodies from serum, did not completely 
remove protection against DENV challenge. Further investigations are being conducted to 
determine the source of this significant residual protection observed in vivo.  
 
4.5 Discussion 
 Until recently, very little was known about the viral epitopes targeted by the 
protective antibody response in humans. Improvements in the development of human 
hybridoma technology have enabled the isolation and characterization of numerous DENV-
specific human antibodies (4, 5, 15, 17, 21, 53, 61, 71). Several recent studies have found 
that the human antibody response is predominantly cross-reactive and weakly neutralizing, 
while strongly neutralizing antibodies make up a minor population of the entire antibody 
response (4, 15, 17, 53). We previously mapped three strongly neutralizing type-specific 
antibodies to a complex, quaternary epitope that includes the EDI-DII hinge (16). Similarly, 
another recent study mapped a DENV1-specific, strongly neutralizing human MAb 
(HM14c10) by cryo-EM to the EDI-DII hinge (59).  
 In the present study we further mapped the EDI-DII hinge epitope and mutated 
residues in the DENV3 EDI-DII hinge region into DENV4 residues. We showed that this 
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hinge mutant (UNC3001-A12) virus not only significantly escapes neutralization from 
primary DENV3-immune human sera, but also gains neutralization by primary DENV4-
immune sera. Therefore, we successfully mapped the dominant DENV epitope responsible 
for type-specific protection in humans. Furthermore, this is the first time in the DENV field 
that a successful epitope transplant has been conducted, and that too against human 
polyclonal sera.  
Comparison studies of the E protein structure between DENV2 and DENV3 
emphasize that in addition to amino acid differences in the EDI-DII hinge, there was also a 
10° angular difference between the serotypes (35, 37). It is possible that serotype-specificity 
is not only achieved by the differences in amino acid residues in the EDI-DII hinge, but also 
by the angular difference between serotypes. Cryo-EM and X-ray crystallography studies 
comparing the WT (UNC3001) and the hinge mutant (UNC3001-A12) should be conducted 
to investigate this.  
It is important to take note that several of the WT DENV passaged in the absence of 
neutralizing antibody pressure led to mutations in the EDI-DII hinge region that led to 
neutralization escape from 1F4 and 5J7 (data not shown). Several published studies have 
indicated the EDI-DII hinge as being one of the areas that accumulated mutations when 
DENV is repeatedly passaged in cell culture (31). It is shown that mutations in the EDI-DII 
hinge changes the pH-threshold of fusion, and better adapts the virus to pH changes in cell 
culture (3, 7, 22, 26, 31, 35, 40). Furthermore, it’s also shown that mutations in this region 
also adapt the virus to mice, leading to an encephalitic phenotype (22, 40).      
The mechanism of virus neutralization by flaviviral antibodies is generally accepted 
as blocking either attachment (13, 23, 43), or a step post-attachment (18, 49, 56, 60, 63). 
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Many flaviviral-specific mouse MAbs that bind the EDIII or the fusion loop has been found 
to neutralize by blocking fusion or a step post-attachment (49, 56, 60). The EDI-EDII hinge 
plays an important role in viral fusion. The EDI-DII hinge undergoes a large conformational 
change during viral fusion as E protein dimers disengaged and form E trimers (reviewed in 
(41)). As expected, we found that the EDI-DII hinge binding antibodies all neutralized 
DENV by blocking a post-attachment step. Investigation with polyclonal sera, showed that 
primary DENV-immune human sera is more complicated and does not necessarily always 
neutralize through a post-attachment blocking mechanism. The EDI-DII hinge binging MAb, 
HM14c10, was found to neutralize predominantly by blocking virus attachment to cells (59). 
Therefore, EDI-DII hinge binding antibodies can neutralize by blocking either attachment or 
a step post-attachment.      
In vitro analysis of antibody neutralization is often complicated by the cell line being 
used to conduct the assay. The presence of FcγR-bearing cell lines can distinguish between 
homotypic neutralization and heterotypic neutralization by human immune-sera (9, 38, 39, 
68). Chan, et al 2011 (9), provided the molecular mechanism of this observation; weakly 
neutralizing antibodies at high concentrations form aggregates, which then binds to the 
inhibitory FcγRIIB on the surface of monocytes or macrophages. At low concentrations, 
these antibodies promote ADE of the virus that it binds (9). We initially hypothesized that 
maybe the difference in 5J7 neutralization in the two cell lines (Vero and U937+DC-SIGN) 
was due to the presence of FcγR in U937+DC-SIGN cells (Figure 4.5). Neutralization 
experiments in the presence and absence of blocked FcγR showed no difference in 
neutralization. This was not unexpected since the cell-specific 5J7 neutralization difference 
was only observed with the 5J7 Fab and not with the whole MAb. Unpublished data by our 
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group show that virus with higher partially immature states cannot infect Vero cells, while 
infection in FcγR-bearing cells (such as U937+DC-SIGN cells) is not very sensitive to 
different states of virus maturity. It is possible that the 5J7 Fab is especially sensitive to virus 
maturity, and hence is unable to neutralize a fraction of the virus population. This hypothesis 
is presently being tested.         
 Cross-protection is observed transiently following a primary DENV infection and 
long-term after a secondary DENV infection (1, 2, 14, 50). The only cross-protective MAbs 
described in literature to date are weakly to moderately neutralizing human MAbs. These 
MAbs either bind the highly conserved fusion loop or the prM protein (4, 12, 15, 17, 53). In 
the present study, we described two strongly cross-neutralizing human MAbs, 1N5 and 
1C19. Although there is some discrepancy in the mapping data using escape mutants or 
mutant E proteins, 1N5 and 1C19 does not map to the same region (i.e. fusion loop or prM 
protein) as cross-neutralizing MAbs described in literature.  
  The AG129 mouse model is traditionally used as a lethal enhancing model for 
investigating ADE of DENV (reviewed in (73)). However, the AG129 model has also been 
optimized for studying the neutralization properties of DENV-specific antibodies (6, 74). We 
showed using in vivo experiments that cross-reactive antibodies do not contribute to long-
term protection of the homotypic virus after a primary DENV infection. Surprisingly, 
removal of >95% of in vitro neutralization in a primary DENV-immune sera using the 
homotypic virus, did not ablate protection in vivo. Depletion with DENV virus only removes 
antibodies specific to the structural proteins, E and prM. Primary DENV infections also 
produce detectable amounts of NS1-specific antibodies. Although there is some controversy 
around the role of anti-NS1 antibodies, there are several studies that show that NS1-specific 
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antibodies can offer some protection against DENV challenge in vivo (11, 24, 52, 69). 
 This chapter attempts to further characterize the human antibody response. To date, 
natural DENV infections have resulted in the most successful DENV immunizations in 
humans. We are hoping that the identified immune and mechanistic role of the EDI-DII 
hinge in long-term, type-specific protection will help current vaccine developers to assess the 
quality and epitopes targeted by their vaccines. Furthermore, we realize the complexity of 
antibody neutralization, and caution basic scientists and vaccine developers to take into 
consideration the effects of different cell lines, in vivo components and NS1-specific 
antibodies when assessing neutralization properties of antibodies in vitro.  
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Figure 4.1 Additional mapping data for 5J7. A) Neutralization assays showed the 
generation of two additional escape mutants (with mutations L53P or K128G). B) An 
intracellular prM-E-binding assay was used to further characterize the binding epitope of 5J7. 
Proper folding of the prM-E proteins being tested were confirmed using a panel of mapped 
MAbs, such as D004 (anti-fusion loop) and D178 (anti-EDII) The binding assays were 
conducted by Kristen Kahle and Jen pfaff from Integral Molecular, Inc.  
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Figure 4.2 Twenty-six amino acid residues on the DI-DII hinge of DENV3 E protein was 
successfully mutated to the corresponding residues in DENV4. A) The 26 mutated 
positions highlighted on the WT DENV3 E protein dimer structure. As expected, the non-
EDI-DII hinge-binding control MAb, 1N5, neutralizes both WT (UNC3001) and EDI-DII 
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hinge mutant (UNC3001-A12) similarly, in both B) U937+DC-SIGN and D) Vero cells. 
Mutating the EDI-DII hinge in DENV3, significantly ablates neutralization by the EDI-DII 
hinge-binding MAb, 5J7, in both C) U937+DC-SIGN and E) Vero cells. 
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Figure 4.3 Mapping 1N5 and 1C19 through neutralization escape mutants. EDII mutants 
show significant neutralization escape, but not binding escape from 1C19 (A & C) and 1N5 
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(B & D). E) All the escape mutations selected against 1C19 and 1N5 mapped to the middle 
of EDII. The binding data of 1C19 and 1N5 to the neutralization escape mutants were 
generated by Jennifer McGraw. 
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Figure 4.4 Epitope mapping of 1C19 using a DENV3 prM-E mutant library. A) Show 
that the mutations R73A and G78A significantly ablates binding of 1C19 as compared to WT 
DENV. B) Amino acid residues R73 and G78 are on a loop situated above the fusion peptide 
in EDII. The binding assays were conducted by Integral Molecular, Inc.  
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Figure 4.5 Neutralization differences of 5J7 fAb in Vero versus U937+DC-SIGN not due 
to Fcγ  receptors. Both 5J7 whole Ab (A) and fAb (B) neutralizes DENV3 to 100% in Vero 
cells. Unlike the whole Ab (C), the neutralization of of 5J7 fAb (D) against DENV3 saturates 
before 100%. (F) Apart from bivalency, the main difference between whole Ab and fAb is 
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the absence of an Fc portion in the fAb. (E) However, this difference in neutralization 
between U937+DC-SIGN and Vero cells is not due to the presence of FcγR, because pre-
blocking the FcγR in U937+DC-SIGN cells with 1% normal human sera did not affect 
neutralization. 
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Figure 4.6. Pre-attachment and post-attachment neutralization analysis of strongly 
neutralizing human monoclonal antibodies. A) As shown, pre-attachment and post-
attachment neutralization assays were conducted at 4°C. The type-specific MAbs, 1F4 (B), 
	  	   156	  
2D22 (C), and 5J7 (D), can neutralize the respective DENV serotype at a step after viral 
attachment to cells. DENV neutralization by the cross-reactive MAbs, 1C19 (E) and 1N5 (F), 
is sensitive to temperature and difficult to assess by this assay.     
 
 
 
 
 
 
 
 
 
 
	  	   157	  
 
 
 
 
Figure 4.7 Neutralization analysis of virus-depleted human serum in AG129 mice. Mice 
were administered 50 µl of each human serum diluted to a final volume of 400 µl, 24 hrs 
prior to challenge with DENV2 D2S10. A) About 4-6 hrs prior to DENV infection, small 
retro-orbital or sub-mandibular bleeds were taken and analyzed for circulating pre-infection 
neutralization titers. Four days post-infection, mice were sacrificed, organs harvested, and 
A. B.
C. D.
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viral load in the serum (B), bone marrow (C) and spleen (D) assessed by Q-RT-PCR. Data 
collected by Katherine Williams (in the laboratory of Dr. Eva Harris). Data representative of 
experiments conducted with two different primary DENV2-immune sera.  
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Table 4.1 Effects of swapping the DENV3 EDI-DII hinge with DENV4 residues on 
neutralization by DENV-immune human sera.   
 
Reciprocal of Neut50 titer (SEM) 
Infection  
type 
Serum 
Sample ID 
WT 
(UNC 3001) 
Hinge Mutant 
(3001-A12) 
IRB 003 812 (1200-550) 
98* 
(115-85) 
DT 105 602 (900-400) 
60 * 
(190-20) 
DT 118 8500 (13,250 -5500) 
600* 
(1200-325) 
Primary DENV3 
DT 125 3390 (4700-2450) 
102* 
(150-70) 
DT 100 60 (115-30) 
590* 
(760-460) 
Primary DENV4 
DT 102 56 (90-35) 
630* 
(840-475) 
IRB 000 470 (600-370) 
380 
(560-260) 
Secondary 
IRB 027 590 (930-370) 
860 
(1200-600) 
 
*Hinge mutant Neut50 statistically different from WT Neut50 at P<0.001 
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Table 4.2 Binding and neutralization characteristics of two broadly neutralizing human 
MAbs that were isolated.  
 
  Binding (2 µg/ml) Neut50 titer (µg/ml)a 
MAb Donor Virus rE EDI/DII EDIII Prc DV1 DV2 DV3 DV4 
1N5b Secondary Complex (All four DV) + + - - 0.14 0.20 0.50 0.40 
1C19 Secondary Complex (All four DV) + + - - 0.06 0.03 0.04 2.74 
 
aNeutralization assay for represented neutralization data was conducted using U937+DC-
SIGN cells. 
bPre-inoculation with 1N5 was observed to significantly reduce viremia in the liver, spleen, 
bone marrow and serum of AG129 mice challenged with D2S10.     
c1N5 and 1C19 did not bind to viral prM by Western blot analysis either.    
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Table 4.3 Successful generation of several DENV2 neutralization escape mutants 
against 1C19 and 1N5.  
 
Human MAb Serotype Mutant # Escape Mutation 
1 M118K 1C19 DENV2 
2 E126K 
1 E62Q 
2 M118K 
1N5 DENV2 
3 T120K 
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Table 4.4 Neutralization properties of DENV by whole MAb versus fAb in two different 
cell lines.   
 50 % Neutralization titer [nM] (SEM) 
 U937+DC-SIGN cells Vero cells 
 Whole MAb fAb Whole MAb fAb 
1F4 0.19 
(0.17-0.21) 
2.15 
(1.86-2.45) 
0.16 
(0.11-0.22) 
1.20 
(0.10-1.50) 
2D22 1.47 
(1.35-1.62) 
12.40 
(5.00-35.01) 
0.59 
(0.48-0.72) 
2.00 
(1.60-2.45) 
5J7 0.57 
(0.49-0.68) 
3.75* 
(0.01-1862) 
0.04 
(0.03-0.04) 
0.70 
(0.45-1.12) 
 
  *Neutralization curve of 5J7 fAb against DENV3 virus saturated before reaching a 100%. 
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Table 4.5. Pre- and post-attachment neutralization assays with a panel of late 
convalescent primary DENV-immune human sera.    
 
  Reciprocal of Neut50 titer (SEM) 
Infection 
type 
Serum 
Sample ID Pre-attachment 4°C Post-attachment 4°C 
IRB 006 300 (200-430) 
90* 
(53-140) 
DT 106 310 (235-400) 
25* 
(20-35) 
GL 010 1100 (725-1660) 
580 
(400-870) 
Primary DENV1 
 
GL 024 880 (560-1350) 
200* 
(135-300) 
IRB 001 155 (130-180) 
87 
(52-145) 
Primary DENV2 
DT 110 1000 (830-1200) 
575 
(430-800) 
DT 100 70 (40-125) <10 
Primary DENV4 
DT 102 200 (120-330) 
330 
(250-560) 
  
    *Post-attachment Neut50 statistically different from pre-attachment Neut50 at P<0.05 
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CHAPTER FIVE 
Mapping Enhancing Antibodies Produced by the Human Immune Response After 
Primary Dengue Virus Infections. 
 
 
5.1 Overview 
 Antibody dependent enhancement (ADE) is the leading theory for why some people 
develop severe disease following a secondary dengue virus (DENV) infection. The viral 
epitopes recognized by enhancing antibodies after natural infections have not been fully 
defined. We used antibody-depletion techniques to remove heterotypic DENV-specific and 
rE-specific antibodies from primary DENV-immune sera. The depletion effects of specific 
antibodies on ADE of heterotypic virus infection were tested both in vitro (K562 cells) and in 
vivo (AG129 mouse model). Removal of cross-reactive antibodies ablated enhancement of 
heterotypic virus infection. Furthermore, we observed that both rE-specific and prM-specific 
antibodies in primary DENV-immune sera significantly contribute to enhancement of 
heterotypic DENV infection. We hope that the identification of enhancing epitopes would 
facilitate the development of safe, non-enhancing vaccines against DENV. 
5.2 Introduction 
 Primary infections with DENV produce a cross-reactive immune response in humans, 
but protection is only against the serotype of infection. Due to the phenomenon of antibody 
dependent enhancement (ADE), these weakly neutralizing, cross-reactive antibodies lead to a
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higher probability of severe disease (DHF/DSS) during secondary infections (10, 11, 32). 
During ADE, cross-reactive antibodies bind virus at sub-neutralizing concentrations, and 
enter host cells (such as monocytes and macrophages) through FcγR-mediated endocytosis 
(reviewed in (30)). Productive DENV infections through ADE (as compared to the 
conventional route of entry) have been found to result in higher viremia and a suppressed 
host antiviral state (3, 4, 9, 12, 15, 23, 30). The possibility of exacerbating DENV infections 
through ADE presents vaccine developers with a challenging task. Therefore, it is imperative 
that we identify the viral epitopes targeted by enhancing populations of antibodies in humans.     
Development of a suitable small animal model for investigation of DENV infection 
and antibody responses have been severely hindered by the low or lack of DENV replication 
in wild type immune-competent mouse models. The earliest mouse models consisted of 
intracranial DENV challenges in immune-competent suckling mice. Unfortunately, these 
models resulted in death through non-human-like DENV-induced disease, such as 
neurological disease and paralysis (21, 25). Replication in a rodent model was first shown in 
the IFN α/β and γ receptor deficient mouse mode, AG129 (13). It was further discovered that 
the AG129 mouse model also presents a human-like vascular leakage lethal syndrome when 
challenged with DENV in the presence of DENV-specific antibodies (1, 26, 36). Therefore, 
the AG129 is presently the most suitable animal model available for testing ADE of DENV 
infections.     
 Recent studies (including chapter 2) investigating the memory B-cell response after 
natural DENV infections have revealed that the antibody response in humans is dominated 
by cross-reactive, weakly neutralizing antibodies (2, 5, 7, 28). These cross-reactive 
antibodies were found to efficiently enhance DENV infection, and usually over a wide range 
	   175	  
of concentrations (2, 5, 7, 28). A study analyzing the memory B-cell response after human 
immunization with a leading DENV vaccine candidate, observed a similar dominantly cross-
reactive, weakly neutralizing and highly heterotypic virus-enhancing antibody response (27). 
A majority of these cross-reactive human MAbs mapped to either the prM or the E protein 
(2, 5, 7, 28).  
Any DENV-specific antibody, regardless of neutralization potency, will at some 
concentration enhance infection in FcγR-bearing cells. To investigate the viral epitopes 
targeted by antibodies responsible for enhancement of secondary infection, it is insufficient 
to analyze enhancement properties of isolated human MAbs. We need to look at the antibody 
repertoire in circulation prior to infection, and conduct ADE assays at Ab concentrations that 
approximate physiological concentrations in circulation. Therefore, the present study 
investigates the antibody groups responsible for enhancement of heterotypic serotypes by 
studying late convalescent human sera following natural primary DENV infections. The 
proposed studies will be conducted both in vitro (using the FcγR-bearing cell line, K562) and 
in vivo (using the AG129 mouse model).      
 
5.3 Methods 
Virus and cell lines 
 All in vitro assays were conducted with the DENV WHO reference strains, i.e. 
DENV1 West Pac 74, DENV2 S-16803, DENV3 CH54389 and DENV4 TVP-360. The 
WHO reference viruses were initially obtained from Dr. Robert Putnak (Walter Reed Army 
Institute of Research, Silver Spring, MD). All in vivo assays in the AG129 mice were 
conducted using the widely used mouse-adapted DENV2 D2S10 stain (26). All viruses were 
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infectious assays were grown as described previously in chapter 4 using the mosquito cell 
line, C6/36 (33). All viruses for antigen purification were grown in the mammalian cell line, 
Veros. In vitro ADE assays were conducted using K562 and/or U937 cells. Cell lines were 
obtained from ATCC.     
 
Human sera and Fabs 
 As described in chapter 4, blood donations were obtained from individuals who had 
travelled to DENV endemic regions and experienced a primary DENV2 or DENV3 infection. 
These human samples were obtained with informed consent and approximately 2 to 10 yrs 
after DENV infection. All donations were taken in compliance with the Institutional Review 
Board of the University of North Carolina at Chapel Hill. The whole blood samples were 
processed to serum for use in the following experiments. 
The MAbs 2D22 (DENV2-specific, EDI-DII hinge binding), 1C19.2 (cross-reactive, 
EDIII-binding), 1B22 (cross-reacitve, prM-binding) and 2K2 (cross-reacitve, prM-binding) 
were generated in collaboration with Scott Smith in the laboratory of Dr. James Crowe (VU). 
The Fab fragments of 2D22 (2D22 Fab), 1C19.2 (1C19 Fab), 1B22 (1B22 Fab) and 2K2 
(2K2 Fab) were generated through enzymatic digestion of the respective MAbs.      
  
Depletion of virus-specific antibodies from human sera 
 Human sera were depleted of virus-specific antibodies as previously described in 
chapter 3 (6). Briefly, heterotypic virus was grown in vero cells and purified using 
ultracentrifugation, sucrose cushion and Opti-prep gradients as described previously (6, 33). 
The highly purified DENV virus was then passively adsorbed to polystyrene beads (4.5 µm), 
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and incubated with human sera at 37°C to remove the appropriate DENV-specific antibodies. 
Successful depletion was assessed using a virus-binding ELISA. 
 
Depletion of rE-specific antibodies from human sera 
 Human sera were depleted of rE-binding antibodies as previously described in 
chapter 3 (6). Briefly, purified rE protein from all four serotypes were bought from Hawaii 
Biotech. Purified rE was covalently conjugated to cyanogen bromide (CNBr) activated beads 
using amine chemistry. The rE conjugated beads were then incubated with human sera at 
37°C to remove rE-specific antibodies. Successful removal of all cross-reactive rE-specific 
antibodies was confirmed using a rE-binding ELISA.   
 
ELISA binding assays 
 Binding assays of depleted sera to purified DENV virus and/or rE protein was 
conducted as previously described in chapter 3 (6). DENV Virus or rE were either directly 
coated or captured by the anti-E protein mouse MAb, 4G2, blocked with 1% normal goat 
serum, incubated with human serum diluted to 1:20, and binding detected with an alkaline 
phosphatase-conjugated anti-human secondary antibody.    
 
ADE assay in K562 cells 
 In vitro ADE assays were conducted in K562 cells as previously described (35). 
Human sera were diluted 2-fold starting from 1:20, then incubated for 1 hr at 37°C with virus 
at an MOI of 1.0. Approximately 5x104cells were added to each well containing virus-
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antibody mixtures and then incubated for 2 hrs at 37°C, after which cells were washed 2x 
with fresh media and incubated at 37°C for another 22 hrs. Cells are fixed 24 hrs post-
infection, stained for infection and run on a flow-cytometer to measure percent infections.        
 
ADE assay in AG129 mice 
 In vivo ADE assays in AG129 mice were conducted in Eva Harris Lab as previously 
described (35). AG129 mice were administered with DENV-immune sera or naïve sera in a 
final volume of 400 ul, about 24 hrs prior to i.v. challenge with a sub-lethal 104 pfu dose of 
DENV2 D2S10. Mice were then observed over a 10 day period, and scored for morbidity and 
mortality.    
 
5.4   Results  
ADE of DENV in K562 cells and the AG129 mouse model 
 First, we optimized the ADE assay with the human erythromyeloblastoid leukemia 
cell line, K562, for investigation of enhancing antibodies in human sera. As shown in Figure 
5.1, primary DENV-immune human sera enhanced the heterotypic serotypes at very high 
serum concentrations (i.e. ≥ 1:80), while homotypic serotypes (as expected) were only 
enhanced at low serum concentrations (i.e. ≤ 1:640). Homotypic serotypes are neutralized at 
high serum concentrations; therefore understandably, no enhancement can be seen at these 
serum concentrations.  
Similarly, human sera (both naïve and DENV-immune) were titrated in the AG129 
mouse model to optimize the serum concentration of peak DENV enhancement. The AG129 
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mice were passively administered with human immune sera 24 hrs prior to challenge with the 
mouse-adapted virus, DENV2 D2S10 (Figure 5.2A). As shown in Figure 5.2B, the 
homotypic immune human sera (i.e. primary DENV2-immune) protects the mice from a 
lethal DENV2 challenge, while passive transfer of the same quantity of heterotypic human 
serum (i.e. primary DENV1, DENV3 or DENV4-immune sera) leads to an ADE-induced 
mortality.  
 
Depletion of cross-reactive antibodies ablated ADE of heterotypic DENV virus 
 Next we used the in vitro and in vivo models to identify specific Ab populations in 
polyclonal sera that drive ADE. Several primary DENV2-immune sera were depleted with 
the heterotypic virus, DENV3, while several primary DENV3-immune sera were depleted 
with the heterotypic virus, DENV2. As shown in Figure 5.3A, successful virus-specific 
depletion was confirmed using a virus-binding ELISA. Further characterization of DENV 
binding and neutralization by heterotypic virus-depleted primary DENV-immune sera is 
described in chapter 3 (6). In vitro ADE studies with heterotypic-virus depleted sera, showed 
that removal of heterotypic DENV virus-binding antibodies from human sera, completely 
ablated enhancement of heterotypic serotypes (Figure 5.3).   
  Heterotypic virus-depleted DENV-immune sera were then passively transferred into 
AG129 mice to indirectly assess the role of cross-reactive antibodies in DENV enhancement 
in vivo. Passive transfer of primary DENV3-immune sera into AG129 showed significant 
morbidity and mortality when challenged with a sub-lethal dose of DENV2 D2S10 (Figure 
5.4). However, removal of all heterotypic virus-binding antibodies from primary DENV3-
immune sera decreased morbidity and percent survival to levels similar to mice administered 
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with naïve human sera (Figure 5.4). Thus, cross-reactive antibodies binding to the virion (and 
therefore the structural proteins) are the main antibody component in human immune sera 
responsible for heterotypic DENV enhancement. 
Depletion of rE-specific antibodies decreased ADE of heterotypic virus 
 We then investigated the role of rE-binding antibodies in heterotypic DENV virus 
enhancement. Primary DENV-immune human sera was depleted of cross-reactive rE-binding 
antibodies using purified heterotypic rE protein (purchased from Hawaii Biotech). Removal 
of cross-reactive rE-binding antibodies from primary immune serum significantly reduced 
binding to homotypic rE as well, indicating that a majority of the rE-binding antibodies in 
DENV serum were cross-reactive (Figure 5.5A). Furthermore, in vitro ADE investigations 
showed that removal of cross-reactive rE-binding antibodies significantly reduced 
enhancement of heterotypic DENV serotypes by shifting the ADE curve about 0.5-1.0 
logarithmic values (Figure 5.5B and C).  
 The DENV enhancement properties of cross-reactive rE-depleted human sera was 
then tested in the AG129 mice. Depletion of cross-reactive rE-binding antibodies resulted in 
survival of 50% of the mice (Figure 5.6A) and was significantly different from the 
undepleted serum sample (P<0.01). Similar results were observed for two different primary 
DENV3-immune sera. Therefore, we took a closer look at the morbidity scores of each 
individual mouse in the control depleted primary DENV3 serum group versus rE-depleted 
serum group. Interestingly, compared to the control depleted primary DENV3 serum group, 
there was greater variability in morbidity scores within the rE-depleted sera group (Figure 
5.6B and C). It is surprising that the removal of rE-specific antibodies did not lead to partial 
morbidity of all the mice in that group, but rather led to a consistently decreased morbidity 
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and mortality of 50% of the group (in comparison to the control depleted DENV3 serum 
group). It seems that DENV rE-binding antibodies in primary DENV-immune human sera 
are only partially responsible for ADE of heterotypic DENV infections.    
Competition ADE assays with prM-binding Fab indicates a role for prM-binding Abs in ADE 
 Since we found that E-binding antibodies were only partially responsible for 
enhancement of heterotypic serotypes, we investigated the role of prM-binding antibodies. 
The prM protein is a transmembrane protein that is expressed at very low quantities in cell 
culture. Therefore, we are presently still in the process of optimizing expression and 
purification of the prM protein (and recombinant versions of the prM protein). However, we 
still probed the importance of prM-binding antibodies by conducting competitive ADE 
assays with primary DENV-immune sera and Fabs that bound to prM. Collaborators in the 
laboratory of Dr. James Crowe generated Fabs from the prM-binding MAbs, 1B22 and 2K2. 
As shown in Figures 5.7, both 1B22 Fab and 2K2 Fab did not neutralize DENV1 or DENV2 
at the concentrations used in the competitive ADE assay. Primary DENV3-immune sera 
enhanced infection of DENV1 and DENV2 to approximately 40% in the presence of a 
negative control binding Fab, 2D22 Fab (DENV2-specific) and 1F4 Fab (DENV1-specific) 
respectively. However, addition of 1B22 Fab or 2K2 Fab competed for virus-binding with 
DENV-specific antibodies in immune sera and reduced enhancement of heterotypic virus 
infection by 25-50% (Figure 5.7).  Although further experiments need to be conducted with a 
larger panel of Fabs to confirm the above results, it seems that prM-binding antibodies in 
primary immune sera also play a role in ADE of heterotypic DENV serotypes.         
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5.5  Discussion 
 
The cause of severe disease in secondary DENV infections has been a topic of much 
controversy, and has been attributed to either the phenomenon of ADE or “cytokine storm” 
(22). It has also been shown that NS1-specific antibodies contribute to severe disease by 
cross-reacting with human platelets and endothelial cells (18). However, our present results 
show that ADE of heterotypic serotypes both in vitro and in vivo are caused by cross-reactive 
antibodies that bind the virus particle (i.e. antibodies that bind the E protein and/or the prM 
protein). As expected, both our in vitro and in vivo results also indicate that heterotypic virus 
enhancement is at high serum concentrations, as compared to homotypic virus enhancement.  
 Several groups have shown that the DENV-specific antibody response generates a 
large quantity of cross-reactive E-specific antibodies capable of enhancing DENV infection 
(2, 5, 7, 27, 28). In the present study, we show that rE-specific antibodies in primary immune 
sera contribute significantly to enhancement of heterotypic virus infection. Several studies 
with immune sera from individuals who were naturally infected with DENV have indicated 
that greater than 90% of the DENV-specific antibody response is to the highly conserved 
fusion loop within the DENV E protein. However, these studies were conducted using either 
western blot analysis or binding to subviral particles (17, 19). Proteins rarely preserve their 
tertiary and quaternary structures during western blotting, and subviral particles lack the 5-3-
2 axis of symmetry in whole mature DENV viral particles. Comparison of virus-specific and 
rE-specific antibodies has shown that less than 35% of the DENV-specific antibody response 
is rE-specific in humans after natural primary infections (5). Furthermore, an interesting 
study has shown that LALA variants of fusion loop-specific MAbs can be used to 
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therapeutically prevent enhancement by anti-DENV-immune mouse sera (34). Therefore, 
although our present studies indicate the significant contribution of rE-specific antibodies in 
ADE of heterotypic DENV viruses, further experiments need to be conducted to determine 
the contribution of fusion loop-specific antibodies to enhancement of heterotypic DENV.  
 In addition to E-specific antibodies, several groups have recently isolated many 
weakly neutralizing, cross-reactive prM-binding antibodies from human PBMCs from 
individuals after natural primary infections (2, 5, 7, 27, 28). However, western blot analysis 
indicates that very little prM-binding antibodies are present in primary DENV-immune 
human sera as compared to immune sera after secondary DENV infections (2, 31). Therefore, 
till now the role of prM-antibodies in ADE of secondary infections has been unclear. Our 
preliminary results indicate that prM-specific antibodies contribute to 25-50% of the in vitro 
heterotypic DENV enhancing capabilities of primary immune sera.  
Although the currently presented work further establishes the AG129 mouse model as 
appropriate for studying DENV enhancement with human immune serum, this model does 
have its limitations. For example, despite many labs are working on generating several 
mouse adapted DENV strains, at present we are limited to conducting our ADE experiments 
in AG129 with the best characterized DENV2 strain, D2S10 (26). Furthermore, there is much 
criticism in the DENV field that the lack of IFNα/β and γ receptors in AG129 severely 
compromise its ability to produce a full humoral and cellular immune response to viral 
infections. Therefore, it is unclear whether E and prM-binding antibodies would have a 
different effect in a fully immune-competent DENV model.   
 Severe disease during DENV infections has been found to be multi-factorial. In 
addition to sub-protective pre-immunity to DENV, numerous host factors (such as female 
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sex, human leukocyte antigen (HLA) class I alleles, variant of the DC-SIGN receptor gene, 
polymorphism in the tumour necrosis factor (TNF) gene and AB blood group, race, and 
polymorphisms in the Fcγ receptor and vitamin D receptor genes) also increase the risk of 
severe disease (8, 14, 16, 20, 24, 29). Therefore, it is important to expand our panel of human 
sera before we firmly establish the role of prM and E targeting antibodies in ADE of 
heterotypic DENV infections.  
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Figure 5.1 Primary DENV immune sera enhance heterotypic serotypes at high serum 
concentrations. The above primary DENV3-immune human serum enhances the heterotypic 
serotypes, DENV1 (A), DENV2 (B) and DENV4 (D) at very high serum concentrations, 
while it enhances the homotypic DENV3 (C) virus at a much lower serum concentration. 
K562 cells were used in this assay. DENV infects K562 through FcγR mediated endocytosis. 
Data representative of 8 serum samples. 
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Figure 5.2 In the AG129 mouse model, heterotypic sera enhance DENV2 infection and 
causes ADE-induced lethality, while homotypic sera protects from DENV challenge. A) 
Human sera was passively transferred 24 hrs prior to challenge with the DENV2 mouse 
adapted strain, D2S10. The mice were then scored for morbidity and mortality. B) All 
heterotypic sera (primary DENV1, primary DENV3 and primary DENV4 sera) caused 
significantly lethality compared to naïve human sera, while the same quantity of homotypic 
sera protected the mice from ADE-induced mortality. Data collected by Kate Williams  (Eva 
Harris Lab, UC Berkley). α-DENV1 = primary DENV1, α-DENV2 = primary DENV2, α-
DENV3 = primary DENV3, α-DENV4 = primary DENV4, NHS = naïve human sera.  
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Figure 5.3 Removal of cross-reactive antibodies from primary DENV-immune human 
sera, removes enhancement of heterotypic DENV infection in vitro. A) Binding ELISA to 
DENV virus show that depletion of a primary DENV3 sera with DENV2 virus removes 
binding to heterotypic DENV2 and DENV4, while significantly reducing binding to 
heterotypic DENV1. Depletion of cross-reactive antibodies from primary DENV3-immune 
serum, ablated enhancement of heterotypic DENV1 (B) and DENV2 (C), while significantly 
reduced enhancement of homotypic DENV3 virus (D). Data representative of both primary 
DENV2 and DENV3-immune human sera.     
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Figure 5.4 Removal of cross-reactive antibodies from primary DENV3-immune sera 
significantly protected AG129 mice from ADE of DENV2. Depletion of primary DENV3-
immune human sera with heterotypic DENV virus (DENV1, DENV2 and DENV4) 
significantly increased percent asymptomatic (A) and percent survival (B) in AG129 mice. 
Percent asymptomatic and percent survival of virion depleted anti-DENV3 significantly 
different from control depleted anti-DENV3 (P<0.001). Data collected by Kate Williams and 
Michael schmidt (Eva Harris Lab, UC Berkley). Data is representative of two primary 
DENV3-immune human sera.   
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Figure 5.5 Recombinant E-binding cross-reactive antibodies make up a significant 
portion of the heterotypic virus-enhancing antibodies. A) Primary DENV3 serum was 
successfully depleted of DENV1,2 and 4 rE-binding antibodies. Removal of cross-reactive 
rE-specific antibodies from a primary DENV3-immune human serum significantly reduced 
enhancement of the heterotypic viruses, DENV1 (B) and DENV2 (C), but did not similarly 
effect enhancement of the homotypic virus, DENV3 (D). Data representative of a serum 
panel including both primary DENV2 and DENV3-immune human sera.         
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Figure 5.6 DENV recombinant E-binding antibodies in human serum are only partially 
responsible for ADE of heterotypic DENV infections in AG129 mice. A) Removal of E-
specific antibodies from a primary DENV3-immune human sera resulted in partial 
phenotype, where 50% of the mice survived. A closer observation of the morbidity scores 
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indicated that although morbidity was consistent within the mice injected with control 
depleted DENV3-immune sera (B), there was high variability within the mice group injected 
with cross-reactive rE-depleted DENV3-immune sera (C). Data collected by Kate Williams, 
Michael schmidt and Sarah Killingbeck (Eva Harris Lab, UC Berkley). Data is representative 
of two different primary DENV3-immune human sera.        
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Figure 5.7 Between 25-50% of heterotypic virus enhancement by primary DENV-
immune sera can be attributed to prM-binding antibodies. The Fab fragments of the 
prM-specific human antibodies, 1B22 and 2K2, do not neutralize DENV1 (A) and DENV2 
(B) in the concentration range used in the competition ADE assays. Anti-prM Fab from 1B22 
and 2K2 competes with a primary DENV3-immune human serum (at peak enhancement 
concentration) and reduces 25-50% of enhancement of the heterotypic serotypes, DENV1 
(C) and DENV2 (D).    
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CHAPTER SIX 
Discussion 
 
6.1 A snapshot of the human antibody response to DENV 
 Recent findings that the mouse antibody response to DENV is different from that of 
the human response instigated several groups to investigate the human long-lived memory 
plasma and B-cell response after natural DENV infections (40, 41, 47, 58, 59). Our depletion 
experiments concluded that primary DENV-infections in humans stimulate circulating 
plasma cell-secreted antibodies that can be divided into two groups; 1) a large fraction of 
cross-reactive, weakly neutralizing antibodies responsible for heterotypic virus enhancement, 
and 2) a small fraction of strongly neutralizing antibodies responsible for type-specific 
protection (10). As a parallel approach, PBMCs were isolated and in depth analysis was 
conducted on the DENV-specific memory B-cell response in individuals that had had natural 
DENV infections. Surprisingly, in several individuals over 9% of the EBV-transformed B-
cells were found to be DENV-positive even 8 years after DENV infections (2, 50). This is 
further evidence of life long antibody responses stimulated by natural DENV infections. One 
study primarily characterized the memory B-cell response in individuals very early (i.e. 
within 2 weeks of day of defervescence) after infection and estimated about 40-70% of the 
virionDENV structural protein-specific antibodies as being directed against the prM protein 
(11). These antibodies were found to be highly cross-reactive and weakly neutralizing
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Similar prM-binding antibodiesratios were describedput forward in chapter 2 and other 
studies that characterized the late convalescent memory B-cell response following primary or 
secondary DENV infections (2, 9, 49, 50). A large proportion of the DENV-specific 
antibodies also bound E protein, and several of these cross-reactive, weakly neutralizing 
antibodies were mapped to the highly conserved fusion loop.  
Since weakly neutralizing, cross-reactive antibodies dominated the human antibody 
response, neutralizing antibodies were infrequently isolated (less than 5% of the DENV 
virus-specific response) (50). Weakly neutralizing, cross-reactive antibodies capable of ADE 
of DENV infection further explains why primary DENV-immune sera offer type-specific 
protection and heterotypic virus enhancement. It is interesting that weakly DENV 
neutralizing memory B-cells are kept in circulation years after infection. It is possible that 
these same weakly neutralizing, cross-reactive antibodies at higher numbers are responsible 
for the transient cross-protection observed right after primary infections. As of yet, in depth 
analysis of the human memory B-cell response has not been conducted for other flaviviral 
infections. Therefore, it is difficult to postulate whether this dominant weakly neutralizing, 
cross-reactive response is a trend across flaviviruses, or whether it’s DENV-specific.     
 
6.2  Lessons learnt from protective antibodies following natural DENV infections in 
humans. 
Role of EDI-DII hinge-specific Abs in type-specific protection  
Prior antibody mapping studies using mouse mAbs had identified EDIII as the target 
of neutralizing antibodies (16, 17, 33, 53, 54). Screening memory B cells from naturally 
DENV-infected individuals with DENV rE or EDIII successfully isolated EDIII-specific 
	  	   200	  
antibodies (2, 9). However, EDIII-specific antibodies were found to be rare in DENV-
immune indviduals, and did not contribute to significant protection in humans (40, 41, 47, 
58, 59). Therefore, Surprisingly, DENV EDIII is not the major target of protective antibodies 
in humans (40, 41, 47, 58, 59). WeTherefore, we isolated potently neutralizing, type-specifc 
human mAbs, and mapped them to a complex quaternary epitope that focused around the DI-
DII hinge of the DENV E protein (10). Cryo-EM studies mapped a type-specific, strongly 
neutralizing anti-DENV1 human mAb to the same region and further solidified our findings 
(55). Our studies with the EDI-DII hinge mutant (UNC3001-A12) and human DENV-
immune sera firmly establish the importance of the EDI-DII hinge region in protection 
following primary infections. It seems that other flaviviral infections in humans may also 
elicit protective antibodies that target the EDI-DII hinge. Escape mutant analysis have 
mapped strongly protective mAbs raised in mice or chimpanzee to residues in the EDI-DII 
hinge of JEV and Murray Valley encephalitis virus (14, 18, 19, 26, 27, 35). Since several of 
these complex JEV EDI-DII hinge-binding antibodies were generated in mice, it is evidence 
that mice are able to generate these types of complex neutralizing antibodies (18, 26, 27). 
Therefore, the difference in the mouse and human antibody responses to DENV maybe 
attributed to the lack of DENV replication and growth in immune competent mice. 
Additionally, cryo-EM studies also mapped a potently neutralizing anti-WNV human 
antibody (CR4354) to a complex quaternary epitope, which included the EDI-DII hinge of 
one WNV E dimer and EDIII of the adjacent WNV E protein dimer (23, 57). Therefore, it 
seems that protection through antibody binding to complex quaternary epitopes focused 
around the EDI-DII hinge may be a common trend within the flaviviruses.      
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Flaviviruses are not the only enveloped viruses to elicit protective antibodies against 
conformational, complex epitopes. Recent X-ray crystallography structures mapped a rare 
Sudan virus (genus Ebolovirus) neutralizing human mAb to an epitope created by the close 
proximity of two glycoproteins (GP1 and GP2) on the virion particle (12). Furthermore, 
despite the lack of detailed structural information, Hepatitis C virus (HCV) has also been 
found to induce strongly neutralizing antibodies that recognize complex, conformational 
epitopes (24, 25, 45). In the HIV (retroviridae) field, several potently neutralizing human 
antibodies have been mapped to what has been termed the quaternary neutralizing epitope 
(QNE); these antibodies do not bind monomeric pg120, instead recognize the gp120 trimeric 
form of the mature envelope spike (15, 51). Therefore, it seems that antibodies targeting 
complex, quaternary conformational epitopes play a large role in human protection against 
enveloped viruses.       
 
DENV EDI-DII hinge-specific Abs and mechanism of neutralization 
 Binding the EDI-DII hinge offers antibodies several distinct advantages towards 
successful neutralization. The flavivral EDI-DII hinge plays vital roles in virus maturation, 
entry and fusion (reviewed in (22)). During the DENV life cycle, the EDI-DII hinge angle 
undergoes over a 35° change, which effects the relative positioning of DII and DIII regions 
of the DENV E protein (36-38). A majority of the antibodies that bind the EDI-DII hinge 
block steps post-attachment, such as entry and fusion (Chapter 4 & (23, 57)). DENV is 
observed to infect several different cell lines using various host attachment receptors (such as 
C-type lectins, glycosaminoglycans and phosphatidylserine receptors (5, 8, 42)). Therefore, 
neutralization by attachment-blocking antibodies is restricted to the cell type expressing the 
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relevant host attachment factor. However, since DENV entry and fusion mechanism are 
universal and to a large extent cell line independent, antibodies that block steps post-
attachment would be capable of neutralization in any DENV-susceptible cell line.  
 The EDI-DII hinge region has also been attributed to play a role in maintaining the 
pH-threshold of fusion (1, 3, 18, 20, 31, 36, 39). Continuous passage of flaviviruses in cell 
culture leads to point mutations in this region that changes the pH at which fusion events are 
triggered (31). It is important to keep in mind that although there is fairly high amino acid 
sequence variability in the EDI-DII hinge sequence between serotypes attributing to type-
specificity, the sequence variability within serotypes is relatively conserved (57). Therefore, 
accumulation of mutations in the EDI-DII hinge region of cell culture-passaged virus is 
probably due to pH changes that occur in cell culture settings, and hence probably only a cell 
culture phenomenon.  
The EDI-DII hinge region is fairly well exposed in both the mature and immature 
virion (28, 36-38, 61), enabling EDI-DII hinge specific antibodies to efficient neutralize 
DENV irrespective of virus maturity. The dynamic nature of both the DENV virion structure 
and the EDI-DII hinge region increases the accessibility of antibodies to this region. 
Furthermore, it is highly unlikely that an excess of weakly neutralizing anti-fusion loop 
antibodies would interfere with EDI-DII hinge-specific antibodies, as was recently shown for 
neutralizing EDIII-specific antibodies (60). Therefore, a DENV vaccine platform that 
stimulates protective EDI-DII hinge-specific antibodies might be the solution to a successful 
DENV vaccine.  
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Role of DII-binding Abs in cross-reactive protection 
 Very little is known about the role of cross-protective antibodies and the epitopes that 
they bind. Several studies have mapped cross-reactive antibodies to prM and the E fusion 
loop (2, 4, 6, 7, 9, 11, 30, 32, 41, 43, 50, 56). However, these antibodies were moderately 
neutralizing at best (2, 4, 7, 9, 11, 43, 50). Our work in chapter 4 identifies a novel cross-
protective epitope in EDII. The 1N5 and 1C19 antibodies that mapped to this region were 
isolated from secondary DENV infected individuals. A recent study also isolated strongly 
cross-neutralizing antibodies from PBMCs of individuals experiencing acute secondary 
DENV infections (48). Furthermore, long term cross-protection has been observed in humans 
only after secondary or tertiary DENV infections. It seems that these long-lived potently 
cross-neutralizing antibodies are produced only after secondary or tertiary infections.  	  
6.3 ADE, protection and implications for vaccine design 
 The cause of severe disease (DHF/DSS) during DENV infections is multi-factorial. 
Several host factors that increase the risk of severe disease include female sex, human 
leukocyte antigen (HLA) class I alleles, variant of the DC-SIGN receptor gene, 
polymorphism in the tumour necrosis factor (TNF) gene and AB blood group, race, and 
polymorphisms in the Fcγ receptor and vitamin D receptor genes (13, 21, 29, 34, 46, 52). 
ADE has been attributed to be a risk factor for severe disease during secondary infections. 
Therefore, the characterization of the antibodies responsible for ADE of heterotypic DENV 
virus during natural infections is vital for developing safe vaccines.  
 As characterized in this dissertation and recent papers, the human antibody response 
to DENV is dominated by weakly neutralizing, cross-reactive antibodies that are capable of 
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efficient ADE of DENV infections (2, 10, 11, 49, 50). Unlike protective antibodies, 
antibodies responsible for DENV enhancement bind to regions on both prM and the E 
protein. The amino acid sequence of both prM and the fusion loop of E protein are more than 
70% conserved among the four DENV serotypes. A recent study analyzing the memory B-
cell compartment of individuals who had received the live-attenuated DV1 vaccine 
(DENV1Δ30) versus individuals who had had natural DENV1 infections, showed similar 
antibody profiles (49). Therefore, it is highly likely that other leading DENV vaccines also 
elicit a dominant weakly neutralizing, enhancing antibody repertoire.   
 Using the results in this dissertation and presently available knowledge of the human 
antibody response to natural DENV infections, there seems to be two ways of designing a 
successful DENV vaccine. The first approach is the same approach that current vaccine 
developers are trying to achieve, i.e. balanced, life long protective immunity against each of 
the four DENV serotypes. For this vaccine approach to be successful, it is important to elicit 
strongly neutralizing immunity capable of over coming the inherently produced weakly 
neutralizing, cross-reactive, DENV-enhancing antibodies. Since the most potently 
neutralizing type-specific antibodies were found to recognize complex, quaternary epitopes 
that are only preserved on the virion particle (10, 23, 55, 57), it is understandable that the 
most successful, leading vaccine platforms are live-attenuated vaccines (as opposed to 
subunit vaccines). Surprisingly, the leading live DENV vaccine candidate (i.e. the yellow 
fever dengue chimeric vaccine) in phase IIB clinical trials failed to produced balanced 
protective responses against the four DENV serotypes (44). Therefore, it seems important 
that vaccine developers assess the viral epitopes recognized by the neutralizing antibodies 
produced by the vaccine recipients.  The second approach for a successful DENV vaccine is 
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to present the human immune system with only the viral epitopes responsible for potently 
neutralization. More specifically, the complex, quaternary epitope, including the EDI-DII 
hinge can be re-created either in an unrelated protein, or a distantly related flavivirus. This 
approach removes conserved regions in the immunogen that may otherwise produce cross-
reactive antibodies that have the potential to cause ADE of DENV. At the same time, this 
vaccine approach presents the body with an epitope that can elicit life-long, potently 
neutralizing antibodies.    
 The findings in this dissertation expand our knowledge of the human antibody 
response to DENV. It also reveals novel viral epitopes responsible for type-specific 
protection, and attempts to characterize the mechanism of neutralization. Furthermore, this 
dissertation investigates the viral epitopes that lead to ADE of heterotypic DENV infections. 
Finally, we hope the findings in this dissertation will contribute to the development of safe 
and successful DENV vaccine designs.      
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